


**TUFTS CENTER FOR THE STUDY OF DRUG DEVELOPMENT
RESEARCH BIBLIOGRAPHY
1976 - 2017**



Getz KA, Campo. Trial watch: Trends in clinical trial design complexity. *Nature Reviews Drug Discovery*. Online publish date: April 18, 2017 [RS 3706]

<http://dx.doi.org/10.1038/nrd.2017.65>

Getz K, Brown C, Stergiopoulos S, Beltre C. Baseline assessment of a global clinical investigator landscape poised for structural change. *Therapeutic Innovation & Regulatory Science*. Online publish date: March 30, 2017 [RS 3705]

<http://dx.doi.org/10.1177/2168479017701504>

Kaitin KI, editor. Approval time for 505(b)(2) drugs is nearly five months longer than for NMEs. *Tufts Center for the Study of Drug Development Impact Report*. 2017 Mar/Apr;19(2)** [RS 3704]

Stergiopoulos S, Getz KA. Diagnosing protocol amendment experience to drive clinical trial performance. *Pharmaceutical Outsourcing*. 2017;18(1):30-32 [RS 3703]

<http://www.pharmoutsourcing.com/Featured-Articles/333834-Diagnosing-Protocol-Amendment-Experience-to-Drive-Clinical-Trial-Performance/>

Milne CP. More efficient compliance with European Medicines Agency and Food and Drug Administration regulations for pediatric oncology drug development: problems and solutions. *Clinical Therapeutics*. 2017;39(2):238-245 [RS 3702]

<http://dx.doi.org/10.1016/j.clinthera.2017.01.002>

Kaitin KI. Developing new medicines for pediatric oncology: assessing needs and overcoming challenges. *Clinical Therapeutics*. 2017;39(2):236-237 [RS 3701]

<http://dx.doi.org/10.1016/j.clinthera.2017.01.014>

Kaitin KI, editor. Poor physician and nurse engagement driving low patient recruitment. *Tufts Center for the Study of Drug Development Impact Report*. 2017 Jan/Feb;19(1)** [RS 3700]

**This publication is for sale at our website <http://csdd.tufts.edu/reports>

- Stergiopoulos S, Surgeon L, Getz K. Quantifying the magnitude and cost of collecting nice-to-have clinical trial data. *Chimica Oggi [Chemistry Today]*. 2016;34(6):48-51. [RS 3630]
http://www.teknoscienze.com/tks_article/quantifying-the-magnitude-and-cost-of-collecting-nice-to-have-clinical-trial-data/
- Getz, KA. Finally, standardized KPIs are front and center. *Applied Clinical Trials*. 2016; 25(10/11):24-25 [RS 3629]
<http://www.appliedclinicaltrials.com/finally-standardized-kpis-are-front-and-center>
- Kaitin KI, editor. Pediatric regulatory science, clinical trial networks hold promise for studies. *Tufts Center for the Study of Drug Development Impact Report*. 2016 Nov/Dec;18(6)** [RS 3628]
- Lamberti MJ, Hsia R, Mahon C, Milligan C, Getz KA. Assessing global clinical supply logistics. *Applied Clinical Trials*. 2016;25(10):26-34 [RS 3627]
<http://www.appliedclinicaltrials.com/assessing-global-clinical-supply-logistics>
- Kaitin KI, editor. Pediatric oncology drug development: maximizing efficiency while complying with FDA & EMA regulations. *Tufts Center for the Study of Drug Development R&D Management Report*. 2016 Oct;11(2)** [RS 3626]
- Kaitin KI, editor. Diabetes drug development is riskier compared to all drug development. *Tufts Center for the Study of Drug Development Impact Report*. 2016 Sep/Oct;18(5)** [RS 3625]
- Stella Stergiopoulos S, Brown CA, Felix T, Grampp G, Getz KA. A survey of adverse event reporting practices among US healthcare professionals. *Drug Safety*. 2016;39(11)1117–1127 [RS 3624]
<http://dx.doi.org/10.1007/s40264-016-0455-4>
- DiMasi JA, Chakravarthy R. Competitive development in pharmacologic classes: Market entry and the timing of development. *Clinical Pharmacology & Therapeutics*. 2016;100(6): 754-760 [RS 3623]
<http://dx.doi.org/10.1002/cpt.502>
- Carter PH, Berndt ER, DiMasi JA, Trusheim M. Investigating investment in biopharmaceutical R&D. *Nature Reviews Drug Discovery*. 2016;15(10):673-674 [RS 3622]
<http://dx.doi.org/10.1038/nrd.2016.104>
- Getz, KA. Insights into capturing collaborative value. *Applied Clinical Trials*. 2016; 25(8/9):24-25 [RS 3621]
<http://www.appliedclinicaltrials.com/insights-capturing-collaborative-value>

Lamberti MJ, Chakravarthy R, Getz K. *Assessing practices & inefficiencies with site selection, study start-up, and site activation. *Applied Clinical Trials*. Online publish date: Aug 5, 2016 [RS 3620]

*Note: Article subsequently appears in print publication with a different title: New benchmarks for trial initiation activities. *Applied Clinical Trials*. (Dec 2016/Jan 2017);25(12): 28-32.

<http://www.appliedclinicaltrials.com/assessing-practices-inefficiencies-site-selection-study-start-and-site-activation>

Lamberti MJ, Awatin J, Getz K, Cohen M. Setting the standard. *European Pharmaceutical Contractor*. Summer 2016;7-10 [RS 3619]

<http://www.samedanltd.com/magazine/11/issue/255/article/4390>

Getz K, Lamberti MJ. Hard truths about executing outsourcing relationships. *Pharmaceutical Outsourcing*. 2016;17(4):18-20 [RS 3618]

<http://www.pharmoutsourcing.com/Featured-Articles/189343-Hard-Truths-about-Executing-Outsourcing-Relationships/>

Kaitin KI, editor. Global regenerative medicine market is poised for strong growth. *Tufts Center for the Study of Drug Development Impact Report*. 2016 Jul/Aug;18(4)** [RS 3617]

Chakravarthy R, Cotter K, DiMasi J, Milne C-P, Wendel N. Public- and private-sector contributions to the research and development of the most transformational drugs in the past 25 years: from theory to therapy. *Therapeutic Innovation & Regulatory Science*. 2016;50(6):759-768 [RS 3616]

<http://dx.doi.org/10.1177/2168479016648730>

Beninger P, Boumil M, Salem D, Getz K, Klapholz H, Curfman G, Jotwani R, Berman H. Bridging the academia/industry chasm: proposed solutions. *The Journal of Clinical Pharmacology*. 2016;56(12):1457-1460 [RS 3615]

<http://dx.doi.org/10.1002/jcph.762>

Milne C-P, Mitra J, Kojima N, Sugiyama, Awatin J, Simmons G. Prospects for harmonizing regulatory science programs in Europe, Japan, and the United States to advance regenerative medicine. *Therapeutic Innovation & Regulatory Science*. 2016;50(6):724-733 [RS 3614]

<http://dx.doi.org/10.1177/2168479016650716>

Kaitin KI, editor. Rapid growth in PBM exclusion lists poses challenge to drug developers. *Tufts Center for the Study of Drug Development Impact Report*. 2016 May/Jun;18(3)** [RS 3613]

Getz KA. Acknowledging cycle time impact from protocol amendments. *Applied Clinical Trials*. 2016;25(4/5) [RS 3612b]

<http://www.appliedclinicaltrials.com/acknowledging-cycle-time-impact-protocol-amendments?pageID=2>

**This publication is for sale at our website <http://csdd.tufts.edu/reports>

Hochberg AM, Stergiopoulos S. Is earlier signal detection always better? *Drug Safety*. 2016;39(8):777-778 [RS 3612]
<http://dx.doi.org/10.1007/s40264-016-0425-x>

Cohen JP, Silva L, Cohen A, Awatin J, Sturgeon R. Progress report on neglected tropical disease drug donation programs. *Clinical Therapeutics*. 2016; 38(5):1193–1204 [RS 3611]
<http://dx.doi.org/10.1016/j.clinthera.2016.02.031>

Bruen B, Docteur E, Lopert R, Cohen J, DiMasi J, Dor A, Neumann P, DeSantis R, Shih C. The impact of reimbursement policies and practices on healthcare technology innovation. Washington DC: Office of the Assistant Secretary for Planning and Evaluation/U.S. Department of Health and Human Services; 2016. [RS 3610]
<https://aspe.hhs.gov/pdf-report/impact-reimbursement-policies-and-practices-healthcare-technology-innovation>).

Kaitin KI, editor. *Optimizing collaboration Effectiveness in Alliance Partnerships* Boston: Tufts Center for the Study of Drug Development; 2016 R&D Senior Leadership Brief. (Lamberti, Chakravarthy, Getz) [RS 3609b]

Kaitin KI, editor. Promise of immuno-oncology therapies is boosting R&D funding, alliances. *Tufts Center for the Study of Drug Development Impact Report*. 2016 Mar/Apr;18(2)** [RS 3609]

Getz K, Stergiopoulos S, Short M, Surgeon L, Krauss R, Pretorius S, Desmond J, Dunn D. The impact of protocol amendments on clinical trial performance and cost. *Therapeutic Innovation & Regulatory Science*. 2016;50(4):436-441 [RS 3608]
<http://dx.doi.org/10.1177/2168479016632271>

DiMasi JA, Grabowski HG, Hansen RW. Innovation in the pharmaceutical industry: new estimates of R&D costs. *Journal of Health Economics*. 2016; 47:20-33 [RS 3607]
<http://dx.doi.org/10.1016/j.jhealeco.2016.01.012>

Getz, KA. Clinical trial knowledge missed, gained, and shared. *Applied Clinical Trials*. 2016;25(2/3):12-13 [RS 3606b]
<http://www.appliedclinicaltrials.com/clinical-trial-knowledge-missed-gained-and-shared>

Lamberti MJ, Birch P, Chakravarthy R, Getz K. Optimizing collaboration effectiveness in alliance partnerships. *Contract Pharma*. 2016;18(1):58-60 [RS 3606]
http://www.contractpharma.com/issues/2016-01-01/view_features/optimizing-collaboration-effectiveness-in-alliance-partnerships/

Evens RP. Pharma success in product development—does biotechnology change the paradigm in product development and attrition. *American Association of Pharmaceutical Scientists journal*. 2016;18(1):281-285. [RS 3605]
<http://dx.doi.org/10.1208/s12248-015-9833-6>

Stergiopoulos S, Wilkinson M, Awatin J, Getz K. Assessing the discovery outsourced services market. *Life Sciences Leader*. 2016 Feb:32-37. [RS 3604]
<http://www.lifescienceleader.com/doc/assessing-the-discovery-outsourced-services-market-0001>

Stergiopoulos S, Eustace C, Stem K, Getz K. Mobile nurse services in clinical trials: usage and industry perceptions. *Therapeutic Innovation & Regulatory Science*. 2016; 50(4) 442-449 [RS 3603]
<http://dx.doi.org/10.1177/2168479015625712>

Kaitin KI, editor. Patient recruitment and retention 2.0. *Tufts Center for the Study of Drug Development R&D Management Report*. 2016 Jan;11(1)** [RS 3602]

Kaitin KI, editor. Amendments reduce number of patients, but at high cost, longer study times. *Tufts Center for the Study of Drug Development Impact Report*. 2016 Jan/Feb;18(1)** [RS 3601]

Outlook 2016. Boston: Tufts Center for the Study of Drug Development, 2016** [RS 3600]

Cohen JP. Known knowns and unknowns of U.S. drug pricing. *PLOS Blogs Network*. Posted November 10, 2015. [RS 3542]
<http://blogs.plos.org/yoursay/2015/11/10/known-knowns-and-unknowns-of-u-s-drug-pricing/>

Kaitin KI, editor. First-in-class drugs in competitive development races with later entrants. *Tufts Center for the Study of Drug Development Impact Report*. 2015 Nov/Dec;17(6)** [RS 3541]

Getz KA. New look at the arsenal of technology solutions. *Applied Clinical Trials* 2015;24(10/11):16-17. [RS 3540b]
<http://www.appliedclinicaltrials.com/new-look-arsenal-tech-solutions>

Kaitin KI, editor. Novel approaches to overhauling the clinical development process. *Tufts Center for the Study of Drug Development R&D Management Report*. 2015 Oct;10(4)** [RS 3540]

Milne C-P, Cohen JP, Chakravarthy R. Where is personalized medicine in industry heading? *Nature Reviews Drug Discovery*. 2015;14(12):812–813. [RS 3539]
<http://dx.doi.org/10.1038/nrd4759>

Kaitin KI, editor. Adverse drug event reporting in U.S. beset by incompleteness and inaccuracy. *Tufts Center for the Study of Drug Development Impact Report*. 2015 Sept/Oct;17(5)** [RS 3538]

Milne C-P. FDA's breakthrough therapy designation. *Pharmaceutical Executive*. 2015;35(9):48-50. [RS 3537b]
<http://www.pharmexec.com/fda-s-breakthrough-therapy-designation?pageID=3>

Getz KA, Lamberti MJ. The unintended inefficiencies of outsourcing practice. *Pharmaceutical Outsourcing*. 2015;16(4):28-30. [RS 3537]
<http://www.pharmoutsourcing.com/Featured-Articles/177660-The-Unintended-Inefficiencies-of-Outsourcing-Practice/>

Getz KA. ROI for patient-centric drug development. *Applied Clinical Trials*. 2015;24(8/9):16,18 [RS 3536b]
<http://www.appliedclinicaltrials.com/roi-patient-centric-drug-development>

Kaitin KI, editor. Diagnostic-therapeutic co-development strategies. *Tufts Center for the Study of Drug Development R&D Management Report*. 2015 Aug;10(3)** [RS 3536]

Cohen JP. Biosimilars: improving patient access to biologics while bending the cost curve. *In Vivo*. 2015;33(6):14-18. [RS 3535]
<https://www.pharmamedtechbi.com/publications/in-vivo/33/6/biosimilars-improving-patient-access-to-biologics-while-bending-the-cost-curve>

Cohen JP. Biosimilars: the big picture. *The Medicine Maker*. 2015;(8):20-21. [RS 3534] <https://themedicinemaker.com/issues/0515/biosimilars-the-big-picture/>

Cohen JP. The caring economy [letter to the editor]. *Harper's Magazine*. 2015;Sept:2-3. [RS 3533]
<http://harpers.org/archive/2015/09/letters-837/>

DiMasi JA, Hermann JC, Twyman K, Kondru RK, Stergiopoulos S, Getz KA, Rackoff W. A tool for predicting regulatory approval after phase II testing of new oncology compounds. *Clinical Pharmacology & Therapeutics*. 2015;98(5):506-513. [RS 3532]
<http://dx.doi.org/10.1002/cpt.194>

Kaitin KI. The quest to develop new medicines to treat alzheimer's disease: present trends and future prospects. *Clinical Therapeutics*. 2015;37(8):1618-1621. [RS 3531b]
<http://dx.doi.org/10.1016/j.clinthera.2015.07.004>

Milne C-P, Cohen JP, Felix A, Chakravarthy R. Impact of postapproval evidence generation on the biopharmaceutical industry. *Clinical Therapeutics*. 2015;37(8):1852-1858. [RS 3531]
<http://dx.doi.org/10.1016/j.clinthera.2015.05.514>

Milne C-P. Prospects for personalised medicines in the Asia-Pacific Region. *Pharma Focus Asia*. 2015;(22):34-39. [RS 3530]
<http://www.pharmafocusasia.com/strategy/personalised-medicines>

Stergiopoulos S, Getz K. Evaluating AE reporting of two off-patent biologics to inform future biosimilar naming and reporting practices. *Drug Safety*. 2015;38(8):687-692. [RS 3529]
<http://dx.doi.org/10.1007/s40264-015-0310-z>

Kaitin KI, editor. Vaccine products in the R&D pipeline have more than tripled since 2005. *Tufts Center for the Study of Drug Development Impact Report*. 2015 Jul/Aug;17(4)** [RS 3528]

Cohen JP, Dong J, Lu CY, Chakravarthy R. Restricting access to florbetapir: Medicare coverage criteria for diagnostics and drugs are inconsistent. *BMJ*. 2015;351:h3333. [RS 3527]
<http://dx.doi.org/10.1136/bmj.h3333>

Getz KA. Characterizing the real cost of site regulatory compliance. *Applied Clinical Trials*. 2015;24(6/7):18,20. [RS 3526b]
<http://www.appliedclinicaltrials.com/characterizing-real-cost-site-regulatory-compliance>

Lamberti MJ, Getz KA. *White paper: Profiles of new approaches to improving the efficiency and performance of pharmaceutical drug development*. Boston: Tufts Center for the Study of Drug Development. May 2015. [RS 3526]
http://csdd.tufts.edu/files/uploads/CSSD_PhRMAWhitePaper_FINAL.pdf

Cohen JP. Who pays the doctor? [letter to the editor]. *New York Review of Books*. 2015;62(10):80. [RS 3525]
<http://www.nybooks.com/articles/archives/2015/jun/04/who-pays-doctor/>

Naik P, Umrath T, van Stekelenborg J, Ruben R, Abdul-Karim N, Boland R, Ibara M, Ekuta J, Washburn D, Stergiopoulos S. Regulatory definitions and good pharmacovigilance practices in social media: challenges and recommendations. *Therapeutic Innovation & Regulatory Science*. 2015;49(6):840-851. [RS 3524]
<http://dx.doi.org/10.1177/2168479015587362>

Lamberti MJ, Kush R, Kubick W, Henderson C, Hinkson B, Kamenju P, Getz KA. An examination of eClinical technology usage and CDISC standards adoption. *Therapeutic Innovation & Regulatory Science*. 2015;49(6): 869-876. [RS 3523]

<http://dx.doi.org/10.1177/2168479015586003>

Kaitin KI, editor. Personalized medicine gains traction but still faces multiple challenges. *Tufts Center for the Study of Drug Development Impact Report*. 2015 May/Jun;17(3)** [RS 3522]

DiMasi JA, Grabowski HG, Hansen RW. The cost of drug development [letter to the editor]. *New England Journal of Medicine*. 2015;372(20):1972. [RS 3521]

<http://dx.doi.org/10.1056/NEJMc1504317>

Getz KA. The transformative promise of patient centric R&D. *Pharmaceutical Business Review*. Online publish date: May 7, 2015. [RS 3520]

<http://clinicaltrials.pharmaceutical-business-review.com/news/the-transformative-promise-of-patient-centric-rd-070515-4571105>

Nelson AM, Martin IG, Getz KA. Generational value differences affecting public perceptions of and willingness to participate in clinical trials. *Therapeutic Innovation & Regulatory Science*. 2015;49(6): 940-946. [RS 3519]

<http://dx.doi.org/10.1177/2168479015583727>

Krumholz-Bahner S, Garibbo M, Getz KA, Widler BE. An overview and analysis regarding the use of adjudication methods in EU and US drug approvals.

Therapeutic Innovation & Regulatory Science. 2015;49(6): 831-839. [RS 3518]

<http://dx.doi.org/10.1177/2168479015580382>

Getz KA. Establishing return-on-investment expectations for patient-centric initiatives. *Therapeutic Innovation & Regulatory Science*. 2015;49(5):745-749. [RS 3517]

<http://dx.doi.org/10.1177/2168479015579521>

Getz KA. Giving pharma credit for medical innovation. *Applied Clinical Trials*. 2015;24(4/5): 20,22. [RS 3516b]

<http://www.appliedclinicaltrials.com/giving-pharma-credit-medical-innovation>

Stergiopoulos S, Brown CA, Grampp G, Felix T, Getz KA. Identifying and quantifying the accuracy of product name attribution of US-sourced adverse event reports in MedWatch of somatropins and insulins. *Therapeutic Innovation & Regulatory Science*. 2015;49(5):706-716. [RS 3516]

<http://dx.doi.org/10.1177/2168479015578156>

Lu CY, Cohen JP. Can genomic medicine improve financial sustainability of health systems? *Molecular Diagnosis & Therapy*. 2015;19(2):71-77. [RS 3515]
<http://dx.doi.org/10.1007/s40291-015-0138-3>

Kaitin KI, editor. Assessing the FDA's breakthrough therapy designation. *Tufts Center for the Study of Drug Development R&D Management Report*. 2015 Apr;10(2)** [RS 3514]

Cohen JP. Implementing the Affordable Care Act: remaining hurdles. *Clinical Therapeutics*. 2015;37(4):717-719. [RS 3513]
<http://dx.doi.org/10.1016/j.clinthera.2015.02.026>

Getz KA. Charting a course for the patient centricity movement. *Clinical Researcher*. 2015;29(2):36-40. [RS 3512]
<http://www.acrpnet.org/PDF/ClinicalResearcher/2015April/Getz.pdf>

Kaitin KI, editor. Biosimilars entering the U.S. market are likely to face multiple challenges. *Tufts Center for the Study of Drug Development Impact Report*. 2015 Mar/Apr;17(2)** [RS 3511]

Getz KA. Closing in on opportunities to simplify protocol design. *Applied Clinical Trials*. 2015;24(2/3):18-19. [RS 3510b]
<http://www.appliedclinicaltrials.com/closing-opportunities-simplify-protocol-design>

Milne C-P, Kaitin KI. Meeting unmet medical needs: the disparity dilemma. *Pharmaceutical Executive*. 2015;35(2):26-28. [RS 3510]
<http://www.pharmexec.com/meeting-unmet-medical-needs-disparity-dilemma-0>

Chakravarthy R, Cotter K, DiMasi JA, Milne C-P, Wendel N. *White paper: Public and private sector contributions to the research & development of the most transformational drugs of the last 25 years*. Boston: Tufts Center for the Study of Drug Development. January 2015. [RS 3509]
<http://csdd.tufts.edu/files/uploads/PubPrivPaper2015.pdf>

Grabowski HG, DiMasi JA, Long G. The roles of patents and research and development incentives in biopharmaceutical innovation. *Health Affairs*. 2015;34(2):302-310. [RS 3508]
<http://dx.doi.org/10.1377/hlthaff.2014.1047>

Evens R, Kaitin KI. The evolution of biotechnology and its impact on health care. *Health Affairs*. 2015;34(2):210-219. [RS 3507]
<http://dx.doi.org/10.1377/hlthaff.2014.1023>

Kaitin KI, editor. Anticipating and managing a changing site landscape. *Tufts Center for the Study of Drug Development R&D Management Report*. 2015 Jan;10(1)** [RS 3506]

Milne C-P, Bryan C, Garafalo S, McKiernan M. Complementary versus companion diagnostics: apples and oranges? *Biomarkers in Medicine*. 2015;9(1):25-34. [RS 3505]
<http://dx.doi.org/10.2217/bmm.14.84>

Cohen JP. Roadblocks preventing personalized medicine from reaching its potential. *Biomarkers in Medicine*. 2015;9(1):5-8. [RS 3504]
<http://dx.doi.org/10.2217/bmm.14.66>

Kaitin KI, editor. High turnover, protocol noncompliance plague the global site landscape. *Tufts Center for the Study of Drug Development Impact Report*. 2015 Jan/Feb;17(1)** [RS 3503]

Getz KA, Kaitin KI. The impact of bad protocols. In: Schuler P, Buckley B, eds. *Re-engineering Clinical Trials: Best Practices for Streamlining Drug Development*. Amsterdam: Academic Press; 2015:105-116. [RS 3502]
<http://store.elsevier.com/Re-Engineering-Clinical-Trials/isbn-9780124202467/>

Getz KA, Kaitin KI. Why is the pharmaceutical and biotechnology industry struggling? In: Schuler P, Buckley B, eds. *Re-engineering Clinical Trials: Best Practices for Streamlining Drug Development*. Amsterdam: Academic Press; 2015:3-15. [RS 3501]
<http://store.elsevier.com/Re-Engineering-Clinical-Trials/isbn-9780124202467/>

Outlook 2015. Boston: Tufts Center for the Study of Drug Development, 2015** [RS 3500]

Stergiopoulos S, Surgeon L. The facilitated clinical trial protocol review: is the theory being put into good practice? *Chimica Oggi [Chemistry Today]*. 2014;32(6):52-56. [RS 3439]
<http://www.teknoscienze.com/Articles/Chimica-Oggi-Chemistry-Today-The-Facilitated-Clinical-Trial-Protocol-Review-Is-the-theory-being.aspx>

Cohen JP. Is Ebola diverting resources from other neglected diseases? *The Conversation*. Online publish date: December 8, 2014. [RS 3438b]
<http://theconversation.com/is-ebola-diverting-resources-from-other-neglected-diseases-34475>

Kaitin KI, editor. CNS drugs take longer to develop, have lower success rates, than other drugs. *Tufts Center for the Study of Drug Development Impact Report*. 2014 Nov/Dec;16(6)** [RS 3438]

Getz KA, Lamberti MJ, Kaitin KI. Taking the pulse of strategic outsourcing relationships. *Clinical Therapeutics*. 2014;36(10):1349-1355. [RS 3437]
<http://dx.doi.org/10.1016/j.clinthera.2014.09.008>

Getz, KA. Is 'Open Integration' beyond our reach?
Applied Clinical Trials. 2014;23(10/11):16,18 [RS 3436b]
<http://www.appliedclinicaltrials.com/open-integration-beyond-our-reach>

Stergiopoulos S, Getz KA. Social listening to enhance clinical research.
Global Forum. 2014;6(5):17-20 [RS 3436]

Cost Study Press Event Webcast and Briefing, November 18, 2014

To access materials related to the Cost Study click here:

http://csdd.tufts.edu/news/complete_story/cost_study_press_event_webcast

Kaitin KI, editor. New directions in clinical study outsourcing practices. *Tufts Center for the Study of Drug Development R&D Management Report*. 2014 Oct;9(4)** [RS 3435]

Kaitin KI. Integrated partnerships and the transformation of pharmaceutical research and development. *Clinical Therapeutics*. 2014;36(10):1346-1348 [RS 3434]
<http://dx.doi.org/10.1016/j.clinthera.2014.09.007>

Cohen JP. Patient access to orphan drugs faces new set of challenges. *Formulary*. Online publish date: September 15, 2014. [RS 3433]
<http://formularyjournal.modernmedicine.com/formulary-journal/news/patient-access-orphan-drugs-faces-new-set-challenges>

Kaitin KI, editor. Protocol design optimization starting to improve study performance. *Tufts Center for the Study of Drug Development Impact Report*. 2014 Sep/Oct;16(5)** [RS 3432]

Von Eschenbach A, Sharp P, Kaitin KI. An Rx for making wonder drugs [Op-Ed]. *Boston Herald*. August 24, 2014:16. [RS 3431]

Cohen JP, Felix AE, Riggs K, Gupta A. Barriers to market uptake of biosimilars in the US. *Generics and Biosimilars Initiative Journal (GaBI Journal)*. 2014;3(3):107-114 [RS 3430]
<http://dx.doi.org/10.5639/gabij.2014.0303.028>

Kaitin KI, editor. Risk-Sharing Partnerships and Alliances: Strategic and operational challenges. *Tufts Center for the Study of Drug Development R&D Management Report*. 2014 Aug;9(3)** [RS 3429]

Kaitin KI, editor. Patients face new challenges accessing a growing number of orphan drugs. *Tufts Center for the Study of Drug Development Impact Report*. 2014 Jul/Aug;16(4)** [RS 3428]

Lamberti MJ, Stergiopoulos S, Naik P, Getz KA. *White paper: Industry Usage of Social and Digital Media Communities in Clinical Research*. Boston: Tufts Center for the Study of Drug Development. June 2014. [RS 3427]
http://csdd.tufts.edu/files/uploads/TCSDD_Social_Media_Final.pdf

Getz K, Birch P, Stergiopoulos S. Adaptive trial design: prepping for adoption. *Pharmaceutical Executive*. 2014;34(6):48. [RS 3426]
<http://www.pharmexec.com/pharmexec/article/articleDetail.jsp?id=845307&pageID=1&sk=&date=>

Cohen JP, Sturgeon G, Cohen A. Measuring progress in neglected disease drug development. *Clinical Therapeutics*. 2014;36(7):1037-1042 [3425]
<http://dx.doi.org/10.1016/j.clinthera.2014.05.004>

Getz K. *The Gift of Participation: A Guide to Making Informed Decisions About Volunteering for a Clinical Trial*. 2nd ed. Boston: CISCRP; 2014 [RS 3424]
<https://www.ciscrp.org/store/books/the-gift-of-participation-a-guide-to-making-informed-decisions-about-volunteering-for-a-clinical-trial/>

Stergiopoulos S. Non-clinical drug development in Asia. *Pharma Focus Asia*. 2014;(20):5-6. [RS 3423]
<http://pharmafocusasia.com/strategy/non-clinical-drug-development-asia.html>

Getz KA. Q&A with Jean Burns: Insights from a study volunteer. *Applied Clinical Trials Online*. Online publish date: May 28, 2014. [RS 3422]
<http://www.appliedclinicaltrials.com/appliedclinicaltrials/Blogs/QampA-With-Jean-Burns-Insights-from-a-Study-Volunt/ArticleStandard/Article/detail/844098>

Lamberti MJ, Getz KA, Naik P, Costello M. Clinical supply capabilities, practices, and perceptions among investigative sites. *Applied Clinical Trials*. 2014;23(8/9):20-24. [RS 3421]
<http://www.appliedclinicaltrials.com/appliedclinicaltrials/Online+Extras/Clinical-Supply-Capabilities-Practices-and-Percept/ArticleStandard/Article/detail/843108>

Getz K. Improving protocol design feasibility to drive drug development economics and performance. *International Journal of Environmental Research and Public Health*. 2014;11(5):5069-5080. [RS 3420]
<http://dx.doi.org/10.3390/ijerph110505069>

Urban L, Valentin JP, Kaitin KI, Wang J. Current social, clinical, and scientific environment of pharmaceutical R&D. In: Wang J, Urban L, eds. *Predictive ADMET: Integrated approaches in drug discovery and development*. Hoboken, NJ: Wiley; 2014:3-21. [RS 3419]
<http://dx.doi.org/10.1002/9781118783344.ch1>

Kaitin KI, editor. Collaboration & risk-sharing programs experience longer development times. *Tufts Center for the Study of Drug Development Impact Report*. 2014 May/Jun;16(3)** [RS 3418]

Getz KA. Coming to terms with interrupted drug development programs. *Applied Clinical Trials*. 2014;23(4/5):22-23. [RS 3417b]
<http://www.appliedclinicaltrials.com/appliedclinicaltrials/Trial+Design+Articles/Coming-to-Terms-with-Interrupted-Drug-Development-/ArticleStandard/Article/detail/840065>

Milne C-P, Garafalo S, Bryan C, McKiernan M. Trial watch: personalized medicines in late-stage development. *Nature Reviews Drug Discovery*. 2014;13(5):324–325. [RS 3417]
<http://dx.doi.org/10.1038/nrd4325>

Evens RP, Kaitin KI. The biotechnology innovation machine: a source of intelligent biopharmaceuticals for the pharma industry—Mapping biotechnology’s success. *Clinical Pharmacology & Therapeutics*. 2014;95(5): 528–532. [RS 3416]
<http://dx.doi.org/10.1038/clpt.2014.14>

Getz KA. Opportunities to optimize study design to drive development performance and efficiency. *Clinical Researcher*. 2014;28(1):28-31. [RS 3415]
<http://www.acrpnet.org/MainMenuCategory/Resources/Clinical-Researcher/April-2014.aspx>

DiMasi JA, Milne C-P, Tabarrok A. An FDA report card: wide variance in performance found among agency’s drug review divisions. *Project FDA Report*. No. 7, April 2014; Manhattan Institute for Policy Research. [RS 3414]
http://www.manhattan-institute.org/html/fda_07.htm#.U1_t61dUinw

Christini A, Kaitin K. Regional trends in bioinnovation investment. *Pharmaceutical Executive*. 2014;34(4):43-46. [RS 3413]
<http://www.pharmexec.com/pharmexec/Strategy/Regional-Trends-in-Bioinnovation-Investment/ArticleStandard/Article/detail/840194>

Milne CP, editor of compilation. *FDA Trends: Path to Approval*. Boston: Tufts Center for the Study of Drug Development; 2014 [RS 3412]
<http://csdd.tufts.edu/reports/ebooks>

Kaitin KI, editor. Predictors of clinical success to boost success rates. *Tufts Center for the Study of Drug Development R&D Management Report*. 2014 Apr;9(2)** [RS 3411]

Cohen JP, Felix AE. Personalized medicine's bottleneck: diagnostic test evidence and reimbursement. *Journal of Personalized Medicine*. 2014;4(2):163-175. [RS 3410]
<http://dx.doi.org/10.3390/jpm4020163>

Smed M, Getz KA. Site characteristics influencing the translation of clinical research into clinical practice. *Therapeutic Innovation & Regulatory Science*. 2014;48(5):628-634. [RS 3409]
<http://dx.doi.org/10.1177/2168479014525957>

Kaitin KI, editor. Drug sponsors tread cautiously using social media to aid clinical research. *Tufts Center for the Study of Drug Development Impact Report*. 2014 Mar/Apr;16(2)** [RS 3408]

Milne C-P, Davis J. The Pediatric studies initiative: after 15 years have we reached the limits of the law? *Clinical Therapeutics*. 2014;36(2):156-162. [RS 3407]
<http://dx.doi.org/10.1016/j.clinthera.2013.11.007>

Cohen JP, Felix A. Complying with state and federal regulations on essential drug benefits: implementing the Affordable Care Act. *American Journal of Managed Care*. 2014;20(2):31-36. [RS 3406]
<http://www.ajmc.com/publications/issue/2014/2014-vol20-n2/Complying-With-State-and-Federal-Regulations-on-Essential-Drug-Benefits-Implementing-the-Affordable-Care-Act>

Getz KA, Stergiopoulos S. Therapeutic area variability in the collection of data supporting protocol end points and objectives. *Clinical Investigation*. 2014;4(2):125-130. [RS 3405]
<http://dx.doi.org/10.4155/cli.13.134>

DiMasi JA, Kim J, Getz KA. The impact of collaborative and risk-sharing innovation approaches on clinical and regulatory cycle times. *Therapeutic Innovation & Regulatory Science*. 2014;48(4): 482-487 [RS 3404]
<http://dx.doi.org/10.1177/2168479014521419>

Kaitin KI, editor. New breakthrough therapy designation program aims to cut clinical trial time. *Tufts Center for the Study of Drug Development Impact Report*. 2014 Jan/Feb;16(1)** [RS 3403]

Kaitin KI, editor. Enhancing product value through comparator and co-therapy clinical trials. *Tufts Center for the Study of Drug Development R&D Management Report*. 2014 Jan;9(1)** [RS 3402]

Milne CP. Prospects for rapid advances in the development of new medicines for special medical needs. *Clinical Pharmacology & Therapeutics*. 2014;95(1):98-109. [RS 3401b] <http://dx.doi.org/10.1038/clpt.2013.155>

**This publication is for sale at our website <http://csdd.tufts.edu/reports>

Cohen JP, Felix A. Are payers treating orphan drugs differently? *Journal of Market Access & Health Policy*. 2014;2:1-5. [RS 3401]
<http://dx.doi.org/10.3402/jmahp.v2.23513>

Outlook 2014. Boston: Tufts Center for the Study of Drug Development, 2014 [RS 3400]

Millier A, Cohen JP, Toumi M. Economic impact of a triptan Rx-to-OTC switch in six EU countries. *PLoS ONE*. 2013;8(12):e84088. [RS 3345]
<http://dx.doi.org/10.1371/journal.pone.0084088>

Selker HP, Oye KA, Eichler H-G, Stockbridge NL, Mehta CR, Kaitin KI, McElwee NE, Honig PK, Erban JK, D'Agostino RB. A proposal for integrated efficacy-to-effectiveness (E2E) clinical trials. *Clinical Pharmacology & Therapeutics*. 2014;95(2):147-153; Epub 2013 Sep 23. [RS 3344]
<http://dx.doi.org/10.1038/clpt.2013.177>

Kaitin KI. Is The Prescription Drug Pipeline Too Slow? [Cognoscenti: Policy for a Healthy America Series]. WBUR, Boston's NPR® News Station. December 18, 2013. [RS 3343]
<http://cognoscenti.wbur.org/2013/12/18/series-prescription-drug-pipeline-sidney-wolfe-kenneth-kaitin>

Kaitin KI, editor. *A new tool for predicting marketing approval of oncology drugs* Boston: Tufts Center for the Study of Drug Development; 2013. R&D Senior Leadership Brief. [DiMasi, Getz, Stergiopoulos] [RS 3342b]
http://csdd.tufts.edu/files/uploads/CSDD-Janssen_Oncology_Predictive_Tool.pdf

Cohen JP. European warning raises question on access to Plan B [letter to the editor]. *The Boston Globe*. December 4, 2013:A14. [RS 3342]
<http://www.bostonglobe.com/opinion/editorials/2013/12/04/european-warning-raises-question-access-plan/u745CxwZFtbva2coT4t19J/story.html>

Getz KA. Adoption of adaptive trial designs poised to accelerate. *Applied Clinical Trials*. 2013;22(11):16-18. [RS 3341]
<http://www.appliedclinicaltrials.com/appliedclinicaltrials/article/articleDetail.jsp?id=828039>

Kaitin KI, editor. Biotech products in Big Pharma clinical pipelines have grown dramatically. *Tufts Center for the Study of Drug Development Impact Report*. 2013 Nov/Dec;15(6)** [RS 3340]

Getz KA, Campo R. Drug development study designs have reached the danger zone. *Expert Review of Clinical Pharmacology*. 2013;6(6):589-591. [RS 3338]
<http://dx.doi.org/10.1586/17512433.2013.841539>

Getz KA. Leveraging pharmacists as a channel to raise clinical research literacy among patient communities. *Applied Clinical Trials*. 2013;22(10):30-33.

[RS 3337]

<http://www.appliedclinicaltrials.com/appliedclinicaltrials/Articles/Leveraging-Pharmacists-as-a-Channel-to-Raise-Clini/ArticleStandard/Article/detail/825673>

Lamberti MJ, Naik P, Stergiopoulos S, Kim J, Getz KA. Characterizing the global market for Contract R&D Services. *Chimica Oggi [Chemistry Today]: Monograph Supplement Series CROs/CMOs*. 2013;31(4):9-13. [RS 3336]

<http://www.teknoscienze.com/Articles/Chimica-Oggi-Chemistry-Today-Characterizing-the-global-market-for-Contract-R-amp-D-Services.aspx#.Ul6Pq1Ckqn4>

Kaitin KI, editor. Outsourcing to maximize clinical trial operating efficiency. *Tufts Center for the Study of Drug Development R&D Management Report*. 2013 Oct;8(4)** [RS 3335]

Getz KA, Kim J, Stergiopoulos S, Birch P. Flexible, global, more adaptive: clinical trials 2.0. *Scrip100: 2014*. 2013:38-39. [RS 3334]

<http://www.scripintelligence.com/home/Flexible-global-more-adaptive-clinical-trials-2.0-346528>

Kaitin KI, Honig PK, guest editors. Reinventing bioinnovation. *Clinical Pharmacology & Therapeutics*. 2013;94(3). [RS 3333b] *Includes:* Kaitin KI, Honig PK. Reinventing bioinnovation: 279-283 [RS 3333]; DiMasi JA, Reichert JM, Feldman L, Malins A. Clinical approval success rates for investigational cancer drugs: 329-335. [RS 3328].

Kaitin KI, Honig PK. Reinventing bioinnovation. *Clinical Pharmacology & Therapeutics*. 2013;94(3):279-283. [RS 3333]

<http://dx.doi.org/10.1038/clpt.2013.129>

Kaitin KI, editor. Causes of clinical failures vary widely by therapeutic class, phase of study. *Tufts Center for the Study of Drug Development Impact Report*. 2013 Sep/Oct;15(5)** [RS 3332]

Getz KA. Lifting up a fragmented study conduct landscape. *Applied Clinical Trials*. 2013; 22(7/8):22,24. [RS 3331]

<http://www.appliedclinicaltrials.com/appliedclinicaltrials/Articles/Lifting-Up-a-Fragmented-Study-Conduct-Landscape/ArticleStandard/Article/detail/820680>

Kaitin KI, editor. New approaches to risk-sharing collaborations. *Tufts Center for the Study of Drug Development R&D Management Report*. 2013 Aug;8(3)** [RS 3330]

Cohen JP, Milne C-P. Is the increasing cost of treating rare diseases sustainable? *Expert Opinion on Orphan Drugs*. 2013;1(8): 581-583. [RS 3329]
<http://dx.doi.org/10.1517/21678707.2013.819289>

DiMasi JA, Reichert JM, Feldman L, Malins A. Clinical approval success rates for investigational cancer drugs. *Clinical Pharmacology & Therapeutics*. 2013; 94(3): 329-335. [RS 3328]
<http://dx.doi.org/10.1038/clpt.2013.117>

Malins A, Milne CP. Population dynamics, demographics, and disease burden of infants and children across the world. In: Mulberg AE, Murphy D, Dunne D & Mathis LL, eds. *Pediatric Drug Development*. 2nd ed. Singapore: John Wiley & Sons, Inc.; 2013:16-36. [RS 3327]
<http://www.wiley.com/WileyCDA/WileyTitle/productCd-1118312155.html>

Milne CP, Malins A. Pharmaceutical economics and market access for pediatric medicines. In: Mulberg AE, Murphy D, Dunne D & Mathis LL, eds. *Pediatric Drug Development*. 2nd ed. Singapore: John Wiley & Sons, Inc.; 2013:37-56. [RS 3326]
<http://www.wiley.com/WileyCDA/WileyTitle/productCd-1118312155.html>

Kaitin KI, editor. Annual approvals for neglected diseases rose from 2.6 in 2000-08 to 5 in 2009-12. *Tufts Center for the Study of Drug Development Impact Report*. 2013 Jul/Aug;15(4)** [RS 3325]

Getz KA, Kim J, Stergiopoulos S, Kaitin KI. New governance mechanisms to optimize protocol design. *Therapeutic Innovation & Regulatory Science*. 2013;47(6):651-655. [RS 3324]
<http://dx.doi.org/10.1177/2168479013494386>

Milne CP. On the partnering path from the US to Asia: how far, how fast for university-industry collaborations? *Pharma Focus Asia*. 2013;(18):40-45. [RS 3323]
<http://www.pharmafocusasia.com/strategy/partnering-path-us-asia>

Stergiopoulos S, Kim J, Getz KA. Characterizing the cost of non-clinical development activity: understanding a critical R&D segment. *Contract Pharma*. 2013;15(5):70-73. [RS 3322]
http://www.contractpharma.com/issues/2013-06/view_features/characterizing-the-cost-of-non-clinical-development-activity/

DiMasi JA. Innovating by developing new uses of already-approved drugs: trends in the marketing approval of supplemental indications. *Clinical Therapeutics*. 2013;35(6):808-818. [RS 3321]
<http://dx.doi.org/10.1016/j.clinthera.2013.04.004>

Milne CP, Mitra J. Is translational medicine the future of therapy? In: Mitra J, Milne CP, eds. *Translational Medicine: The Future of Therapy?* Singapore: Pan Stanford Publishing Pte. Ltd.; 2013:259-273. [RS 3320d]

Milne CP, Kohn C. Translational medicine: the industry perspective. In: Mitra J, Milne CP, eds. *Translational Medicine: The Future of Therapy?* Singapore: Pan Stanford Publishing Pte. Ltd.; 2013:55-80. [RS 3320c]

Mitra J, Milne CP. Introduction to translational medicine. In: Mitra J, Milne CP, eds. *Translational Medicine: The Future of Therapy?* Singapore: Pan Stanford Publishing Pte. Ltd.; 2013:3-16. [RS 3320b]

Mitra J, Milne CP, eds. *Translational Medicine: The Future of Therapy?* Singapore: Pan Stanford Publishing Pte. Ltd.; 2013. [RS 3320]
<http://www.panstanford.com/books/9789814316996.html>

Kaitin KI, editor. *The adoption and impact of adaptive trial design*. Boston: Tufts Center for the Study of Drug Development; 2013. R&D Senior Leadership Brief. [Getz, Stergiopoulos, Kim] [RS 3319]
http://csdd.tufts.edu/files/uploads/tuftscsddbrieffinal_new.pdf

Lamberti MJ, Walsh T, Getz KA. Tracking trial cost drivers: the impact of comparator drugs and co-therapies. *Pharmaceutical Executive*. 2013;33(5):34-37. [RS 3318]
<http://images2.advanstar.com/PixelMags/pharma-executive/digitaledition/05-2013.html#38>

Kaitin KI, editor. Clinical success rates for new cancer drugs double while more enter testing. *Tufts Center for the Study of Drug Development Impact Report*. 2013 May/Jun;15(3)** [RS 3317]

Cohen JP, Millier A, Karray S, Toumi M. Assessing the economic impact of Rx-to-OTC switches: systematic review and guidelines for future development. *Journal of Medical Economics*. 2013;16(6):835-844 [RS 3316]
<http://dx.doi.org/10.3111/13696998.2013.793693>

Getz KA. Building clinical trial awareness for patients: why not try the pharmacist? *Pharmaceutical Executive*. Published March 1, 2013 [web document] [RS 3315]
<http://www.pharmexec.com/pharmexec/Strategy/Building-Clinical-Trial-Awareness-for-Patients-Why/ArticleStandard/Article/detail/808517?contextCategoryId=43776&ref=25&utm>

Cohen JP. Think twice about how we let overseas use of Plan B guide us [letter to the editor]. *The Boston Globe*. April 21, 2013:K8. [RS 3314]
<http://www.bostonglobe.com/opinion/letters/2013/04/20/think-twice-about-how-let-overseas-use-plan-guide/u5LiSuwzufnOKxiAlzvjkK/story.html>

**This publication is for sale at our website <http://csdd.tufts.edu/reports>

Kaitin KI, editor. Optimizing protocol design to improve clinical study performance, efficiency, and cost. *Tufts Center for the Study of Drug Development R&D Management Report*. 2013 Apr;8(2)** [RS 3313]

Cohen JP, Malins A, Shahpurwala Z. Compared to US practice, evidence-based reviews in Europe appear to lead to lower prices for some drugs. *Health Affairs*. 2013;32(4):762-770 [RS 3312]
<http://dx.doi.org/10.1377/hlthaff.2012.0707>

Cohen JP. Comparative-effectiveness research: does it matter? *Clinical Therapeutics*. 2013;35(4):371-379 [RS 3311]
<http://dx.doi.org/10.1016/j.clinthera.2012.12.018>

Smed M, Getz KA. Unfulfilled translation opportunities in industry sponsored clinical trials. *Contemporary Clinical Trials*. 2013;35:80-86. [RS 3310]
<http://dx.doi.org/10.1016/j.cct.2013.02.007>

Getz KA. Impact of in-pharmacy education on patients' knowledge and attitudes about clinical trials. *Therapeutic Innovation & Regulatory Science*. 2013; 47(3):336-340. [RS 3309]
<http://dx.doi.org/10.1177/2168479013478953>

Kaitin KI, editor. Global site landscape remains highly fragmented with variable performance. *Tufts Center for the Study of Drug Development Impact Report*. 2013 Mar/Apr;15(2)** [RS 3308]

Getz KA, Stergiopoulos S, Marlborough M, Whitehill J, Curran M, Kaitin KI. Quantifying the magnitude and cost of collecting extraneous protocol data. *American Journal of Therapeutics*. 2013. [Published Ahead-of-Print; Last Updated: April 9, 2013] [RS 3307]
<http://dx.doi.org/10.1097/MJT.0b013e31826fc4aa>

Getz KA. Has the study coordinator landscape reached a tipping point? *Forté Research Systems: Clinical Research Blog*. January 29, 2013. [RS 3306b]
<http://forteresearch.com/news/study-coordinator-landscape/>

Lamberti MJ, Getz KA. The scoop on drug shortages. *Pharmaceutical Executive*. 2013;33(1):24-27. [RS 3306]
<http://www.pharmexec.com/pharmexec/Strategy/The-Scoop-on-Drug-Shortages/ArticleStandard/Article/detail/803316>

Getz KA. Assessing global CRA workload and utilization. *ACRP Monitor*. 2013;27(1):11-18. [RS 3305]

DiMasi JA. Pharmaceutical R&D performance by firm size: approval success rates and economic returns. *American Journal of Therapeutics*. 2014;21(1):26-34 [Published Ahead-of-Print: January 24, 2013] [RS 3304]
<http://dx.doi.org/10.1097/MJT.0b013e318269198f>

Kaitin KI, editor. Development strategies for companion diagnostics. *Tufts Center for the Study of Drug Development R&D Management Report*. 2013 Jan;8(1)** [RS 3303]

Kaitin KI, editor. 89% of trials meet enrollment, but timelines slip, half of sites under-enroll. *Tufts Center for the Study of Drug Development Impact Report*. 2013 Jan/Feb;15(1)** [RS 3302]

Lamberti MJ, Brothers C, Manak D, Getz KA. Benchmarking the study initiation process. *Therapeutic Innovation & Regulatory Science*. 2013;47(1):101-109 [RS 3301]
<http://dx.doi.org/10.1177/2168479012469947>

Outlook 2013. Boston: Tufts Center for the Study of Drug Development, 2013 [RS 3300]

Getz KA. Op/ed: A way for biopharma to disclose more trial data [editorial]. *Medical Marketing and Media*. 2012 Dec 26. [web document] [RS 3240]
<http://www.mmm-online.com/oped-a-way-for-biopharma-to-disclose-more-trial-data/article/273868>.

Tilles SA, Borish L, Cohen JP. Management of hereditary angioedema in 2012: scientific and pharmacoeconomic perspectives. *Annals of Allergy, Asthma & Immunology*. 2013;110(2):70-74. [RS 3239]
<http://dx.doi.org/10.1016/j.anai.2012.11.014>

Martell RE, Sermer D, Getz K, Kaitin KI. Oncology drug development and approval of systemic anticancer therapy by the U.S. Food and Drug Administration. *The Oncologist*. 2013;18(1):104-111; (first published on December 20, 2012). [RS 3238]
<http://dx.doi.org/10.1634/theoncologist.2012-0235>

Getz KA. Perils and promise of risk imbalance. *Inside Outsourcing*. 2012;(December):10-16 [RS 3237]
http://www.nxtbook.com/nxtbooks/advanstar/insideoutsourcing_201212/index.php

Kaitin KI, Cohen JP. Weighing access and affordability. *Pharmaceutical Technology*. 2012; 36(9):30 [RS 3236]
<http://www.pharmtech.com/pharmtech/Ingredients/Weighing-Access-and-Affordability/ArticleStandard/Article/detail/787881>

Kaitin KI, editor. One in five procedures generates extraneous clinical trials data *Tufts Center for the Study of Drug Development Impact Report*. 2012 Nov/Dec;14(6)** [RS 3235]

Getz KA, Kaitin KI. Open innovation: the new face of pharmaceutical research and development. *Expert Review of Clinical Pharmacology*. 2012;5(5):481-483 [RS 3234]
<http://dx.doi.org/10.1586/ecp.12.44>

Reichert JM. What's special about peptide therapeutics development? *Journal of Molecular Neuroscience*. 2012; 48(Suppl 1): S186 [RS 3233b]
<http://dx.doi.org/10.1007/s12031-012-9803-8>

Kaitin KI, editor. The technical and support services outsourcing landscape. *Tufts Center for the Study of Drug Development R&D Management Report*. 2012 Oct;7(4)** [RS 3233]

Getz KA, Stergiopoulos S, Kaitin KI. Evaluating the completeness and accuracy of MedWatch data. *American Journal of Therapeutics*. 2014;21(6):442-446 [RS 3232] (Note: originally available online in 2012)
<http://dx.doi.org/10.1097/MJT.0b013e318262316f>

Milne C-P. New drugs for predicted cancer epidemic: who will lead the way? *Regulatory Rapporteur*. 2012;9(10):10-11 [RS 3231]
<http://www.topra.org/regulatory-rapporteur-oct-2012>

Stergiopoulos S, Getz KA. Mapping and characterizing the development pathway from non-clinical through early clinical drug development. *Pharmaceutical Medicine*. 2012;26(5):297-307 [RS 3230]
<http://dx.doi.org/10.1007/BF03262374>

Lamberti MJ, Costello M, Getz K. Global supply chain management *Applied Clinical Trials* 2012;21(9):36-38,40-42 [RS3229b]
<http://www.appliedclinicaltrials.com/global-supply-chain-management>

Kaitin KI, editor. Oncology drugs get faster approvals than non-oncology drugs in the U.S. *Tufts Center for the Study of Drug Development Impact Report*. 2012 Sep/Oct;14(5)** [RS 3229]

Kaitin KI. Translational research and the evolving landscape for biomedical innovation. *Journal of Investigative Medicine*. 2012;60(7):995-998 [RS 3228]
<http://dx.doi.org/10.231/JIM.0b013e318268694f>

Cohen JP. Evaluating the impact of Medicare Part D on quality metrics. *Expert Review of Pharmacoeconomics & Outcomes Research*. 2012;12(3):271-273 [RS 3227]
<http://dx.doi.org/10.1586/erp.12.25>

**This publication is for sale at our website <http://csdd.tufts.edu/reports>

Kaitin KI, editor. Making academic-industry partnerships work for both parties. *Tufts Center for the Study of Drug Development R&D Management Report*. 2012 Aug;7(3)** [RS 3226]

Lamberti MJ, Mathias A, Myles JE, Howe D, Getz K. Evaluating the impact of patient recruitment and retention practices. *Drug Information Journal*. 2012;46(5):573-580 [RS 3225]
<http://dx.doi.org/10.1177/0092861512453040>

Kaitin KI, editor. U.S. offers patients faster, greater access to cancer drugs than Europe. *Tufts Center for the Study of Drug Development Impact Report*. 2012 Jul/Aug;14(4)** [RS 3224]

Milne C-P, Malins A, Namita J. The biopharmaceutics classification system: canary in the coal mine for regulatory science! *American Pharmaceutical Review*. Published July 17, 2012. [web document] [RS 3223]
<http://www.americanpharmaceuticalreview.com/Featured-Articles/115933-The-Biopharmaceutics-Classification-System-Canary-in-the-Coal-Mine-for-Regulatory-Science/>

Orfali M, Feldman L, Bhattacharjee V, Harkins P, Kadam S, Lo C, Ravi M, Shringarpure DT, Mardekian J, Cassino C, Coté T. Raising orphans: how clinical development programs of drugs for rare and common diseases are different. *Clinical Pharmacology & Therapeutics*. 2012;92(2):262-264 [RS 3222]
<http://dx.doi.org/10.1038/clpt.2012.87>

Getz KA, Kaitin KI. Transforming pharmaceutical R&D through integrated and open partnerships. *Global Forum*. 2012;4(3):16-21 [RS 3221]

Milne C-P. Innovation boom towns. *Pharmaceutical Technology*. 2012;36(6):30 [RS 3220]
http://digital.findpharma.com/nxtbooks/advanstar/pt_201206/#/30

Malins A, Milne C-P. Application of biopharmaceutics classification system in drug development. *Pharma Focus Asia*. 2012;(16):24-31 [RS 3219]
http://www.pharmafocusasia.com/research_development/application-Biopharmaceutics-Classification-System-Drug-Development.htm

Getz K, Lamberti MJ, Mathias A, Stergiopoulos S. Resizing the global contract R&D services market. *Contract Pharma*. 2012;14(5):54-62 [RS 3218]
http://www.contractpharma.com/issues/2012-06/view_features/resizing-the-global-contract-rd-services-market/

Getz KA. Outsourcing landscape. *Applied Clinical Trials*. 2012; 21(5)(suppl):S22-S26 [RS 3217]
<http://www.appliedclinicaltrials.com/appliedclinicaltrials/Feature+Article/Outsourcing-Landscape/ArticleStandard/Article/detail/772232>

**This publication is for sale at our website <http://csdd.tufts.edu/reports>

Kaitin KI, editor. User fee era in U.S. currently poses mixed regulatory burden for sponsors. *Tufts Center for the Study of Drug Development Impact Report*. 2012 May/Jun;14(3)** [RS 3216]

Reichert JM, Dhimolea E. Foundation review: the future of antibodies as cancer drugs. *Drug Discovery Today*. 2012;17(17/18):954-963[RS 3215c]
<http://dx.doi.org/10.1016/j.drudis.2012.04.006>

Reichert JM. Marketed therapeutic antibodies compendium. *mAbs*. 2012;4(3):413-415 [RS 3215b]
<http://dx.doi.org/10.4161/mabs.19931>

Kaitin KI, editor. Managing the transition from nonclinical to early clinical development. *Tufts Center for the Study of Drug Development R&D Management Report*. 2012 Apr;7(2)** [RS 3215]

DiMasi JA, Grabowski HG. R&D costs and returns to new drug development: a review of the evidence. In: Danzon PM, Nicholson S, eds. *The Oxford Handbook of The Economics of the Biopharmaceutical Industry*. Oxford: Oxford University Press; 2012:21-46 [RS 3214]

Milne C-P, Malins A. *White paper: Academic-industry partnerships for biopharmaceutical research & development: advancing medical science in the U.S.* Boston: Tufts Center for the Study of Drug Development. April 2012 [RS 3213]
http://csdd.tufts.edu/files/uploads/tuftscsdd_academic-industry.pdf

Getz K, Hallinan Z, Simmons D, Brickman MJ, Jumadilova Z, Pauer L, Wilenzick M, Morrison B. Meeting the obligation to communicate clinical trial results to study volunteers. *Expert Review of Clinical Pharmacology*. 2012;5(2):149-156 [RS 3212b]
<http://dx.doi.org/10.1586/ecp.12.7>

Milne C-P. Defining conflict of interest. *Pharmaceutical Technology*. 2012;36(3):38 [RS 3212]
<http://www.pharmtech.com/pharmtech/article/articleDetail.jsp?id=763940&sk=&date=&&pageID=1>

Cohen JP. Can after-birth abortion do harm?: a response to After-birth abortion: why should the baby live? [published online first: February 23, 2012]. *Journal of Medical Ethics* 2012 [RS 3211]
<http://dx.doi.org/10.1136/medethics-2011-100411>

Cohen JP. Overcoming regulatory and economic challenges facing pharmacogenomics. *New Biotechnology*. 2012;29(6):751-756 [RS 3210]
<http://dx.doi.org/10.1016/j.nbt.2012.02.001>

Wilson AW, Neumann PJ. The cost-effectiveness of biopharmaceuticals: a look at the evidence. *mAbs*. 2012;4(2):281-288 [RS 3209]
<http://dx.doi.org/10.4161/mabs.4.2.18812>

Shader RI, Milne C-P. The use of generic drugs in pediatric psychopharmacology. In: Rosenberg DR, Gershon S, eds. *Pharmacotherapy of child and adolescent psychiatric disorders*. 3rd ed. Hoboken, NJ: Wiley; 2012:39-50 [RS 3208]

Kaitin KI, editor. Pace of CNS drug development and FDA approvals lags other drug classes. *Tufts Center for the Study of Drug Development Impact Report*. 2012 Mar/Apr;14(2)** [RS 3207]

Getz KA. Profound changes in the outsourcing landscape. *Pharmaceutical Executive*. Published February 29, 2012. [web document] [RS 3206]
<http://www.pharmexec.com/pharmexec/Outsourcing/Profound-Changes-in-the-Outsourcing-Landscape/ArticleStandard/Article/detail/762383>

Zuckerman R, Milne C-P. Market watch: industry perspectives on personalized medicine. *Nature Reviews Drug Discovery*. 2012;11(3):178. [RS 3205]
<http://dx.doi.org/10.1038/nrd3677>

Milne C-P, Kaitin KI. FDA review divisions: performance levels and the impact on drug sponsors. *Clinical Pharmacology & Therapeutics*. 2012;91(3):393-404 [RS 3204]
<http://dx.doi.org/10.1038/clpt.2011.338>

Feldman L, Milne C-P. Current landscape of orphan product developers. *Global Forum*. 2012;4(1):40-43 [RS 3203]

Lamberti MJ, Costello M, Getz K. Trends and novel approaches to clinical supply outsourcing: how are sponsor/provider relationships changing? *Contract Pharma*. 2012;14(1):40-43 [RS 3202b]
http://www.contractpharma.com/issues/2012-01/view_features/trends-and-novel-approaches-to-clinical-supply-outsourcing/

Kaitin KI, editor. Resource management strategies to optimize R&D performance. *Tufts Center for the Study of Drug Development R&D Management Report*. 2012 Jan;7(1)** [RS 3202]

Kaitin KI, editor. Study monitor workload high & varied with wide disparity by global region. *Tufts Center for the Study of Drug Development Impact Report*. 2012 Jan/Feb;14(1)** [RS 3201]

Outlook 2012. Boston: Tufts Center for the Study of Drug Development, 2012 [RS 3200]

Wilson A, Milne C-P. FDA's risk evaluation and mitigation strategies (REMS): effective safety tools or process poltergeist? *Food and Drug Law Journal*. 2011;66(4):569-586 [RS 3132b]

[http://www.fdpi.org/resources/resources-order-box-detail-view/fda's-risk-evaluation-and-mitigation-strategies-\(rems\)-effective-and-efficient-safety-tools-or-process-poltergeist-66-food-and-drug-law-journal-569-586-\(2011\)](http://www.fdpi.org/resources/resources-order-box-detail-view/fda's-risk-evaluation-and-mitigation-strategies-(rems)-effective-and-efficient-safety-tools-or-process-poltergeist-66-food-and-drug-law-journal-569-586-(2011))

Kaitin KI. Creating innovation nodes to meet unmet medical needs. *Pharmaceutical Technology*. 2011;35(12):27 [RS 3132]

<http://pharmtech.findpharma.com/pharmtech/Formulation/Creating-Innovation-Nodes-to-Meet-Unmet-Medical-Ne/ArticleStandard/Article/detail/751287>

Getz KA. Transforming legacy R&D through open innovation. *ACRP Monitor*. 2011;25(7):17-21 [RS 3131b]

Cohen JP, Christensen K, Feldman L. Disease management and medication compliance. *Population Health Management*. 2012;15(1):20-28 [RS 3131]

<http://dx.doi.org/10.1089/pop.2011.0020>

Kaitin KI, editor. New mAbs entering clinical study rose steadily from 1997 through 2010. *Tufts Center for the Study of Drug Development Impact Report*. 2011 Nov/Dec;13(6)** [RS 3130]

Getz KA. Profound shifts in outsourcing landscape. *Inside Outsourcing*. 2011 Nov;10-15 [RS 3129b]

http://digital.findanalytichem.com/nxtbooks/advanstar/insideoutsourcing_201111/index.php/

Kaitin KI, editor. Designing and maintaining successful innovation partnerships. *Tufts Center for the Study of Drug Development R&D Management Report*. 2011 Oct;6(4)** [RS 3129]

Kaitin KI, editor. Nearly 60% of all protocols require amendments; one-third are avoidable. *Tufts Center for the Study of Drug Development Impact Report*. 2011 Sep/Oct;13(5)** [RS 3128]

Cohen JP, Wilson A, Manzillo K. Clinical and economic challenges facing pharmacogenomics. *Pharmacogenomics Journal*. 2012 Jan 10;13(4):378-388. [RS 3127b]

<http://dx.doi.org/10.1038/tpj.2011.63>

Wilson A, Cohen J. Patient access to new cancer drugs in the United States and Australia. *Value in Health*. 2011;14:944-952 [RS 3127]

<http://dx.doi.org/10.1016/j.jval.2011.05.004>

Beck A, Reichert JM. Therapeutic fc-fusion proteins and peptides as successful alternatives to antibodies. *MAbs*. 2011;3(5):415-416 [RS 3126c]
<http://dx.doi.org/10.4161/mabs.3.5.17334>

Milne C-P. The case for pediatric exclusivity. *BioPharm International*. 2011;24(12):57-58 [RS 3126b]
<http://www.biopharminternational.com/biopharm/Final+Word/The-Case-for-Pediatric-Exclusivity/ArticleStandard/Article/detail/750858>

Milne C-P. The case for pediatric exclusivity. *Pharmaceutical Technology*. 2011;35(9):38 [RS 3126]
<http://pharmtech.findpharma.com/pharmtech/Drug+Delivery/The-Case-for-Pediatric-Exclusivity/ArticleStandard/Article/detail/738366>

Cohen J. Dearth of clinically useful diagnostics limits growth of personalized medicine. *Expert Review of Clinical Pharmacology*. 2011;4(5):527-529 [3125b]
<http://dx.doi.org/10.1586/ecp.11.45>

Milne C-P, Zuckerman R. Biopharmaceutical industry perspectives on the business prospects for personalized medicine. *Personalized Medicine*. 2011;8(5):541-550 [RS 3125]
<http://dx.doi.org/10.2217/pme.11.51>

Kaitin KI, editor. Management implications of the global regulatory environment. *Tufts Center for the Study of Drug Development R&D Management Report*. 2011 Aug;6(3)** [RS 3124]

Kaitin KI, Milne C-P. A dearth of new meds. *Scientific American*. 2011;305(2):16 [RS 3123]
<http://dx.doi.org/10.1038/scientificamerican0811-16>

Reichert JM. Bispecific antibodies and ADCs: once and future kings. *mAbs*. 2011;3(4):329-330; doi.org/10.4161/mabs.3.4.16589 [RS 3122b]
<http://dx.doi.org/10.4161/mabs.3.4.16589>

Kaitin KI, editor. Lack of clinically useful diagnostics hinder growth in personalized medicines. *Tufts Center for the Study of Drug Development Impact Report*. 2011 Jul/Aug;13(4)** [RS 3122]

Getz KA, Campo RA, Kaitin KI. Variability in protocol design complexity by phase and therapeutic area. *Drug Information Journal*. 2011;45(4):413-420 [RS 3121]
<http://dx.doi.org/10.1177/009286151104500403>

Simmons D, Chappell J, Getz K, Hallinan Z. Are pharmacists a viable channel for education about clinical trial participation? *Drug Information Journal*. 2011;45(4):443-453 [RS 3120]
<http://dx.doi.org/10.1177/009286151104500406>

Getz, KA. Transforming R&D through open innovation. *Applied Clinical Trials*. 2011;20(7):28-29 [RS 3119 b]
<http://appliedclinicaltrialsonline.findpharma.com/appliedclinicaltrials/article/articleDetail.jsp?id=730576>

Kaitin KI. 21st Century innovation: academic-industry partnerships are increasingly important in biopharmaceutical innovation. *Pharmaceutical Technology*. 2011;35(6):32 [RS 3119]
<http://pharmtech.findpharma.com/pharmtech/article/articleDetail.jsp?id=724982&sk=&date=&&pageID=1>

Cohen JP. America's patient access scheme: coverage with evidence development. *EMAUD Market Access Newsletter*. 2011;3:2-3 [RS 3118]
http://www.emaud.org/Doc/Market_Access_Newsletter_EMAUD_June%202011.pdf

Kaitin KI, editor. Biopharmaceutical product approvals in the U.S. rose dramatically in 2000s. *Tufts Center for the Study of Drug Development Impact Report*. 2011 May/Jun;13(3)** [RS 3117]

Reichert JM. The amazing, multipurpose antibody. *mAbs*. 2011;3(3):22 1-222. [RS 3116b]
<http://dx.doi.org/10.4161/mabs.3.3.15625>

Cohen JP. Personalized medicine: Are payers the weak link? *Personalized Medicine*. 2011;8(3):293-296 [RS 3116]
<http://dx.doi.org/10.2217/pme.11.38>

Lamberti M, Zuckerman R, Howe D, Shapiro L, Getz K. Factors influencing investigative site willingness and ability to participate in clinical trials. *Drug Information Journal*. 2011;45(3):377-390 [RS 3115]
<http://dx.doi.org/10.1177/009286151104500316>

Getz KA, Zuckerman R, Cropp AB, Hindle AL, Krauss R, Kaitin KI. Measuring the incidence, causes, and repercussions of protocol amendments. *Drug Information Journal*. 2011;45(3):265-275 [RS 3114]
<http://dx.doi.org/10.1177/009286151104500307>

Getz KA. Protocol amendments: a costly solution. *Applied Clinical Trials*. 2011;20(5):28-30 [RS 3113]
<http://appliedclinicaltrialsonline.findpharma.com/appliedclinicaltrials/article/articleDetail.jsp?id=719542&sk=9270beba3a37ef7e37f3fa5477eea1cf9%22>

**This publication is for sale at our website <http://csdd.tufts.edu/reports>

Kaitin KI, editor. Managing global investigative sites for peak operational efficiency. *Tufts Center for the Study of Drug Development R&D Management Report*. 2011 Apr;6(2)** [RS 3112]

Kaitin KI, editor. New or modified indications for existing drugs have steadily increased in the U.S. *Tufts Center for the Study of Drug Development Impact Report*. 2011 Mar/Apr;13(2)** [RS 3111]

Beck A, Wurch T, Reichert JM. 6th Annual European Antibody Congress 2010: November 29 - December 1, 2010, Geneva, Switzerland. *mAbs*. 2011;3(2):111-132 [RS 3110]

<http://dx.doi.org/10.4161/mabs.3.2.14788>

Getz KA. The promise and progress of DIA 2011. *Drug Information Journal*. 2011;45(2):119-120 [RS 3109b]

<http://dx.doi.org/10.1177/009286151104500203>

Getz KA. Low hanging fruit in the fight against inefficiency. *Applied Clinical Trials*. 2011;20(3):30-32 [RS 3109]

<http://appliedclinicaltrialsonline.findpharma.com/appliedclinicaltrials/Articles/Low-Hanging-Fruit-in-the-Fight-Against-Inefficiency/ArticleStandard/Article/detail/711311?contextCategoryId=37194>

Kaitin KI, DiMasi JA. Pharmaceutical innovation in the 21st century: New drug approvals in the first decade, 2000-2009. *Clinical Pharmacology & Therapeutics*. 2011;89(2):183-188 [RS 3108]

<http://dx.doi.org/10.1038/clpt.2010.286>

Stergiopoulos S, Soenen M, Getz KA. Honing reforms from clinical development. *Pharmaceutical Executive*. Published February 1, 2011 [web document]. [RS 3107]

<http://pharmexec.findpharma.com/pharmexec/Sales/Honing-Reforms-from-Clinical-Development/ArticleStandard/Article/detail/707517?ref=25>

Getz KA. The ultimate act of appreciation of study volunteers. *Focus*. 2011;3:8-12 [RS 3106b]

http://www.ttc-llc.com/Portals/0/images/PDFLibrary/Controlling%20Costs%20of%20Clinical%20Trials%20in%20Oncology%20Request-Pharma_FOCUS_Issue3.pdf

Reichert JM. Antibody-based therapeutics to watch in 2011. *MAbs*. 2011;3(1):76-99 [RS 3106]

<http://dx.doi.org/10.4161/mabs.3.1.13895>

Kaitin KI, editor. U.S. healthcare stakeholders uncertain on benefits of risk evaluation strategy. *Tufts Center for the Study of Drug Development Impact Report*. 2011 Jan/Feb;13(1)** [RS 3105]

Kaitin KI, editor. Using translational science to improve drug development. *Tufts Center for the Study of Drug Development R&D Management Report*. 2011 Jan;6(1)** [RS 3104]

DiMasi JA, Faden LB. Competitiveness in follow-on drug R&D: a race or imitation? *Nature Reviews Drug Discovery*. 2011;10(1):23-27 [RS 3103]
<http://dx.doi.org/10.1038/nrd3296>

Zuckerman R, Getz KA, Kaitin KI. A new mechanism for tracking publicly available study volunteer demographics. *Drug Information Journal*. 2011;45(1):55-64 [RS 3102]
<http://dx.doi.org/10.1177/009286151104500106>

Getz KA. Frustration with IRB bureaucracy & despotism. *Applied Clinical Trials*. 2011;20(1):26-28 [RS 3101]
<http://www.appliedclinicaltrials.com/appliedclinicaltrials/article/articleDetail.jsp?id=703033&sk=&date=&pageID=2>

Outlook 2011. Boston: Tufts Center for the Study of Drug Development, 2011 [RS 3100]

Kaitin KI, editor. Personalized medicine is playing a growing role in development pipelines. *Tufts Center for the Study of Drug Development Impact Report*. 2010 Nov/Dec;12(6)** [RS 3030]

Reichert JM. Metrics for antibody therapeutics development. *mAbs*. 2010;2(6):695-700 [RS 3029]
<http://dx.doi.org/10.4161/mabs.2.6.13603>

Milne CP, Kaitin KI. Impact of the new US health-care-reform legislation on the pharmaceutical industry: who are the real winners? *Clinical Pharmacology & Therapeutics*. 2010;88(5):589-92 [RS 3028]
<http://dx.doi.org/10.1038/clpt.2010.167>

Cohen JPA, Looney W. What is the value of oncology medicines? *Nature Biotechnology*. 2010;28(11):1160-3 [RS 3027]
<http://dx.doi.org/10.1038/nbt1110-1160>

Getz KA. Hurry up and wait, pharma puts the brakes on strategic outsourcing partnering. *Inside Outsourcing*. 2010 Nov;10-16 [RS 3026b]
http://www.nxtbook.com/nxtbooks/advanstar/insideoutsourcing_201011/#/12

Getz KA. Chasing veteran US sites out of the enterprise. *Applied Clinical Trials*. 2010;19(11):26-28 [RS 3026]
<http://www.appliedclinicaltrials.com/appliedclinicaltrials/article/articleDetail.jsp?id=693552>

Getz K, Zuckerman R. Anticipating structural change in the CRO market. *Contract Pharma*. 2010;12(8):70-74 [RS 3025]
http://www.contractpharma.com/issues/2010-10/view_features/anticipating-structural-change-in-the-cro-market/

Kaitin KI, editor. Outsourcing strategies across the supply chain. *Tufts Center for the Study of Drug Development R&D Management Report*. 2010 Oct;5(4)** [RS 3024]

Getz KA. Providing results to volunteers. *Applied Clinical Trials*. 2010;19(10):52-59 [RS 3023b]
<http://appliedclinicaltrials.findpharma.com/appliedclinicaltrials/article/articleDetail.jsp?id=690485&sk=&date=&pageID=7>

Getz KA. Ominous clouds over outsourcing. *Applied Clinical Trials*. 2010;19(9):28-30 [RS 3023]
http://license.icopyright.net/rights/tag.act?tag=3.7442%3fidx_id=686210

RS 3022 Nelson AL, Dhimolea E, Reichert JM. Development trends for human monoclonal antibody therapeutics. *Nature Reviews/Drug Discovery*. 2010;9:767-774
<http://dx.doi.org/10.1038/nrd3229>

RS 3021 Vernon JA, Golec JH, DiMasi JA. Drug development costs when financial risk is measured using the Fama-French three-factor model. *Health Economics*. 2010;19(8):1002-1005
<http://dx.doi.org/10.1002/hec.1538>

RS 3020 Slater EE, Kaitin K. Explaining the drug drought. *Pharmaceutical Executive*. 2010;30(9):22-24
<http://pharmexec.findpharma.com/pharmexec/Explaining-the-Drug-Drought/ArticleStandard/Article/detail/687358>

RS 3019 Getz KA, Zuckerman R. Today's global site landscape. *Applied Clinical Trials*. 2010;19(6):34-38
<http://www.appliedclinicaltrials.com/appliedclinicaltrials/article/articleDetail.jsp?id=673673&sk=&date=&pageID=3>

RS 3018 Kaitin KI, editor. Clinical approval success highest for smallest firms among the top 50. *Tufts Center for the Study of Drug Development Impact Report*. 2010 Sep/Oct;12(5)**

**This publication is for sale at our website <http://csdd.tufts.edu/reports>

- RS 3017 Kaitin KI, editor. Maintaining portfolio diversity to manage drug development risk. *Tufts Center for the Study of Drug Development R&D Management Report*. 2010 Aug;5(3)**
- RS 3016d Getz KA. Engaging pharmacists in research education. *Applied Clinical Trials*. 2010;19(7):30-32
<http://www.appliedclinicaltrials.com/appliedclinicaltrials/article/articleDetail.jsp?id=678141>
- RS 3016c Kaitin KI. Response to “A Perfect Storm for Innovation.” *Clinical Pharmacology & Therapeutics*. 2010;88(1):23-24
<http://dx.doi.org/10.1038/clpt.2010.86>
- RS 3016b Reichert JM. Changes in regulations for approval of therapeutics. *MAbs*. 2010;2(4):359-360
<http://dx.doi.org/10.4161/mabs.12369>
- RS 3016 Cohen J, Looney W. Re: how much is life worth: cetuximab, non-small cell lung cancer, and the \$440 billion question. *Journal of the National Cancer Institute*. 2010 Jun 22
<http://dx.doi.org/10.1093/jnci/djq246>
- RS 3015 Milne C-P, Tait J. Evolution along the government-governance continuum: FDA’s orphan products and fast track programs as exemplars of “what works” for innovation and regulation. *Food and Drug Law Journal*. 2009;64(4):733-753
<http://www.fdpi.org/resources/resources-order-box-detail-view/evolution-along-the-government--governance-continuum-fda's-orphan-products-and-fast-track-programs-as-exemplar-of-what-works-for-innovation-and-regulation>
- RS 3014 Cohen J, Dibner MS, Wilson A. Development of and access to products for neglected diseases. *PLoS ONE*. 2010;5(5)
<http://dx.doi.org/10.1371/journal.pone.0010610>
- RS 3013 Kaitin KI, editor. Comparative effectiveness research impacts patient access to cancer drugs. *Tufts Center for the Study of Drug Development Impact Report*. 2010 Jul/Aug;12(4)**
- RS 3012 Getz K. FIPNet: Pharma’s new, sexy, but not yet ready for print-time model. *Applied Clinical Trials*. 2009;Suppl:10-12,14,16
- RS 3011 Kaitin KI. The landscape for pharmaceutical innovation: Drivers of cost-effective clinical research. *Pharmaceutical Outsourcing*. 2010;11(3):28,30,32
Author manuscript; available in PMC 2011 August 4. PMID: PMC3150117
<http://www.pharmoutsourcing.com/Featured-Articles/37572-The-Landscape-for-Pharmaceutical-Innovation-Drivers-of-Cost-Effective-Clinical-Research/>

**This publication is for sale at our website <http://csdd.tufts.edu/reports>

- RS 3010b Getz KA. Conversations with study volunteers. *Applied Clinical Trials*. 2010;19(5):32-34
<http://www.appliedclinicaltrials.com/appliedclinicaltrials/CRO%2FSponsor/Conversations-With-Study-Volunteers/ArticleStandard/Article/detail/668513>
- RS 3010 Kaitin KI, editor. Rising protocol complexity, execution burden varies widely by phase and TA. *Tufts Center for the Study of Drug Development Impact Report*. 2010 May/Jun;12(3)**
- RS 3009 Getz KA. Sizing up the clinical research market. *Applied Clinical Trials*. 2010;19(3):32-34
<http://www.appliedclinicaltrials.com/appliedclinicaltrials/article/articleDetail.jsp?id=660749>
- RS 3008 Getz KA. With clinical data, less is more. *Applied Clinical Trials*. 2010;19(1):28-30
<http://www.appliedclinicaltrials.com/appliedclinicaltrials/CRO%2FSponsor/With-Clinical-Data-Less-is-More/ArticleStandard/Article/detail/652123>
- RS 3007c Reichert JM. Editorial for PEDS special issue on antibodies. *Protein Engineering, Design & Selection*. 2010;23(4):153-154.
<http://dx.doi.org/10.1093/protein/gzq018>
- RS 3007b Getz KA. Understanding clinical trials: Appreciating medical heroes. *Media Planet*. 2010 Apr
<https://www.ciscrp.org/wp-content/uploads/2014/01/Clinical-Trials-article.pdf>
- RS 3007 Kaitin KI, editor. Improving ROI and late stage clinical success rates. *Tufts Center for the Study of Drug Development R&D Management Report*. 2010 Apr;5(2)**
- RS 3006b Reichert JM. Letter from the editor: stratified medicine. *MABs*. 2010;2(2):107;
<http://dx.doi.org/10.4161/mabs.2.2.11320>
- RS 3006 Zycher B, DiMasi JA, Milne C-P. Private sector contributions to pharmaceutical science: Thirty-five summary case histories. *American Journal of Therapeutics*. 2010;17(1):101-120
<http://dx.doi.org/10.1097/MJT.0b013e3181ca7f10>
- RS 3005 Kaitin KI, editor. Rising demand is expanding scope and workload of regulatory affairs function. *Tufts Center for the Study of Drug Development Impact Report*. 2010 Mar/Apr;12(2)**
- RS 3004b Stergiopoulos S, Feldman L, Getz KA. *White paper: mapping adoption of centralized cardiac safety assessment: report on the results of a study conducted by the Tufts Center for the Study of Drug Development (Tufts CSDD)*. Boston: Tufts Center for the Study of Drug Development. March 2010.

**This publication is for sale at our website <http://csdd.tufts.edu/reports>

<http://www.ert.com/resources/download/WhitePaper/22>

- RS 3004 Kaitin KI. Deconstructing the drug development process: The new face of innovation. *Clinical Pharmacology & Therapeutics*. 2010;87(3):356-61
<http://dx.doi.org/10.1038/clpt.2009.293>
- RS 3003 DiMasi JA, Feldman L, Seckler A, Wilson A. Trends in risks associated with new drug development: success rates for investigational drugs. *Clinical Pharmacology & Therapeutics*. 2010;87(3):272-277
<http://dx.doi.org/10.1038/clpt.2009.295>
- RS 3002c Reichert JM. mAb therapeutic products and risk management. *MAbs*. 2010;2(1):1-2
<http://dx.doi.org/10.4161/mabs.2.1.10628>
- RS 3002b Reichert JM. Antibodies to watch in 2010. *MAbs*. 2010;2(1):84-100;
<http://dx.doi.org/10.4161/mabs.2.1.10786>
- RS 3002 Kaitin KI, editor. U.S. orphan product designations more than doubled from 2000-02 to 2006-08. *Tufts Center for the Study of Drug Development Impact Report*. 2010 Jan/Feb;12(1)**
- RS 3001 Kaitin KI, editor. Comparative approaches to capacity forecasting. *Tufts Center for the Study of Drug Development R&D Management Report*. 2010 Jan;5(1)**
- RS 3000 *Outlook 2010*. Boston: Tufts Center for the Study of Drug Development, 2010
<http://csdd.tufts.edu/documents/www/Outlook2010.pdf>
- RS 2934 Getz KA Vogel JR. Successful outsourcing: tracking global CRO usage. *Applied Clinical Trials Online*. 2009 Aug 17
<http://appliedclinicaltrialsonline.findpharma.com/appliedclinicaltrials/Online+Extras/Successful-Outsourcing-Tracking-Global-CRO-Usage/ArticleStandard/Article/detail/619120?ref=25>
- RS 2933 Milne C-P. Can translational medicine bring us out of the R&D wilderness? *Personalized Medicine*. 2009;6(5):543-553
<http://dx.doi.org/10.2217/pme.09.40>
- RS 2932 Getz KA. Is an investigative site shake-out imminent? *Applied Clinical Trials*. 2009;18(11):34-36
<http://www.appliedclinicaltrialsonline.com/appliedclinicaltrials/CRO%2FSponsor/Is-an-Investigative-Site-Shake-Out-Imminent/ArticleStandard/Article/detail/640464>

**This publication is for sale at our website <http://csdd.tufts.edu/reports>

- RS 2931 Bridges JFP, Cohen JP, Grist PG, Muhlbacher AC. International experience with comparative effectiveness research: case studies from England/Wales and Germany. In: *Pharmaceutical markets and insurance worldwide*. Edited by Dor, A. (Volume 22 of Advances in health economics and health services research) Emerald Books: Bingley UK, 2010:29-50*
- RS 2930 Getz KA. Assessing the downstream impact of protocol design complexity. *Touch Briefings*. 2009:93-5
- RS 2929 Kaitin KI. The changing landscape of drug development. *Mass High Tech*. 2009 16 Dec;27(43):29
- RS 2928 Niezen MGH, de Bont A, Busschbach JJV, Cohen JP, Stolk EA. Finding legitimacy for the role of budget impact in drug reimbursement decisions. *International Journal of Technology Assessment in Health Care*. 2009;25(1):49-55
<http://dx.doi.org/10.1017/S0266462309090072>
- RS 2927 Saladin PM Zhang BD Reichert JM. Current trends in the clinical development of peptide therapeutics. *IDrugs*. 2009;12(12):779-784
- RS 2926 Milne C-P Kaitin KI. Translational medicine: an engine of change for bringing new technology to community health. *Science Translational Medicine*. 2009 Nov 4;1(5):1-4
<http://dx.doi.org/10.1126/scitranslmed.3000222>
- RS 2925 Cohen JP Bridges JFP. Assessing comparative effectiveness research in the US. *Applied Health Economic Health Policy*. 2009;7(4):219-24
<http://dx.doi.org/10.1007/BF03256155>
- RS 2924 Kaitin KI, editor. Drug approvals for neglected diseases increased along with more R&D funding. *Tufts Center for the Study of Drug Development Impact Report*. 2009 Nov/Dec;11(6)**
- RS 2923b Reichert JM. Letter from the editor. *MAbs*. 2009 Nov/Dec;1(6):521-522.
<http://dx.doi.org/10.4161/mabs.1.6.10059>
- RS 2923 Wilson A, Milne C-P. The translational medicine movement in the Asia Pacific region: current progress and future directions. *Pharma Focus Asia*. 2009;(12):30-2
- RS 2922b *Center for the Study of Drug Development Forum on Neglected Diseases in the Developing World: Progress, Current Challenges, and Promising Approaches, Oct 16, 2009*. Washington, DC: Dirksen Senate Office Building.
<http://csdd.tufts.edu/files/uploads/ndfinproceed.pdf>

**This publication is for sale at our website <http://csdd.tufts.edu/reports>

- RS 2922 Kaitin KI, editor. Best R&D practices of top pharma/biotech performers. *Tufts Center for the Study of Drug Development R&D Management Report*. 2009 Oct;4(4)**
- RS2921b Getz KA. Into the aftermath of M&A. *Applied Clinical Trials*. 2009;18(9) <http://appliedclinicaltrialsonline.findpharma.com/appliedclinicaltrials/Drug+Development/Into-the-Aftermath-of-MampA/ArticleStandard/Article/detail/624940>
- RS 2921 Kaitin KI, editor. Marketing exclusivity for first-in-class drugs has shortened to 2.5 years. *Tufts Center for the Study of Drug Development Impact Report*. 2009 Sep/Oct;11(5)**
- RS 2920b Reichert JM. Letter from the editor. *MAbs*. 2009 Sep/Oct;1(5):393. <http://dx.doi.org/10.4161/mabs.1.5.9675>
- RS 2920 Reichert JM. Probabilities of success for antibody therapeutics. *MAbs*. 2009;1(4):387-9 <http://dx.doi.org/10.4161/mabs.1.4.9031>
- RS 2919 Milne C-P Tait J. Evolution along the government-governance continuum: impacts of regulation on medicines innovation in the United States. In: Lyall C, Papaioannou T, Smith J, eds. *The limits to governance: the challenge of policy-making for the new life sciences*. Burlington, VT: Ashgate; 2009:107-132.
- RS 2918 Milne C-P. Pharmaceutical economics and applications to pediatrics: business case development. In: Mulberg A, Silber S, van den Anker J, eds. *Pediatric Drug Development: Concepts and Applications*. Hoboken, NJ: Wiley; 2008:39-57.
- RS 2917 Milne C-P. Population dynamics, demographics, and disease burden in infants and children across the world. In: Mulberg A, Silber S, van den Anker J, eds. *Pediatric drug development: concepts and applications*. Hoboken, NJ: Wiley; 2008:21-38.
- RS 2916 Getz KA Zuckerman R DiMasi JA Kaitin KI. Drug development portfolio and spending practices after mergers and acquisitions. *Drug Information Journal*. 2009;43(4):493-500 <http://dx.doi.org/10.1177/009286150904300415>
- RS 2915 Cohen J. Market access in the wake of NICE: biopharma's friend or foe? *European Pharmaceutical Review*. 2009;48:8-12 <http://csdd.tufts.edu/documents/www/2915Cohen.pdf>
- RS 2914 Cohen J Wilson A Faden L. Off-label use reimbursement. *Food and Drug Law Journal*. 2009;64(2):391-403 <http://www.fdpi.org/resources/resources-order-box-detail-view/off-label-use-reimbursement>

**This publication is for sale at our website <http://csdd.tufts.edu/reports>

- RS2913b Getz KA. Are academia and NIH bastions of integrity? *Applied Clinical Trials*. 2009;18(7):32-36
<http://www.appliedclinicaltrials.com/appliedclinicaltrials/article/articleDetail.jsp?id=609455>
- RS 2913 Kaitin KI, editor. Large pharma success rate for drugs entering clinical trials in 1993-04: 16%. *Tufts Center for the Study of Drug Development Impact Report*. 2009 Jul/Aug;11(4)**
- RS 2912b Reichert JM. Letter from the editor. *MAbs*. 2009 Jul/Aug;1(4):307.
<http://dx.doi.org/10.4161/mabs.1.4.9076>
- RS 2912 Kaitin KI, editor. Moving drug development outsourcing to a higher level. *Tufts Center for the Study of Drug Development R&D Management Report*. 2009 Jun;4(3)**
- RS 2911 Reichert JM. Global antibody development trends. *MAbs*. 2009;1(1):86-7
<http://dx.doi.org/10.4161/mabs.1.1.7645>
- RS2910c Getz KA. A compelling need to usher in alliances. *Applied Clinical Trials*. 2009;18(5):36-38
<http://appliedclinicaltrials.com/appliedclinicaltrials/Project+Management/A-Compelling-Need-to-Usher-in-Alliances/ArticleStandard/Article/detail/597458>
- RS 2910b Reichert JM. Letter from the editor. *MAbs*. 2009;1(3):189.
<http://dx.doi.org/10.4161/mabs.1.3.8590>
- RS 2910 Kaitin KI, editor. Therapeutic peptides in clinical study in 2000—07 nearly doubled 1990s rate. *Tufts Center for the Study of Drug Development Impact Report*. 2009 May/Jun;11(3)**
- RS 2909 Kaitin KI, editor. In-licensing/out-licensing strategies and practices. *Tufts Center for the Study of Drug Development R&D Management Report*. 2009 Apr;4(2)**
- RS 2908 Kaitin KI, editor. Change and opportunity in the Phase I landscape. *Tufts Center for the Study of Drug Development R&D Management Report*. 2009 Jan;4(1)**
- RS 2907b Zuckerman D, Zuckerman R, Getz KA, Piper C. Make a match. *Pharmaceutical Executive*. 2009;29(4):62-66.
<http://www.pharmexec.com/pharmexec/Sales+Articles/Make-a-Match/ArticleStandard/Article/detail/592061>
- RS 2907 Reichert JM Nelson AL. Development trends for therapeutic antibody fragments. *Nature Biotechnology*. 2009;27(4):331-7
<http://dx.doi.org/10.1038/nbt0409-331>

**This publication is for sale at our website <http://csdd.tufts.edu/reports>

- RS 2906 DiMasi JA Faden L Factors associated with multiple FDA review cycles and approval phase times. *Drug Information Journal*. 2009;43(2):201-25
<http://dx.doi.org/10.1177/009286150904300212>
- RS 2905c Getz KA. Is clinical research recession proof? *Applied Clinical Trials*. 2009;18(3):32-34
<http://www.appliedclinicaltrials.com/appliedclinicaltrials/article/articleDetail.jsp?id=586863>
- RS 2905b Sofaer N, Thiessen C, Goold SD, Ballou J, Getz KA, Koski G, Krueger RA, Weisman JS. Subjects' views of obligations to ensure post-trial access to drugs, care and information: qualitative results from the experiences of participants in clinical trials (EPIC) study. *Journal of Medical Ethics*. 2009;35(3):183-188;
<http://dx.doi.org/10.1136/jme.2008.024711>
- RS 2905 Kaitin KI, editor. 75% of U.S. health plans reimburse off-label uses of prescription drugs. *Tufts Center for the Study of Drug Development Impact Report*. 2009 Mar/Apr;11(2)**
- RS 2904d Getz KA, Zuckerman R. Effective collaborations with CROs: identifying agile and robust partnership strategies. *Pharmaceutical Outsourcing*. 2009;10(2):30-35.
- RS 2904c Reichert JM. Letter from the editor. *MAbs*. 2009 Mar/Apr;1(2):91-92;
<http://dx.doi.org/10.4161/mabs.1.2.7946>
- RS 2904b Getz KA. The elusive sponsor-site relationship. *Applied Clinical Trials*. 2009 Feb;18(2):38-40
<http://appliedclinicaltrials.findpharma.com/appliedclinicaltrials/article/articleDetail.jsp?id=579328>
- RS 2904 Reichert JM Rochon SL Zhang BF. Finding value in the U.S. Food and Drug Administration's Fast Track Program. *Drug News Perspectives*. 2009 Jan/Feb;22(1):53-8
<http://dx.doi.org/10.1358/dnp.2009.22.1.1303819>
- RS 2903b Cohen J Wilson A. New challenges to Medicare beneficiary access to mAbs. *MAbs*. 2009 Jan/Feb;1(1):1-11
<http://dx.doi.org/10.4161/mabs.1.1.7246>
- RS 2903 Cohen J Faden L Getz K. Mapping biopharmaceutical innovation and diffusion: how the second translational block (T2) shapes drug diffusion. *The Open Pharmacology Journal*. 2008;2:89-106
<http://dx.doi.org/10.2174/1874143600802010089>
- RS2902c Getz KA. The science of medicine and clinical trials. In: Porter RS, Kaplan JL, Homeier B, eds. *The Merck Manual Home Health Handbook*. 2nd ed. Whitehouse Station, NJ: Merck Research Laboratories; 2009:2024-2030.

**This publication is for sale at our website <http://csdd.tufts.edu/reports>

http://www.merckmanuals.com/home/special_subjects/the_science_of_medicine_and_clinical_trials/the_science_of_medicine.html

- RS 2902b Getz KA. Burying sites under safety reporting. *Applied Clinical Trials*. 2009;18(1):36-38
<http://www.appliedclinicaltrials.com/appliedclinicaltrials/article/articleDetail.jsp?id=574844>
- RS 2902 Reichert JM. Monoclonal antibodies as innovative therapeutics. *Current Pharmaceutical Biotechnology*. 2008 Dec;9(6):423-30
<http://dx.doi.org/10.2174/138920108786786358>
- RS 2901b Reichert JM. Letter from the editor. *MABs*. 2009 Jan/Feb;1(1):1
<http://dx.doi.org/10.4161/mabs.1.1.7646>
- RS 2901 Kaitin, KI editor. Current investigator landscape poses a growing challenge for sponsors. *Tufts Center for the Study of Drug Development Impact Report*. 2009 Jan/Feb;11(1)**
- RS 2900 *Outlook 2009*. Boston: Tufts Center for the Study of Drug Development, 2009
<http://csdd.tufts.edu/documents/www/Outlook2009.pdf>
- RS2833b Getz KA. Should physicians enroll their own patients into clinical trials? *ACRP Monitor*. 2008 Dec;22(7):34-38
- RS 2833 Kaitin KI. Offshoring cost effective clinical research. *Pharma Focus Asia*. 2008; (9):55-6
http://www.pharmafocusasia.com/clinical_trials/offshoring_cost_effective_clinical_research.htm
- RS 2832 Milne C-P. Fixing the paradigm for biopharmaceutical R&D: where to start? *International Journal of Biotechnology*. 2008;10(5):404-15
<http://dx.doi.org/10.1504/IJBT.2008.021307>
- RS 2831 Milne C-P Bruss JB. The economics of pediatric formulation development for off-patent drugs. *Clinical Therapeutics*. 2008;30(11):2133-45
<http://dx.doi.org/10.1016/j.clinthera.2008.11.019>
- RS 2830 Reichert JM Rochon SL Zhang BD. A decade of the Fast Track programme. *Nature Reviews Drug Discovery*. 2008;7(11):885-6
<http://dx.doi.org/10.1038/nrd2733>
- RS 2829c Getz KA. Investigator/Institution. In: D'agostino R, Massaro J, Sullivan L, eds. *Wiley Encyclopedia of Clinical Trials*. Hoboken, NJ: Wiley; 2008.
<http://dx.doi.org/10.1002/9780471462422.eoct382>

**This publication is for sale at our website <http://csdd.tufts.edu/reports>

- RS 2829b Getz KA. Balancing perceptions of risk in clinical research. *Applied Clinical Trials*. 2008;17(11):36-39
<http://appliedclinicaltrialsonline.findpharma.com/appliedclinicaltrials/US/Balancing-Perceptions-of-Risk-in-Clinical-Research/ArticleStandard/Article/detail/563315>
- RS 2829 Kaitin KI, editor. While total approvals decline, U.S. is preferred market for first launch. *Tufts Center for the Study of Drug Development Impact Report*. 2008 Nov/Dec;10(6)**
- RS 2828 Getz KA, Wenger J, Campo RA, Seguire ES, Kaitin KI. Assessing the impact of protocol design changes on clinical trial performance. *American Journal of Therapeutics*. 2008;15:450-7
<http://dx.doi.org/10.1097/MJT.0b013e31816b9027>
- RS 2827 Kaitin KI, editor. Fast track designations more than doubled during the last five years. *Tufts Center for the Study of Drug Development Impact Report*. 2008 Sep/Oct;10(5)**
- RS 2826b Getz KA, Peddicord, D. Tuskegee, a cloud over research. *The Washington Post* 2008. Sep 30:HE05
http://www.washingtonpost.com/wp-dyn/content/article/2008/09/26/AR2008092603126_pf.html
- RS 2826 Getz KA. Restoring public confidence in clinical research. *ACRP Monitor*. 2008 Sep;22(5):59-62
- RS 2825b Getz KA. Getting to the heart of public distrust. *Applied Clinical Trials*. 2008; 17(9):38-42
<http://appliedclinicaltrialsonline.findpharma.com/appliedclinicaltrials/Drug+Development/Getting-to-the-Heart-of-Public-Distrust/ArticleStandard/Article/detail/546111>
- RS 2825 Getz KA. Public confidence and trust today. *ACRP Monitor*. 2008 Sep;22(5):17-21
- RS 2824 Faden LB Milne C-P. Pharmacovigilance activities in the United States, European Union and Japan: harmonic convergence or convergent evolution? *Food and Drug Law Journal*. 2008;63(3):683-700
<http://www.fdi.org/resources/resources-order-box-detail-view/paharmacovigilance-activities-in-the-united-states-european-union-and-japan-harmonic-convergence-or-convergent-evolution->
- RS 2823b Kaitin KI, editor. Optimizing protocol design strategies to improve clinical research performance. *Tufts Center for the Study of Drug Development R&D Management Report*. 2008 Oct;3(4)**

**This publication is for sale at our website <http://csdd.tufts.edu/reports>

- RS 2823 Kaitin, KI, editor. Postmarketing studies are becoming the norm in U.S., Europe, and Japan. *Tufts Center for the Study of Drug Development Impact Report*. 2008 Jul-Aug;10(4)**
- RS 2822b Getz KA. Is investigative site feasibility feasible? *Applied Clinical Trials*. 2008;17(7):36-38
<http://appliedclinicaltrialsonline.findpharma.com/appliedclinicaltrials/Clinical+Trials+Insights/Is-Investigative-Site-Feasibility-Feasible/ArticleStandard/Article/detail/527735>
- RS 2822 Getz KA, Zuckerman R. Clinical research outsourcing: moving from transactional to strategic partnership-based outsourcing. *Contract Pharma*. 2008;10(5):66-71
<http://www.contractpharma.com/articles/2008/06/clinical-research-outsourcing>
- RS 2821 Zycher B, DiMasi JA, Milne C-P. *The truth about drug innovation: thirty-five summary case histories on private sector contributions to pharmaceutical science*. Manhattan Institute Center for Medical Progress. 2008;(6).
http://www.manhattan-institute.org/html/mpr_06.htm
- RS 2820 Getz KA. First things first: patient recruitment. *Scrip*. 2008;3371(6)
- RS 2819b Cabanilla LA, Milne C-P. Accelerated approval. In: D'agostino R, Massaro J, Sullivan L, eds. *Wiley Encyclopedia of Clinical Trials*. Hoboken, NJ: Wiley; 2008.
<http://dx.doi.org/10.1002/9780471462422.eoct336>
- RS 2819 Kaitin KI, editor. Leveraging metrics and market factors for portfolio decision making. *Tufts Center for the Study of Drug Development R&D Management Report*. 2008 Jun;3(3)**
- RS 2818 Cohen JP, Stolk E, Niezen M. Role of budget impact in drug reimbursement decisions. *Journal of Health Politics, Policy and Law*. 2008;Apr;33(2):225-245
<http://dx.doi.org/10.1215/03616878-2007-054>
- RS 2817 DiMasi JA, Hansen RW, Grabowski HG. Commentary: misleading Congress about drug development: reply [to D. Light]. *Journal of Health Politics, Policy and Law*. 2008;Apr;33(2):319-24
<http://dx.doi.org/10.1215/03616878-2007-063>
- RS 2816 Getz KA. Protocol design trends and their effect on clinical trial performance. *Regulatory Affairs Journal – Pharma*. 2008;19(5):315-6
<http://csdd.tufts.edu/documents/www/2816Getz.pdf>
- RS 2815 Getz KA. Beyond outsourcing (interview by Jenefer Trevena). *Scrip Supplement Contract Research Update*. 2008;Apr;4:5-6

**This publication is for sale at our website <http://csdd.tufts.edu/reports>

- RS 2814 Kaitin KI, editor. Drug plans non-compliant with Medicare regulations in six therapeutic classes. *Tufts Center for the Study of Drug Development Impact Report*. 2008 May-Jun;10(3)**
- RS 2813 Cohen JP, Young B, Rochon S, Faden L. Are Medicare plans complying with CMS regulation? *Expert Review of Pharmacoeconomics & Outcomes Research*. 2008 Apr;8(2):133-9
<http://dx.doi.org/10.1586/14737167.8.2.133>
- RS 2812 Kaitin KI, editor. Strategic outsourcing and global drug development. *Tufts Center for the Study of Drug Development R&D Management Report*. 2008 Mar;3(2)**
- RS 2811 Getz KA. The heavy burden of protocol design. *Applied Clinical Trials*. 2008;17(5):38-40
<http://appliedclinicaltrialsonline.findpharma.com/appliedclinicaltrials/Clinical+Trial+Insights/The-Heavy-Burden-of-Protocol-Design/ArticleStandard/Article/detail/513703?contextCategoryId=37194>
- RS 2810 Getz KA. Tackling racial disparities in research. *Applied Clinical Trials*. 2008;17(1):40-42
<http://appliedclinicaltrialsonline.findpharma.com/appliedclinicaltrials/Sites+Articles/Tackling-Racial-Disparities-in-Research/ArticleStandard/Article/detail/483704?contextCategoryId=37194>
- RS 2809 Getz KA. In search of efficiency between trial phases. *Applied Clinical Trials*. 2008;17(3):35-38
<http://appliedclinicaltrialsonline.findpharma.com/appliedclinicaltrials/Clinical+Trial+Insights/In-Search-of-Efficiency-Between-Trial-Phases/ArticleStandard/Article/detail/500433?contextCategoryId=37194>
- RS 2808 Getz KA, Faden L. Racial disparities among clinical research investigators. *American Journal of Therapeutics*. 2008 Jan/Feb;15(1):3-11
<http://dx.doi.org/10.1097/MJT.0b013e31815fa75a>
- RS 2807 Kaitin KI, editor. Number of mAbs entering clinical study nearly tripled in last decade. *Tufts Center for the Study of Drug Development Impact Report*. 2008 Mar/Apr;10(2)**
- RS 2806 Faden LB, Kaitin KI. Assessing the performance of the EMEA's centralized procedure: a comparative analysis with the US FDA. *Drug Information Journal*. 2008;42(1):45-56
<http://dx.doi.org/10.1177/009286150804200108>
- RS 2805 Reichert JM, Wenger JB. Development trends for new cancer therapeutics and vaccines. *Drug Discovery Today*. 2008 Jan;13(1-2):30-7
<http://dx.doi.org/10.1016/j.drudis.2007.09.003>

**This publication is for sale at our website <http://csdd.tufts.edu/reports>

- RS 2804 Cohen JP, Kaitin KI. Follow-on drugs and indications: the importance of incremental innovation to medical practice. *American Journal of Therapeutics*. 2008 Jan/Feb;15(1):89-91
<http://dx.doi.org/10.1097/MJT.0b013e31815f9e52>
- RS 2803 Kaitin KI, editor. Operating models for R&D excellence. *Tufts Center for the Study of Drug Development R&D Management Report*. 2008 Feb;3(1)**
- RS 2802 Kaitin KI. Obstacles and opportunities in new drug development. *Clinical Pharmacology & Therapeutics*. 2008;83(2):210-2
<http://dx.doi.org/10.1038/sj.clpt.6100462>
- RS 2801 Kaitin KI, editor. Growing protocol design complexity stresses investigators, volunteers. *Tufts Center for the Study of Drug Development Impact Report*. 2008 Jan/Feb;10(1)**
- RS 2800 *Outlook 2008*. Boston: Tufts Center for the Study of Drug Development. 2008
<http://csdd.tufts.edu/documents/www/Outlook2008.pdf>
- RS 2730 Kaitin KI, editor. Notable gender & racial disparities exist among clinical investigators. *Tufts Center for the Study of Drug Development Impact Report*. 2007 Nov/Dec;9(6)**
- RS 2729 Getz KA. In search of informed consent improvement. *Applied Clinical Trials*. 2007;16(11):42-45
<http://www.actmagazine.com/appliedclinicaltrials/Clinical+Trial+Insights/In-Search-of-Informed-Consent-Improvement/ArticleStandard/Article/detail/468090>
- RS 2728 DiMasi JA, Grabowski HG. Should the patent system for new medicines be abolished? *Clinical Pharmacology & Therapeutics*. 2007;82(5):488-90
<http://dx.doi.org/10.1038/sj.clpt.6100393>
- RS 2727 Cohen JP. CEA is not a price control (letter). *Health Affairs*. 2007;26(5):1505
<http://dx.doi.org/10.1377/hlthaff.26.5.1505>
- RS 2726 Cohen JP. The new Dutch health insurance system and its implications for pharmaceutical innovation. *International Journal of Pharmaceutical and Healthcare Marketing*. 2007;1(3):214-25
<http://dx.doi.org/10.1108/17506120710818229>
- RS 2725 Cohen JP, Faden L, Predaris S Young B. Patient access to pharmaceuticals: an international comparison. *European Journal of Health Economics*. 2007 Sep;8(3):253-66
<http://dx.doi.org/10.1007/s10198-006-0028-z>

**This publication is for sale at our website <http://csdd.tufts.edu/reports>

- RS 2724 Cohen JP, Paquette C Cairns CP. Can Medicare draw lessons from Dutch experience with a national formulary? *Drug Information Journal*. 2007;41(2):257-72
- RS 2723 Getz KA. Global clinical trials activity in the details. *Applied Clinical Trials*. 2007;16(9):42-44
<http://appliedclinicaltrialsonline.findpharma.com/appliedclinicaltrials/Regulatory/Global-Clinical-Trials-Activity-in-the-Details/ArticleStandard/Article/detail/453243?contextCategoryId=37194>
- RS 2722 Cohen JP, Stolk E, Niezen M. The increasingly complex fourth hurdle for pharmaceuticals. *Pharmacoeconomics*. 2007; 25(9):727-34
<http://dx.doi.org/10.2165/00019053-200725090-00002>
- RS 2721 Kaitin KI, editor. Despite more cancer drugs in R&D, overall U.S. approval rate is 8%. *Tufts Center for the Study of Drug Development Impact Report*. 2007 Sep/Oct;9(5)**
- RS 2720 Cohen JP. Comment on: Should we really worry about "launch delays" of new drugs in OECD countries? by L. Garatinni and S. Ghislandi. *European Journal of Health Economics*. 2007;8:169-70
<http://dx.doi.org/10.1007/s10198-007-0055-4>
- RS 2719 DiMasi JA Grabowski HG. The cost of biopharmaceutical R&D: is biotech different? *Managerial and Decision Economics*. 2007 Jun-Aug;28(4-5):469-79
<http://dx.doi.org/10.1002/mde.1360>
- RS 2718 DiMasi JA. Commentary on Scherer (2007), Berndt *et al.* (2007) and Reiffen and Ward (2007). *Managerial and Decision Economics* 2007 Jun-Aug;28(4-5):285-91
<http://dx.doi.org/10.1002/mde.1341>
- RS 2717 Getz KA. CRA: jack of all trades. *Applied Clinical Trials*. 2007;16(7):36-38
<http://www.actmagazine.com/appliedclinicaltrials/article/articleDetail.jsp?id=439804>
- RS 2716 Kaitin KI, editor. Follow-on drugs and indications play key role for World Health Organization. *Tufts Center for the Study of Drug Development Impact Report*. 2007 Jul/Aug;9(4)**
- RS 2715 Milne C-P, Kaitin KI, DiMasi JA. Mandatory comparator trials for therapeutically similar drugs: an assessment of the facts. *American Journal of Therapeutics*. 2007 May/Jun;14(3):231-4
<http://dx.doi.org/10.1097/MJT.0b013e31809fca83>
- RS 2714 Getz KA. CRO shifts in the outsourcing market. *Applied Clinical Trials*. 2007;16(5):35-38

**This publication is for sale at our website <http://csdd.tufts.edu/reports>

<http://www.actmagazine.com/appliedclinicaltrials/article/articleDetail.jsp?id=424918>

- RS 2713 Reichert JM, Valge-Archer VE. Development trends for monoclonal antibody cancer therapeutics. *Nature Reviews Drug Discovery*. 2007;6(5):349-56
<http://dx.doi.org/10.1038/nrd2241>
- RS 2712 Kaitin KI, editor. Challenges loom for postmarketing study commitments; benefits unclear. *Tufts Center for the Study of Drug Development Impact Report*. 2007 May/Jun;9(3)**
- RS 2711 Getz KA. Industry trials poised to win back academia. *Applied Clinical Trials*. 2007;16(4):35-38
<http://www.actmagazine.com/appliedclinicaltrials/article/articleDetail.jsp?id=416536>
- RS 2710 Getz KA Sergeant E Kremidas J. Mission possible: rebranding clinical research. *Applied Clinical Trials*. 2007;16(4):35-6,8
<http://www.actmagazine.com/appliedclinicaltrials/article/articleDetail.jsp?id=416537>
- RS 2709 Speckman JL Byrne MM Gerson J Getz K Wangsmo G Muse CT Sugarman J. Determining the costs of institutional review boards. *IRB: Ethics & Human Research*. 2007 Mar-Apr;29(2):7-13
<http://www.jstor.org/pss/30033224>
- RS 2708 Getz K Wenger J. High times for the CRO heavyweights. *Scrip supplements*. 2007 Mar;5-6
http://csdd.tufts.edu/_documents/www/2708Getz.pdf
- RS 2707 Kaitin KI, editor. Pediatric study costs increased 8-fold since 2000 as complexity level grew. *Tufts Center for the Study of Drug Development Impact Report*. 2007 Mar/Apr;9(2)**
- RS 2706 Kaitin KI, editor. Structuring the clinical organization to improve R&D productivity. *Tufts Center for the Study of Drug Development R&D Management Report*. 2007 Mar;2(1)**
- RS 2705 Milne C-P. Paediatric assessment: an essential part of standard drug development. *International Journal of Pharmaceutical Medicine*. 2006;20(5):297-301
<http://dx.doi.org/10.2165/00124363-200620050-00003>
- RS 2704 Getz KA. Drowning in the sea of regulatory compliance. *Applied Clinical Trials*. 2007;16(2):32-34
<http://www.actmagazine.com/appliedclinicaltrials/article/articleDetail.jsp?id=401621>

**This publication is for sale at our website <http://csdd.tufts.edu/reports>

- RS 2703 Reichert JM. Trends in the development and approval of monoclonal antibodies for viral infections. *BioDrugs* 2007;21(1):1-7
<http://dx.doi.org/10.2165/00063030-200721010-00001>
- RS 2702 DiMasi JA Grabowski HG. Economics of new oncology drug development. *Journal of Clinical Oncology* 2007 10 Jan;25(2):209-16
<http://dx.doi.org/10.1200/JCO.2006.09.0803>
- RS 2701 Kaitin KI, editor. EMEA meets performance goals, but lags U.S. FDA in drug approvals. *Tufts Center for the Study of Drug Development Impact Report*. 2007 Jan/Feb;9(1)**
- RS 2700 *Outlook 2007*. Boston: Tufts Center for the Study of Drug Development. 2007
<http://bit.ly/jx6LV9>
- RS 2626 Getz KA. Hitching a ride with the speed demons of drug development. *Applied Clinical Trials*. 2006;15(12):22-24
<http://www.appliedclinicaltrials.com/hitching-ride-speed-demons-drug-development>
- RS 2625 Kaitin KI Milne C-P. Just another day at the office? *The Scientist*. 2006;20(12):49-50
<http://www.the-scientist.com/?articles.view/articleNo/24559/title/Just-Another-Day-at-the-Office-/>
- RS 2624b Cohen J Cairns C Paquette C Faden L. Comparing patient access to pharmaceuticals in the UK and US. *Applied Health Economics and Health Policy*. 2006;5(3):177-87
<http://dx.doi.org/10.2165/00148365-200605030-00004>
- RS 2624 Cohen J. The author's reply. *Applied Health Economics and Health Policy*. 2006;5(3):270-2
<http://dx.doi.org/10.2165/00148365-200605040-00009>
- RS 2623 Cohen J Cabanilla L Sosnov J. Role of follow-on drugs and indications on the WHO Essential Drug List. *Journal of Clinical Pharmacy and Therapeutics*. 2006;31(6):585-92
<http://dx.doi.org/10.1111/j.1365-2710.2006.00777.x>
- RS 2622 Getz KA. Lessons from the organ donation playbook. *Applied Clinical Trials*. 2006;15(11):30-36
<http://www.actmagazine.com/appliedclinicaltrials/article/articleDetail.jsp?id=382875>

**This publication is for sale at our website <http://csdd.tufts.edu/reports>

- RS 2621 Kaitin KI, editor. Cost to develop new biotech products is estimated to average \$1.2 billion. *Tufts Center for the Study of Drug Development Impact Report*. 2006 Nov/Dec;8(6)**
- RS 2620 Milne C-P Kaitin K, guest editors. Health reform in Europe and the US: is there common ground?: proceedings of a symposium held at Tufts University European Center, Talloires, France, 13-15 July 2005. *Includes*: Milne. C-P. Foreword:1-3. Cohen J. Transatlantic convergence with respect to the fourth hurdle?:87-94. Kaitin KI. Concluding remarks:121-2. *PharmacoEconomics*. 2006;24(Suppl 2) <http://dx.doi.org/10.2165/00019053-200624002-00013>
- RS 2619 Getz KA. Spotting the 'new' managed site networks. *Applied Clinical Trials*. 2006;15(9):34-36 <http://www.actmagazine.com/appliedclinicaltrials/article/articleDetail.jsp?id=370345>
- RS 2618 Kaitin KI, editor. Fastest drug developers consistently best peers on key performance metrics. *Tufts Center for the Study of Drug Development Impact Report*. 2006 Sep/Oct;8(5)**
- RS 2617b Byrne MM, Speckman J, Getz KA, Sugarman J. Variability in the costs of institutional review oversight. *Academic Medicine*. 2006;81(8):708-712 <http://dx.doi.org/10.1097/00001888-200608000-00006>
- RS 2617 Reichert JM. Trends in US approvals: new biopharmaceuticals and vaccines. *Trends in Biotechnology*. 2006;24(7):293-8 <http://dx.doi.org/10.1016/j.tibtech.2006.05.003>
- RS 2616 Kaitin KI, editor. Number of vaccines entering clinical study rose only modestly since 1990s. *Tufts Center for the Study of Drug Development Impact Report*. 2006 Jul/Aug;8(4)**
- RS 2615 DiMasi JA. A spoonful of data. [letter] *Harper's Magazine*. 2006 Jul;313(1874):6 <http://harpers.org/archive/2006/07/letters-766/>
- RS 2614 Getz KA. Insights from today's CRO renaissance. *Applied Clinical Trials*. 2006;15(6):48-52. <http://www.actmagazine.com/appliedclinicaltrials/article/articleDetail.jsp?id=334568>
- RS 2613 DiMasi JA. A response to Light's rejoinder from DiMasi [13 June letter]. A response to Light from DiMasi [24 March letter]. The real significance of drug development times [14 March [letter]]. *Health Affairs*. eLetters 2006 <http://dx.doi.org/10.1377/hlthaff.25.2.461>
- RS 2612 Cohen JP. Cost-effectiveness and resource allocation. [letter] *JAMA*. 2006 Jun 21;295(23):2723

**This publication is for sale at our website <http://csdd.tufts.edu/reports>

<http://dx.doi.org/10.1001/jama.295.23.2723-a>

- RS 2611 Vogel JR Getz KA. Successful outsourcing of clinical drug developments. *BioExecutive International* 2006 Jun Suppl;2(6):S30-8
<http://www.appliedclinicaltrials.com/appliedclinicaltrials/Successful-Outsourcing-Tracking-Global-CRO-Usage/ArticleStandard/Article/detail/602039>
- RS 2610 Milne C-P. US and European regulatory initiatives to improve R&D performance. *Expert Opinion on Drug Discovery*. 2006 Jun;1(1):11-4
<http://informahealthcare.com/doi/abs/10.1517/17460441.1.1.11?journalCode=edc>
- RS 2609 Reichert JM. Monoclonal antibodies as innovative anti-infective agents. *Discovery Medicine*. 2005 Dec;5(30):544-7
<http://www.discoverymedicine.com/Janice-M-Reichert/2009/07/26/monoclonal-antibodies-as-innovative-anti-infective-agents/>
- RS 2608 Kaitin KI, editor. New drugs entering clinical testing in top 10 firms jumped 52% in 2003-05. *Tufts Center for the Study of Drug Development Impact Report*. 2006 May/June;8(3)**
- RS 2607 Transformational change in clinical development: a special report. *Tufts Center for the Study of Drug Development R&D Management Report*. 2006;1(1)**
- RS 2606b Getz KA. The impact of outsourcing. *Scrip Magazine*. 2006 Apr;155:39-41
- RS 2606 Getz KA. Forgotten voices in the transparency debate: online trial registries alone will not succeed at rebuilding public confidence. *Applied Clinical Trials*. 2006;15(4):42-44
<http://www.actmagazine.com/appliedclinicaltrials/article/articleDetail.jsp?id=316473>
- RS 2605 Kaitin KI, editor. Fast track program firmly established in U.S. drug development landscape. *Tufts Center for the Study of Drug Development Impact Report*. 2006 Mar/Apr;8(2)**
- RS 2604 Reichert JM Dewitz MC. Anti-infective monoclonal antibodies: perils and promise of development. *Nature Reviews Drug Discovery*. 2006;5(4):191-5
<http://dx.doi.org/10.1038/nrd1987>
- RS 2603 Kaitin KI, editor. CRO contribution to drug development is substantial and growing globally. *Tufts Center for the Study of Drug Development Impact Report*. 2006 Jan/Feb;8(1)**
- RS 2602 Kaitin KI. Memo to von Eschenbach. *Pharmaceutical Executive*. 2006 Jan;26(1):36-7
<http://www.pharmexec.com/pharmexec/article/articleDetail.jsp?id=282477>

**This publication is for sale at our website <http://csdd.tufts.edu/reports>

- RS 2601 Getz KA. The imperative to support site adoption of EDC. *Applied Clinical Trials*. 2006;15(1):38-40
<http://www.actmagazine.com/appliedclinicaltrials/article/articleDetail.jsp?id=283027>
- RS 2600 *Outlook 2006*. Boston: Tufts Center for the Study of Drug Development, 2006
- RS 2519 Reichert JM Faden LB. Therapeutic proteins approved in the European Union 2000-2004. *BIO – Greece* 2005 Dec;15:46-9
- RS 2518 Getz KA. Swift predominance of Ex-U.S. sites. *Applied Clinical Trials*. 2005;14(12):21-22
<http://www.actmagazine.com/appliedclinicaltrials/article/articleDetail.jsp?id=261633>
- RS 2517 Getz KA. Have we pushed our PIs too far? *Applied Clinical Trials*. 2005;14(9):34-36
<http://www.actmagazine.com/appliedclinicaltrials/article/articleDetail.jsp?id=176904&&pageID=1>
- RS 2516 Getz KA. The public: a critical initiative partner. *Applied Clinical Trials*. 2005;14(8):50
<http://www.actmagazine.com/appliedclinicaltrials/article/articleDetail.jsp?id=172272>
- RS 2515 Milne C-P Kaitin KI. Down the critical path: who should lead? *Applied Clinical Trials*. 2005;14(8):56
<http://www.actmagazine.com/appliedclinicaltrials/article/articleDetail.jsp?id=172279>
- RS 2514 Koski G Aungst J Kupersmith J Getz K Rimoin D. Cooperative research ethics review boards: a win-win solution? *IRB: a Review of Human Subjects Research*. 2005 May-Jun;27(3):1-7
<http://dx.doi.org/10.2307/3564071>
- RS 2513 Sugarman J Getz K Speckman JL Byrne MM Gerson J Emanuel EJ Consortium to Evaluate Clinical Research Ethics. The cost of institutional review boards in academic medical centers. *New England Journal of Medicine*. 2005 Apr 28;352(17):1825-7
<http://dx.doi.org/10.1056/NEJM200504283521723>
- RS 2512 DiMasi JA Hansen RW Grabowski HG. Reply: setting the record straight on setting the record straight: response to the Light and Warburton rejoinder. *Journal of Health Economics*. 2005 Sep;24(5):1049-53
<http://dx.doi.org/10.1016/j.jhealeco.2005.07.002>

**This publication is for sale at our website <http://csdd.tufts.edu/reports>

- RS 2511 DiMasi JA Hansen RW Grabowski HG. Reply: extraordinary claims require extraordinary evidence. *Journal of Health Economics*. 2005 Sep;24(5):1034-44
<http://dx.doi.org/10.1016/j.jhealeco.2005.07.002>
- RS 2510 Kaitin KI, editor. Longer clinical times are extending time to market for new drugs in U.S. *Tufts Center for the Study of Drug Development Impact Report*. 2005 Nov/Dec;7(6)**
- RS 2509 Reichert JM Rosensweig CJ Faden LB Dewitz MC. Monoclonal antibody successes in the clinic. *Nature Biotechnology*. 2005;23(9):1073-8
<http://dx.doi.org/10.1038/nbt0905-1073>
- RS 2508 Kaitin KI, editor. Drug safety withdrawals in the U.S. not linked to speed of FDA approval. *Tufts Center for the Study of Drug Development Impact Report*. 2005 Sep/Oct;7(5)**
- RS 2507 Getz K, Kremidas J. Educating the public: a critical, unmet need. *Applied Clinical Trials*. 2005;14(3):60-66
<http://www.actmagazine.com/appliedclinicaltrials/article/articleDetail.jsp?id=149965>
- RS 2506 Kaitin KI, editor. U.S. pediatric studies incentive led to new labeling for nearly 100 drugs. *Tufts Center for the Study of Drug Development Impact Report*. 2005 Jul/Aug;7(4)**
- RS 2505b Getz KA. Entering the realm of flexible clinical trials. *Applied Clinical Trials*. 2005;14(6):44-46
<http://appliedclinicaltrialsonline.findpharma.com/appliedclinicaltrials/article/articleDetail.jsp?id=166546>
- RS 2505 Kaitin KI, editor. Numbers of active investigators in FDA-regulated clinical trials drop. *Tufts Center for the Study of Drug Development Impact Report*. 2005 May/Jun;7(3)**
- RS 2504 Milne C-P. Racing the globalization of infectious diseases: lessons from the tortoise and the hare. *New England Journal of International and Comparative Law*. 2004 Fall;11(1):1-36
- RS 2503 Milne C-P. The pediatric studies initiative. In: Mathieu M. *New drug Development: A Regulatory Overview*. 7th ed. Waltham, MA: Parexel; 2005:363-89
- RS 2502 Kaitin KI, editor. Protein therapeutic success rates increase with biotech advance. *Tufts Center for the Study of Drug Development Impact Report*. 2005 Mar/Apr;7(2)**

**This publication is for sale at our website <http://csdd.tufts.edu/reports>

- RS 2501 Kaitin KI, editor. Decline in drug approvals is driving industry, FDA to enhance efficiency. *Tufts Center for the Study of Drug Development Impact Report*. 2005 Jan/Feb;7(1)**
- RS 2500 *Outlook 2005*. Boston: Tufts Center for the Study of Drug Development. 2005
- RS 2424 Cohen J. Are clinical practice guidelines impartial? *International Journal of Technology Assessment in Health Care*. 2004;20(4):415-20
<http://dx.doi.org/10.1017/S0266462304001291>
- RS 2423 Milne C-P. Harbingers, or harvesters of change? *European Pharmaceutical Review Supplement (Outsourcing)*. 2004 Winter:12-17
- RS 2422 Reichert JM. Technology evaluation: Lumiliximab, Biogen Idec. *Current Opinion in Molecular Therapeutics*. 2004;6(6):675-83
- RS 2421 Cohen JP Paquette C Cairns CP. Switching prescription drugs to over the counter. *BMJ*. 2005 Jan 1;330(7481):39-41
<http://dx.doi.org/10.1136/bmj.330.7481.39>
- RS 2420 Milne C-P Kaitin KI, guest editors. Preserving access by protecting innovation: partial proceedings of a symposium held at Tufts University European Center, Talloires, France, 16-18 July 2003. *PharmacoEconomics* 2004;22(Suppl 2). Includes: DiMasi JA Paquette C. The economics of follow-on drug research and development: trends in entry rates and the timing of development:1-14. Kaitin KI. Concluding remarks:95-6
- RS 2419 Cohen J. The emergence of a *de facto* fourth hurdle in the US. *Regulatory Affairs Journal – Pharma*. 2004;15(12):867-70
<http://www.amcp.org/WorkArea/DownloadAsset.aspx?id=12516>
- RS 2418 Kaitin KI, editor. Incremental R&D creates safer, more effective drugs & fosters competition. *Tufts Center for the Study of Drug Development Impact Report*. 2004 Nov/Dec;6(6)**
- RS 2417b DiMasi, J.A., Hansen, R.W., Grabowski, H.G., 2004. Assessing Claims About the Cost of New Drug Development: A Critique of the Public Citizen and TB Alliance Reports, 1 November.
- RS 2417 Reichert JM. New biotechnology therapeutics: challenges for the industry. *BIO – Greece*. 2004;10:38-40
- RS 2416 Pavlou AK Reichert JM. Recombinant protein therapeutics – success rates, market trends and values to 2010. *Nature Biotechnology*. 2004;22(12):1513-19
<http://dx.doi.org/10.1038/nbt1204-1513>

**This publication is for sale at our website <http://csdd.tufts.edu/reports>

- RS 2415 Kaitin KI, editor. Cost issues increasingly drive U.S. formulary and clinical guidelines. *Tufts Center for the Study of Drug Development Impact Report*. 2004 Sep/Oct;6(5)**
- RS 2414 DiMasi JA Grabowski HG Vernon J. R&D costs and returns by therapeutic category. *Drug Information Journal*. 2004;38(3):211-23
<http://dx.doi.org/10.1177/009286150403800301>
- RS 2413 Reichert JM. Biopharmaceutical approvals in the US increase. *Regulatory Affairs Journal – Pharma*. 2004;15(7):491-7
- RS 2412 DiMasi JA Grabowski HG. Patents and R&D incentives: comments on the Hubbard and Love trade framework for financing pharmaceutical R&D. June 25, 2004, W.H.O., Commission on Intellectual Property Rights, Innovation and Public Health [CIPIH]
<http://www.who.int/intellectualproperty/news/en/Submission3.pdf>
- RS 2411 Reichert J. Pharmacopolitics: drug regulation in the United States and Germany by Daemrich AE. [book review] *New England Journal of Medicine* 2004 May 20;350(21):2220-1
<http://dx.doi.org/10.1056/NEJM200405203502127>
- RS 2410 Kaitin KI. From the Editor-in-Chief. A tribute to Dr. Louis C. Lasagna: 1923-2003. *Drug Information Journal*. 2003;37(4):353-4
<http://dx.doi.org/10.1177/009286150303700401>
- RS 2409 Kaitin KI. In Memoriam: Louis C. Lasagna, M.D., 1923-2003. *American Journal of Therapeutics*. 2004;11(1):80-1
- RS 2408 Kaitin KI, editor. FDA requested postmarketing studies in 73% of recent new drug approvals. *Tufts Center for the Study of Drug Development Impact Report*. 2004 Jul/Aug;6(4)**
- RS 2407 Reichert J Pavlou A. Monoclonal antibodies market. *Nature Reviews Drug Discovery*. 2004;3(5):383-4
<http://dx.doi.org/10.1038/nrd1386>
- RS 2406 Milne C-P Paquette C. Meeting the challenge of the evolving R&D paradigm: what role for CROs? *American Pharmaceutical Outsourcing*. 2004 Mar/Apr;5(2):44-50
- RS 2405 Kaitin KI, editor. Therapeutic class a critical determinant of drug development time & cost. *Tufts Center for the Study of Drug Development Impact Report*. 2004 May/Jun;6(3)**

**This publication is for sale at our website <http://csdd.tufts.edu/reports>

- RS 2404 Deng R Kaitin KI. The regulation and approval of new drugs in China. *Drug Information Journal*. 2004;38(1):29-39
<http://dx.doi.org/10.1177/009286150403800105>
- RS 2403 Kaitin KI, editor. Faster review, longer response time mark new EU biopharmaceuticals. *Tufts Center for the Study of Drug Development Impact Report*. 2004 Mar/Apr;6(2)**
- RS 2402 Reichert JM. Trends in the development of therapeutic anti-cytokine antibodies. [letter] *Drug Discovery Today*. 2004 Apr;9(8):348
[http://dx.doi.org/10.1016/S1359-6446\(04\)03025-9](http://dx.doi.org/10.1016/S1359-6446(04)03025-9)
- RS 2401 Kaitin KI, editor. High cost of drug development spurs new ways to assess and manage risk. *Tufts Center for the Study of Drug Development Impact Report*. 2004 Jan/Feb;6(1)**
- RS 2400 *Outlook 2004*. Boston: Tufts Center for the Study of Drug Development. 2004
- RS 2318 Kaitin KI Cairns C. The new drug approvals of 1999, 2000, and 2001: drug development trends a decade after passage of the Prescription Drug User Fee Act of 1992. *Drug Information Journal*. 2003;37(3):357-71
<http://dx.doi.org/10.1177/009286150303700403>
- RS 2317b Cohen JP, Burg E. On the possibility of a positive sum-game between fairness and efficiency in health care. *The Journal of Medicine & Philosophy*. 2003;28(3):327-338.
<http://dx.doi.org/10.1076/jmep.28.3.327.14586>
- RS 2317 Cohen J Paquette C. Impact of disease management on cost-effectiveness of Medicare spending. *Drug Information Journal*. 2003;37(3):329-39
<http://dx.doi.org/10.1177/009286150303700310>
- RS 2316 Rawson NSB Kaitin KI. Canadian and US drug approval times and safety considerations. *Annals of Pharmacotherapy*. 2003;37(10):1403-8
<http://dx.doi.org/10.1345/aph.1D110>
- RS 2315 Cohen J. Switching omeprazole in Sweden and the United States. *American Journal of Therapeutics*. 2003 Sep/Oct;10(5):370-6
<http://dx.doi.org/10.1097/00045391-200309000-00010>
- RS 2314 Kaitin KI, editor. FDA's fast track initiative cut total drug development time by 3 years. *Tufts Center for the Study of Drug Development Impact Report*. 2003 Nov/Dec;5(6)**
- RS 2313 Reichert JM Paquette C. Therapeutic recombinant proteins: trends in US approvals 1982 to 2002. *Current Opinion in Molecular Therapeutics*. 2003;5(2):139-147

**This publication is for sale at our website <http://csdd.tufts.edu/reports>

- RS 2312 Kaitin KI, editor. Switching drugs from prescription to OTC status on rise in U.S. and EU. *Tufts Center for the Study of Drug Development Impact Report*. 2003 Sep/Oct;5(5)**
- RS 2311 Reichert JM Paquette C. Clinical development of therapeutic recombinant proteins. *BioTechniques*. 2003;35(1):176-8, 180, 182-5
http://www.biotechniques.com/multimedia/archive/00011/03351dd01_11442a.pdf
- RS 2310 Milne C-P Cairns C. Generic drug regulation in the US under the Hatch-Waxman Act: a balance between competition and innovation or confusion and intrigue? *Pharmaceutical Development and Regulation*. 2003;1(1):11-27
<http://dx.doi.org/10.1007/BF03257362>
- RS 2309 Reichert JM. Trends in development and approval times for new therapeutics in the United States. *Nature Reviews Drug Discovery*. 2003;2(9):695-703
<http://dx.doi.org/10.1038/nrd1178>
- RS 2308 Kaitin KI, editor. CROs provide gateway to worldwide clinical trial recruitment efforts. *Tufts Center for the Study of Drug Development Impact Report*. 2003 Jul/Aug;5(4)**
- RS 2307 Kaitin KI, editor. Post-approval R&D raises total drug development costs to \$897 million. *Tufts Center for the Study of Drug Development Impact Report*. 2003 May/Jun;5(3)**
- RS 2306 Lasagna L. Informed consent revisited: commentary. *Scrip Magazine*. 2003 Mar;121:21
- RS 2305 Cohen J. State-based versus federal-based approaches to reducing the Medicare pharmaceutical coverage gap. *International Journal of Health Services*. 2003;33(2):345-58
<http://dx.doi.org/10.2190/XD07-L5KF-YBFE-YB52>
- RS 2304 Milne C-P. Exploring the frontiers of law and science: the FDAMA's pediatric studies initiative. *Food and Drug Law Journal*. 2002;57(3):491-517
<https://litigation-essentials.lexisnexis.com/webcd/app?action=DocumentDisplay&crawlid=1&srctype=smi&srcid=3B15&doctype=cite&docid=57+Food+Drug+L.J.+491&key=18c220b0492f394deafe42af1779acfb>
- RS 2303 Kaitin KI, editor. Biopharmaceutical product approval times dropped 21% since 1980s. *Tufts Center for the Study of Drug Development Impact Report*. 2003 Mar/Apr;5(2)**

**This publication is for sale at our website <http://csdd.tufts.edu/reports>

- RS 2302 DiMasi JA Hansen RW Grabowski HG. The price of innovation: new estimates of drug development costs. *Journal of Health Economics*. 2003 May;22(2):151-85
[http://dx.doi.org/10.1016/S0167-6296\(02\)00126-1](http://dx.doi.org/10.1016/S0167-6296(02)00126-1)
- RS 2301 Kaitin KI, editor. Increased pressure on drug industry is leading to greater focus on Japan. *Tufts Center for the Study of Drug Development Impact Report*. 2003 Jan/Feb;5(1)**
- RS 2300 *Outlook 2003*. Boston: Tufts Center for the Study of Drug Development. 2003
- RS 2222 Milne C Kaitin K Ronchi E. Orphan drug laws in Europe and the US: incentives for the research and development of medicines for the diseases of poverty. (CMH Working Paper WG2:9) World Health Organization Commission on Macroeconomics and Health: Posted 6 December 2002
- RS 2221 Cohen J DiMasi J. Modeling a switch of loratadine from prescription to over-the-counter status. *Journal of Research in Pharmaceutical Economics*. 2001;11(3/4):43-54
- RS 2220 Milne C-P Lasagna L. The cost and value of new medicines in an era of change. *PharmacoEconomics* 2002;20(Suppl 3). *Includes*: DiMasi JA. The value of improving the productivity of the drug development process: faster times and better decisions:1-10; Grabowski H Vernon J DiMasi JA. Returns on research and development for 1990s new drug introductions:11-29; Lasagna L. Concluding remarks
<http://dx.doi.org/10.2165/00019053-200220003-00011>
- RS 2219 Spivey RN Lasagna L Jones JK Wardell W. The US FDA in the drug development, evaluation and approval process. In: Griffin JP, O'Grady J, eds. *Textbook of Pharmaceutical Medicine*. 4th ed. London: BMJ Books; 2002:702-18
- RS 2218 Kaitin KI, editor. Approval times for new drugs fell by more than a year during PDUFA. *Tufts Center for the Study of Drug Development Impact Report*. 2002 Nov/Dec;4(6)**
- RS 2217 Franco RJ Kaitin KI. Beyond the blockbuster: big pharma must rethink product development, striving for the speed and flexibility of mid-size players. *Pharmaceutical Executive*. 2002;22(11):74-80
<http://www.pharmexec.com/pharmexec/article/articleDetail.jsp?id=36729>
- RS 2216 Kaitin KI. Speeding access to important new drugs: the challenge of developing new pharmaceutical products for the elderly. In: *Biotechnology and healthy aging: policy implications of new research*. Paris: OECD; 2002:57-62
<http://www.oecd.org/science/biotech/2487386.pdf>

**This publication is for sale at our website <http://csdd.tufts.edu/reports>

- RS 2215 Kaitin KI, editor. Tufts CSDD quantifies savings from boosting new drug R&D efficiency. *Tufts Center for the Study of Drug Development Impact Report*. 2002 Sep/Oct;4(5)**
- RS 2214 Milne C-P. Orphan products – pain relief for clinical development headaches. *Nature Biotechnology*. 2002;20(8):780-4
<http://dx.doi.org/10.1038/nbt0802-780>
- RS 2213 Kaitin KI, editor. Approval times for priority-reviewed new drugs declined under PDUFA. *Tufts Center for the Study of Drug Development Impact Report*. 2002 Jul/Aug;4(4)**
- RS 2212 Reichert JM Paquette C. Therapeutic cancer vaccines on trial. *Nature Biotechnology*. 2002;20(7):659-63
<http://dx.doi.org/10.1038/nbt0702-659>
- RS 2211 Cohen J Chee J. Pharmacy benefit managers’ role in facilitating Medicare beneficiary access to pharmaceutical care. *Disease Management & Health Outcomes*. 2002;10(4):221-7
<http://dx.doi.org/10.1177/009286150103500228>
- RS 2210 Milne C-P. The Pediatric Studies Initiative. In: Mathieu M. *New drug approval in the United States*. Waltham, MA: Parexel;2002:319-45
- RS 2209 Kaitin KI, editor. Biotechnology has become vital to orphan product development. *Tufts Center for the Study of Drug Development Impact Report*. 2002 May/Jun;4(3)**
- RS 2208 Reichert JM Milne C-P. Public and private sector contributions to the discovery and development of ‘impact’ drugs. *American Journal of Therapeutics* 2002 Dec;9(12):543-55 {previously published as a *Tufts Center for the Study of Drug Development white paper*. Boston MA: The Center, May, 2002}
<http://www.ncbi.nlm.nih.gov/pubmed/12424516>
- RS 2207 Kaitin KI, editor. Disease management cuts inpatient costs via greater drug spending. *Tufts Center for the Study of Drug Development Impact Report*. 2002 Mar/Apr;4(2)**
- RS 2206 Cohen J. Are commercial disease managers willing and prepared to enter the Medicare market? *Drug Information Journal*. 2002;36(2):445-52
http://www.diahome.org/DIAHome/resources/content.aspx?type=eopdf&file=%2fproductfiles%2f8357%2fdiaj_11576.pdf
- RS 2205 Milne C-P. The single controlled trial: industry survey indicates that implementation is still a work in progress. *Drug Information Journal*. 2002;36(2):291-302
http://www.diahome.org/DIAHome/resources/content.aspx?type=eopdf&file=%2fproductfiles%2f8357%2fdiaj_11571.pdf

**This publication is for sale at our website <http://csdd.tufts.edu/reports>

- RS 2204 Kaitin KI. From the Editor-in-Chief: regulatory reform at the crossroads. *Drug Information Journal*. 2002;36(2):245-6
http://www.diahome.org/DIAHome/resources/content.aspx?type=eopdf&file=%2fproductfiles%2f8357%2fdiaj_11623.pdf
- RS 2203 Reichert JM Therapeutic monoclonal antibodies: trends in development and approval in the US. *Current Opinion in Molecular Therapeutics*. 2002;4(2):110-8
- RS 2202 DiMasi JA. Uncertainty in drug development: approval success rates for new drugs. In: Cato AE, Sutton L, Cato A III, eds. *Clinical trials and tribulations*. 2d ed. New York: Marcel Dekker;2002:361-77
- RS 2201 Kaitin KI, editor. Portfolio analysis links strategy to operations, improves performance. *Tufts Center for the Study of Drug Development Impact Report*. 2002 Jan/Feb;4(1)**
- RS 2200 *Outlook 2002*. Boston: Tufts Center for the Study of Drug Development. 2002
- RS 2123 Kaitin KI. El papel de la investigación básica. [editorial]. (Original title: The quest for cures -- the role of the research-based drug industry) *La Vanguardia* (Barcelona). 2001 18 Mar*
- RS 2122 Kaitin KI, participant. The importance of innovation in pharmaceutical research. *Pfizer Journal*. 1999;3(2):4-11
- RS 2121 Kaitin KI, editor. Biotech products proliferate, but total development times lengthen. *Tufts Center for the Study of Drug Development Impact Report*. 2001 Nov/Dec;3(6)**
- RS 2120 Kaitin KI, editor. Study measures single controlled trial use in new drug development. *Tufts Center for the Study of Drug Development Impact Report*. 2001 Sep/Oct;3(5)**
- RS 2119 DiMasi JA. Winners and losers in new drug innovation. *Medical Marketing & Media*. 2001;36(9):99-110
- RS2118b Cohen J. The interaction of state, multistate, and federal initiatives to control prescription drug costs in the United States. *Decision Resources*. 2001 Sep;12:1-12
- RS 2118 Reichert JM. Monoclonal antibodies in the clinic. *Nature Biotechnology*. 2001;19(9):819-22
<http://dx.doi.org/10.1038/nbt0901-819>

**This publication is for sale at our website <http://csdd.tufts.edu/reports>

- RS 2117 DiMasi JA Caglarcan E Wood-Armany M. The emerging role of pharmacoconomics in the R&D decision-making process. *PharmacoEconomics*. 2001;19(7):753-66
<http://dx.doi.org/10.2165/00019053-200119070-00004>
- RS 2116 Cohen J, participant. Assessing and communicating risks and benefits: challenges in an evolving health care environment. *Pfizer Journal*. 2001;4(5)
- RS 2115 Kaitin KI, editor. Biopharmaceutical R&D involves fewer studies than pharmaceuticals. *Tufts Center for the Study of Drug Development Impact Report*. 2001 Jul/Aug;3(4)**
- RS 2114 Milne C-P. The 4 ages of fast track. *Regulatory Affairs Focus*. 2001;6(7):9-13
- RS 2113 Cohen J Chee J. Pharmacy benefit managers and Medicare beneficiary access to prescription drugs. *Drug Information Journal*. 2001;35(2):569-76
<http://dx.doi.org/10.1177/009286150103500228>
- RS 2112 Cohen J Ubel P. Accounting for fairness and efficiency in health economics. Chapter 4 in: *The social economics of health care*, Davis JB, editor. New York: Routledge, 2001:94-109
- RS 2111 Reichert JM. Clinical development of therapeutic medicines: a biopharmaceutical versus pharmaceutical product comparison. *Drug Information Journal* 2001;35(2):337-46
<http://dx.doi.org/10.1177/009286150103500203>
- RS 2110 Kaitin KI, editor. Pharmaceutical firms making quicker decisions on compounds in R&D. *Tufts Center for the Study of Drug Development Impact Report*. 2001 May/Jun;3(3)**
- RS 2109 DiMasi JA. Risks in new drug development: approval success rates for investigational drugs. *Clinical Pharmacology & Therapeutics*. 2001;69(5):297-307
<http://dx.doi.org/10.1067/mcp.2001.115446>
- RS 2108 DiMasi JA. New drug development in the United States 1963-1999. *Clinical Pharmacology & Therapeutics*. 2001;69(5):286-96
<http://dx.doi.org/10.1067/mcp.2001.115132>
- RS 2107 Milne C-P. *White paper: the pediatric studies incentive: equal medicines for all*. Boston: Tufts Center for the Study of Drug Development. April 2001
- RS 2106 Kaitin KI, editor. Tufts Center survey describes disease management practice in the U.S. *Tufts Center for the Study of Drug Development Impact Report*. 2001 Mar/Apr;3(2)**

**This publication is for sale at our website <http://csdd.tufts.edu/reports>

- RS 2105 Milne C-P Bergman E. Fast track product designation under the Food and Drug Modernization Act: the industry experience. *Drug Information Journal*. 2001;35(1):71-83
<http://dx.doi.org/10.1177/009286150103500108>
- RS 2104 Reichert JM Chee J Kotzampaltiris C. The effects of the Prescription Drug User Fee Act and the Food and Drug Modernization Act on the development and approval of therapeutic medicines. *Drug Information Journal*. 2001;35(1):85-94
<http://dx.doi.org/10.1177/009286150103500109>
- RS 2103 Milne C-P. The pediatric studies initiative. In: Mathieu M. *New drug development: a regulatory overview*. 5th edition. Waltham, MA: Parexel;2000:439-77
- RS 2102 Kaitin KI, editor. FDA's fast track program results in 62% approval rate after first 3 years. *Tufts Center for the Study of Drug Development Impact Report*. 2001 Jan/Feb;3(1)**
- RS 2101 Reichert J Healy E. Biopharmaceuticals approved in the EU 1995-1999: a European Union--United States comparison. *European Journal of Pharmaceutics and Biopharmaceutics*. 2001;51(1):1-7
[http://dx.doi.org/10.1016/S0939-6411\(00\)00131-4](http://dx.doi.org/10.1016/S0939-6411(00)00131-4)
- RS 2100 *Outlook 2001*. Boston: Tufts Center for the Study of Drug Development. 2001
- RS 2025 DiMasi JA. *Price Trends for Prescription Pharmaceuticals: 1995-1999. A Background Report Prepared for the Department of Health and Human Services Conference on Pharmaceutical Pricing, Practices, Utilization and Costs, August 8-9, 2000, Leavey Conference Center, Georgetown University, Washington DC, 2000*.
<http://aspe.hhs.gov/health/reports/Drug-papers/dimasi-final.htm>
- RS 2024 DiMasi JA. New drug innovation and pharmaceutical industry structure: trends in the output of pharmaceutical firms. *Drug Information Journal*. 2000;34(4):1169-94
<http://dx.doi.org/10.1177/009286150003400425>
- RS 2023 Cross-functional team focus on marketing is key to project success. *Tufts Center for the Study of Drug Development Impact Report*. 2000 Dec;2(9)
- RS 2022 User fees credited with 51% drop in average approval times since 1993. *Tufts Center for the Study of Drug Development Impact Report*. 2000 Oct;2(8)
- RS 2021 Cohen JP Asch D Ubel P. Bioethics and medical decision making: what can they learn from each other? In: Chapman GB, Sonnenberg FA, eds. *Decision making in health care*. New York: Cambridge University Press;2000:253-66

**This publication is for sale at our website <http://csdd.tufts.edu/reports>

- RS 2020 Milne C-P Lasagna L, guest editors. Challenges and opportunities in the international pharmaceutical marketplace: a look to the future. Proceedings of a Symposium held at Talloires, France, 14-16 July, 1999. *PharmacoEconomics*. 2000;(Suppl 1)
<http://dx.doi.org/10.2165/00019053-200018001-00001>
- RS 2019 Cohen J. Patient autonomy and social fairness. *Cambridge Quarterly of Healthcare Ethics*. 2000;9:391-9
<http://dx.doi.org/10.1017/S0963180100903116>
- RS 2018 Kaitin KI. Don't turn back the clock on drug regulatory reform. *Tufts Center for the Study of Drug Development Impact Editorial*. 2000 Sep;2(7)
<http://dx.doi.org/10.1097/01.COT.0000293239.37468.b0>
- RS 2017 Cohen J. PBMs and Medicare prescription drug benefit management. *Food and Drug Law Journal*. 2000;55(3):311-20
<http://www.fdpi.org/resources/resources-order-box-detail-view/pbms-and-a-medicare-prescription-drug-benefit>
- RS 2016 Reichert JM. New biopharmaceuticals in the USA: trends in development and marketing approvals 1995-1999. *Trends in Biotechnology*. 2000;18(9):364-9
[http://dx.doi.org/10.1016/S0167-7799\(00\)01473-6](http://dx.doi.org/10.1016/S0167-7799(00)01473-6)
- RS 2015 Rawson NSB Kaitin KI. New drug approval times and 'therapeutic potential' in Canada, Australia, Sweden and the United States during the period 1992 to 1998. *Canadian Journal of Clinical Pharmacology*. 2000 Summer;7(2):97-101
- RS 2014 Kaitin KI DiMasi JA. Measuring the pace of new drug development in the user fee era. *Drug Information Journal*. 2000;34(3):673-80
<http://dx.doi.org/10.1177/009286150003400303>
- RS 2013 DiMasi JA Lasagna L. The economics of psychotropic drug development. In: Watson SJ, ed. *Psychopharmacology: the fourth generation of progress*. New York: Lippencott; Williams & Wilkins [CD-ROM] 1998
<http://www.acnp.org/g4/GN401000182/Default.htm>
- RS 2012 Milne C-P. The Food and Drug Administration Modernization Act and the Food and Drug Administration: metamorphosis or makeover? *Drug Information Journal*. 2000;34(3):681-92
<http://dx.doi.org/10.1177/009286150003400304>
- RS 2011 Maine enacts drug price controls; 16 other states taking similar action. *Tufts Center for the Study of Drug Development Impact Report*. 2000 Jul/Aug;2(6)
- RS 2010 Pharmaceutical industry innovation is more dispersed despite M&A activity. *Tufts Center for the Study of Drug Development Impact Report*. 2000 Jun;2(5)

**This publication is for sale at our website <http://csdd.tufts.edu/reports>

- RS 2009 Influence of pharmacoeconomics in drug R&D decisions is growing. *Tufts Center for the Study of Drug Development Impact Report*. 2000 May;2(4)
- RS 2008 Drug firms embrace pediatric study program during first 2 years of FDAMA. *Tufts Center for the Study of Drug Development Impact Report*. 2000 Apr;2(3)
- RS 2007 Lasagna L. Diuretics vs α blockers for treatment of hypertension: lessons from ALLHAT. *JAMA*. 2000 Apr 19;283(15):2013-4
<http://dx.doi.org/10.1001/jama.283.15.2013>
- RS 2006 Kaitin KI. The FDA drug review process: a view from the middle ground. In: FDA drug review: the debate over safety, efficacy, and speed. *Medical Crossfire* 1999 Apr 15;1(3):59-60
- RS 2005 *Demystifying central review boards: current options and future directions: central IRB review of multi-site trials: a summary report of outcomes from a conference held October 27-28, 1998, Arlington VA, Levine RJ Lasagna L Chodosh S, program co-chairs*. Boston: Tufts Center for the Study of Drug Development;1999
- RS 2004 European approval of new biotech drugs outpaces US approval. *Tufts Center for the Study of Drug Development Impact Report*. 2000 Mar;2(2)
- RS 2003 Milne C-P. The health of the world's children: what goes around, comes around. *Drug Information Journal*. 2000;34(1):213-21
<http://dx.doi.org/10.1177/009286150003400129>
- RS 2002 Effective data use drives portfolio management and global strategies. *Tufts Center for the Study of Drug Development Impact Report*. 2000 Jan;2(1)
- RS 2001 Kaitin KI Healy EM. The new drug approvals of 1996, 1997, and 1998: drug development trends in the user fee era. *Drug Information Journal*. 2000;34(1):1-14
<http://dx.doi.org/10.1177/009286150003400101>
- RS 2000 *Outlook 2000*. Boston: Tufts Center for the Study of Drug Development;2000
- RS 9915 Healy EM Kaitin KI. The European Agency for the Evaluation of Medicinal Products' centralized procedure for product approval: current status. *Drug Information Journal*. 1999;33(4):969-78
<http://dx.doi.org/10.1177/009286159903300401>
- RS 9914 Shulman SR DiMasi JA Kaitin KI. Patent term restoration: the impact of the Waxman-Hatch Act on new drugs and biologics approved 1984-1995. *Journal of BioLaw & Business*. 1999;2(4):63-8

**This publication is for sale at our website <http://csdd.tufts.edu/reports>

- RS 9913 European and U.S. approval times for new drugs are virtually identical. *Tufts Center for the Study of Drug Development Impact Report*. 1999 Nov;1(4)
- RS 9912 Planning, independence, feedback keep global R&D projects on track. *Tufts Center for the Study of Drug Development Impact Report*. 1999 Sep;1(3)
- RS 9911 Clinical development times for new drugs drop 18%, reversing 12-yr trend. *Tufts Center for the Study of Drug Development Impact Report*. 1999 Jul;1(2)
- RS 9910 Faster approval of new drugs does not compromise US public safety. *Tufts Center for the Study of Drug Development Impact Report*. 1999 Jun;1(1)
- RS 9909 Milne C-P. Pediatric research: coming of age in the new millennium. *American Journal of Therapeutics*. 1999 Sep;6(5):263-82
<http://dx.doi.org/10.1097/00045391-199909000-00006>
- RS 9908 Profile: The Tufts Center for the Study of Drug Development: researching the science, regulation, and economics of drug development. *International Journal of Risk & Safety in Medicine*. 1998 Dec;11(4):275-7
- RS 9907 *Seeking FDA Advice to Speed New Drug Development: The Role of FDA/Sponsor Meetings. A Symposium Organized by The Tufts Center for the Study for Drug Development, January 27, 1999, Philadelphia, Pennsylvania, Executive Summary*. Boston: Tufts CSDD, 1999
- RS 9906 Shulman SR Wood-Armany MJ. Accelerating access to cancer drugs. *Journal of BioLaw and Business*. 1999 Winter;2(2):38-44
- RS 9905 Kaitin KI Levy M, editors. *Speed to Market: Achieving Breakthrough Performance: Case Studies in R&D Management: Proceedings of the First Annual R&D Management Workshop, Sponsored by Tufts Center for the Study of Drug Development, cosponsored by SRI Consulting, November 12, 1997, American Academy of Arts and Sciences, Cambridge MA*. Boston: Tufts CSDD, 1998
- RS 9904 Lasagna L. Balancing risks versus benefits in drug therapy decisions. *Clinical Therapeutics*. 1998;20(Suppl C):C72-9
[http://dx.doi.org/10.1016/S0149-2918\(98\)80010-6](http://dx.doi.org/10.1016/S0149-2918(98)80010-6)
- RS 9903 Lasagna L. Rx: a heftier share for prescription drugs: giving medicine more of the health care pie could cut costs and aid patients. *Boston Globe*. 1998 Nov; 29:D2
- RS 9902 Lasagna L Kaitin KI. Issues facing the new FDA commissioner. *Science*. 1998 13 Nov;282(5392):1263
<http://dx.doi.org/10.1126/science.282.5392.1263>

**This publication is for sale at our website <http://csdd.tufts.edu/reports>

- RS 9901 Kaitin KI. Global drug development and international harmonization: the emergence of China as a world pharmaceutical player. *Drug Information Journal*. 1998;32(Suppl):1187s-92s
<http://dx.doi.org/10.1177/00928615980320S103>
- RS 9813 Kaitin KI, editor. *Improving the Process of Biopharmaceutical Development: Impact of Recent Initiatives. Proceedings from a Forum Sponsored by the Tufts Center for the Study of Drug Development, May 14, 1998 at the American Academy of Arts and Sciences, Cambridge MA*. Boston: Tufts CSDD, 1998
- RS 9812 Rawson NSB Kaitin KI Thomas KE Perry G. Drug review in Canada: a comparison with Australia, Sweden, and the United States. *Drug Information Journal*. 1998;32(4):1133-41
- RS 9811 Effects of U.S. regulatory policies on the research, development, and approval of new biotechnology derived biopharmaceuticals: points to consider for OECD member countries. Contributing authors: Gosse ME Kaitin KI Shulman SR DiMasi JA, Tufts Center for the Study of Drug Development. Chapter five of Part II: Biotechnology, medical innovation and the economy: a survey of the key relationships, in *Economic aspects of biotechnologies related to human health*. (OECD Reference # DSTI/STP/BIO(98)FINAL) Paris, Organization for Economic Co-operation and Development, 1998
- RS 9810 Lasagna L. Presentation of the Louis Lasagna Chair of Pharmacology and Experimental Therapeutics, Tufts University School of Medicine. *Journal of Clinical Pharmacology*. 1998;38:570-1, 575-6
<http://dx.doi.org/10.1002/j.1552-4604.1998.tb04460.x>
- RS 9809 Lasagna L Weintraub M, editors. *Year book of drug therapy*. St. Louis: Mosby, 1998*
- RS 9808 Lasagna L. The powerful placebo: from ancient priest to modern physician, by Shapiro AK and Shapiro E. [book review] *New England Journal of Medicine*. 1998 Apr 23;338(17):1236-7
<http://dx.doi.org/10.1056/NEJM199804233381722>
- RS 9807 Lasagna L. Recent trends in drug development. In: Higby GJ, Stroud EC, eds. *The Inside Story of Medicines: a Symposium*. Madison, WI: American Institute of the History of Pharmacy; 1997:217-22
- RS 9806 Lasagna L. Impacts of health care constraints on pharma research and production. In: Eser A, Just H, eds. *Health care under constraints: where, how and by whom to set priorities*. Berlin: Ernst Schering Research Foundation; 1997:13-6

**This publication is for sale at our website <http://csdd.tufts.edu/reports>

- RS 9805 Shulman SR Healy EM Lasagna L, editors. *PBMs: reshaping the pharmaceutical distribution network*. New York: Haworth, 1998. *Includes*: Shulman SR Lasagna L. PBMs of the 1990s: why they deserve a second look:1-6.* *Simultaneously published in Journal of Pharmaceutical Marketing & Management* 1998;12(2/3)*
http://dx.doi.org/10.3109/J058v12n02_01
- RS 9804 DiMasi JA. Patent term restoration for drugs and biologicals under the Drug Price Competition and Patent Term Restoration Act of 1984: a report prepared for the Subcommittee on Courts and Intellectual Property of the United States House Judiciary Committee, May 21, 1998
- RS 9803 Shulman SR Lasagna L, guest editors. Dynamics of the International Pharmaceutical Marketplace: Major Forces in the Late 1990s. Proceedings of a Symposium held at Talloires, France, 24-25 July, 1997. *PharmacoEconomics* 1998;14(Suppl 1). *Includes*: Shulman SR. Pharmaceutical Benefit Management Companies (PBMs): why should we be interested?:49-56; Lasagna L. Defining our future work:143-6
- RS 9802 Lasagna L. In pursuit of profitability and effectiveness in the global pharmaceutical industry: comments on Professor Walker's four challenges. *Indiana Journal of Global Legal Studies*. 1997 Fall;5(1):85-92
<http://www.jstor.org/stable/20644671>
- RS 9801 Manocchia M Lasagna L. Issues in pharmaceutical lotteries: the case of interferon beta-1b. *Clinical Pharmacology and Therapeutics*. 1997 Sep;62(3):241-7
[http://dx.doi.org/10.1016/S0009-9236\(97\)90026-6](http://dx.doi.org/10.1016/S0009-9236(97)90026-6)
- PS 9728 Shulman SR Lasagna L, editors. *Communicating Complex Medical Information: Can We Do Better? Proceedings from a Forum Sponsored by Tufts Center for the Study of Drug Development, Tufts University, & Emerson-Tufts Program in Health Communication, Center for Ethics in Political & Health Communication, April 17, 1997, American Academy of Arts and Sciences, Cambridge MA*. Boston: Tufts CSDD, 1997
- RS 9727 Shulman SR Manocchia M. The US Orphan Drug Programme: 1983-1995. *PharmacoEconomics*. 1997 Sep;12(3):312-26
<http://dx.doi.org/10.2165/00019053-199712030-00004>
- RS 9726 DiMasi JA Manocchia M. Initiatives to speed new drug development and regulatory review: the impact of FDA-sponsor conferences. *Drug Information Journal*. 1997;31(3):771-88
<http://dx.doi.org/10.1177/009286159703100319>
- RS 9725 Lasagna L Weintraub M, editors. *Year book of drug therapy 1997*. St. Louis: Mosby;1997*

**This publication is for sale at our website <http://csdd.tufts.edu/reports>

- RS 9724 Lasagna L. Medical foods: what is sufficient evidence to support a health-medical claim? *Clinical Research & Regulatory Affairs*. 1997;14(1):39-42
<http://dx.doi.org/10.3109/10601339709019438>
- RS 9723 DiMasi JA. *Improving the new drug development process. Testimony*. Hearing before the Subcommittee on Health and Environment of the Committee on Commerce, House of Representatives. Reauthorization of the Prescription Drug User Fee Act and FDA reform, April 23, 1997. 105th Congress 1st Session:46-52, 62-8
- RS 9722 Kaitin KI. The Prescription Drug User Fee Act of 1992 and the new drug development process. *American Journal of Therapeutics*. 1997 May;4(5/6):167-72
<http://dx.doi.org/10.1097/00045391-199705000-00002>
- RS 9721 Kaitin KI. The changing environment for innovation. *The Pfizer Journal* 1997 Winter;1(1):2
- RS 9720 Shulman SR. *Patent term restoration under Waxman-Hatch: 1984-1995*. Presentation to the House of Commons Standing Committee on Industry, Ottawa, Ontario, Canada, March 11, 1997
- RS 9719 DiMasi JA. *Statement*. Hearing before the Subcommittee on Health and Environment of the Committee on Commerce, House of Representatives. FDA Reform Legislation, May 2, 1996. 104th Congress 2d Session:376-81
- RS 9718 DiMasi JA. *Letter to Chairman Bilirakis*. Hearing before the Subcommittee on Health and Environment of the Committee on Commerce, House of Representatives. FDA Reform Legislation, May 2, 1996. 104th Congress 2d Session:425
- RS 9717 Kaitin KI Manocchia MA. The new drug approvals of 1993, 1994, and 1995: trends in drug development. *American Journal of Therapeutics*. 1997;4(1):46-54
<http://dx.doi.org/10.1097/00045391-199701000-00010>
- RS 9716 Gosse ME Nelson TF. Approval times for supplemental indications for recombinant proteins. *Nature Biotechnology*. 1997;15(2):130-4
<http://dx.doi.org/10.1038/nbt0297-130>
- RS 9715 Kaitin KI. FDA reform: setting the stage for efforts to reform the agency. *Drug Information Journal*. 1997;31(1):27-33
<http://dx.doi.org/10.1177/009286159703100105>
- RS 9714 Lasagna L DiMasi JA. Let's speed up the approval of new indications for old drugs. *Medical Marketing & Media* 1996;31(12):88-9

**This publication is for sale at our website <http://csdd.tufts.edu/reports>

- RS 9713 Gosse ME DiMasi JA Nelson TF. Recombinant protein and therapeutic monoclonal antibody drug development in the United States 1980-1994. *Clinical Pharmacology and Therapeutics*. 1996 Dec;60(6):608-18
[http://dx.doi.org/10.1016/S0009-9236\(96\)90209-X](http://dx.doi.org/10.1016/S0009-9236(96)90209-X)
- RS 9712 Gosse ME Manocchia M. First biopharmaceuticals approved in the U.S.:1980-1994. *Drug Information Journal*. 1996;30(4):991-1001
<http://dx.doi.org/10.1177/009286159603000416>
- RS 9625 DiMasi JA. *Written testimony*. House Subcommittee on Human Resources and Intergovernmental Affairs, Committee on Government Reform and Oversight, U.S. House of Representatives. September 12, 1996
- RS 9624 Lasagna L Frei E 3rd. The impact of regulations, tradition, and experimental design on clinical cancer trials: report and recommendations resulting from Washington Cancer Trials Conference. *American Journal of Clinical Oncology*. 1996 Aug;19(4):325-9
- RS 9623 Kaitin KI. *Statement*. Hearing before the Subcommittee on Health and Environment of the Committee on Commerce, House of Representatives. The Need for FDA Reform, February 27, 1996. 104th Congress 2d Session:81-7, 100-1
- RS 9622 Lasagna L. The safety of ibuprofen-caffeine combinations in clinical use. In: *Advances in the management of acute pain. Proceedings of a symposium sponsored by Proctor & Gamble Company, Monterrey, Mexico, March, 1996*. Holtz A, consulting editor. New York; London: The Royal Society of Medicine Press, 1996:129-35
- RS 9621 Lasagna L. The research dilemma. *The Wilson Quarterly*. 1996 Summer;XX(3):34-42
<http://archive.wilsonquarterly.com/essays/research-dilemma>
- RS 9620 Shulman SR. The dynamics of drug pricing and reimbursement in Canada. In: *International Forum on Pharmaceutical Benefit Scheme and Quality Care: Proceedings*. Pfizer Health Research Foundation, Tokyo, Japan, April 17, 1995:93-9
- RS 9619 Lasagna L. An overview on worldwide situation. In: *International Forum on Pharmaceutical Benefit Scheme and Quality Care: Proceedings*. Pfizer Health Research Foundation. Tokyo April;1995:69-73
- RS 9618 Welling PG Lasagna L Banakar UV, editors. *The drug development process*. New York; Marcel Dekker:1996*

**This publication is for sale at our website <http://csdd.tufts.edu/reports>

- RS 9617 Brown J Kaitin KI McAuslane N Thomas KE Walker SR. Population exposure required to assess clinical safety: report to the International Conference on Harmonization Working Group. *Drug Information Journal*. 1996;30(1):17-27
<http://dx.doi.org/10.1177/009286159603000103>
- RS 9616 Lasagna L. [participant] What's Happened to FDA's Road to Reform? An MM & M Executive Round Table. *Medical Marketing & Media*. 1996;31(4):32-41
- RS 9615 Lasagna L Weintraub M, editors. *Year book of drug therapy 1996*. St. Louis: Mosby;1996*
- RS 9614 Kaitin KI. Pharmaceutical innovation in a changing environment. Chapter 7 in: *Contested ground: public purpose and private interest in the regulation of prescription drugs*. Davis P, editor. New York: Oxford University Press; 1996:109-23
- RS 9613 Lasagna L. Comparison of U.S., European, and Japanese policies affecting pharmaceutical and biotechnology development. Chapter 19 in: *Biotechnology: science, engineering, and ethical challenges for the twenty-first century*. Rudolph FB McIntire LV, editors. Washington DC: Joseph Henry Press;1996:225-45
- RS 9612 Kaitin KI. *Written testimony on the FDA review process*. Subcommittee on Oversight and Investigation of the Committee on Commerce, U.S. House of Representatives, May 25 and June 19, 1995:130-5
- RS 9611 Shulman SR Lasagna L, editors. *Tufts Center for the Study of Drug Development Twentieth Anniversary Commemorative Lectures, Cambridge MA, American Academy of Arts and Sciences, May 1, 1996*. Boston: Tufts CSDD;1996
- RS 9610 DiMasi JA. A new look at United States drug development and approval times. *American Journal of Therapeutics* 1996;3(9):1-11
<http://dx.doi.org/10.1097/00045391-199609000-00008>
- RS 9609 Shulman SR Lasagna L, guest editors. Cost Containment, Health Care Reform and Pharmaceutical Innovation: Taking Stock in 1995. Proceedings of a Symposium held at Talloires, France, July 20-21, 1995. *PharmacoEconomics* 1996;10(Suppl 2). Includes: Shulman SR. Healthcare reform in the US: momentum shifts from federal to state governments:100-9
- RS 9608 DiMasi JA Brown JS Lasagna L. An analysis of regulatory review times of supplemental indications for already-approved drugs: 1989 to 1994. *Drug Information Journal*. 1996 Apr-Jun;30(2):315-37
<http://dx.doi.org/10.1177/009286159603000201>
- RS 9607 Shulman SR Brown JS. The Food and Drug Administration's early access and fast-track approval initiatives: how have they worked? *Food and Drug Law Journal*. 1995;50(4):503-31

**This publication is for sale at our website <http://csdd.tufts.edu/reports>

- RS 9606 Shulman SR Kaitin KI. The Prescription Drug User Fee Act of 1992: a five-year experiment for industry and the FDA. *PharmacoEconomics*. 1996;9(2):121-33
<http://dx.doi.org/10.2165/00019053-199609020-00004>
- RS 9605 Lasagna L. Over-the-counter hypnotics and chronic insomnia in the elderly. *Journal of Clinical Psychopharmacology*. 1995;15(6):383-6
<http://dx.doi.org/10.1097/00004714-199512000-00001>
- RS 9604 Kaitin KI. Pharmaceutical innovation in an era of reform. *American Journal of Therapeutics*. 1995;2(9):730-34
<http://dx.doi.org/10.1097/00045391-199509000-00023>
- RS 9603 Brown JS Bienz-Tadmor B Lasagna L. Availability of anticancer drugs in the United States, Europe, and Japan: 1960-1991. *Clinical Pharmacology and Therapeutics*. 1995 Sep;58(3):243-56
[http://dx.doi.org/10.1016/0009-9236\(95\)90240-6](http://dx.doi.org/10.1016/0009-9236(95)90240-6)
- RS 9507 Bienz-Tadmor B Seo PS Bryant NR. Research and development, manufacturing, and marketing of biopharmaceuticals: an international comparison. *Drug Information Journal*. 1995 Apr-Jun;29(4):523-30
<http://dx.doi.org/10.1177/009286159502900227>
- RS 9506 Shulman SR Seibring M Manocchia M. *Letter to Hon. Judd Gregg, U.S. Senate*. Hearing before the Subcommittee on Aging of the Committee on Labor and Human Resources, United States Senate, July 13, 1995 104th Congress 1st Session:47-8
- RS 9505 Lasagna L. *Statement: drugs and biologics: FDA review process*. Hearings before the Subcommittee on Oversight and Investigations of the Committee on Commerce, U.S. House of Representatives, June 19, 1995 104th Congress 1st Session:130-8
- RS 9504 Lasagna L Weintraub M, editors. *Year book of drug therapy 1995*. St. Louis: Mosby;1995*
- RS 9503 Lasagna L. The Helsinki Declaration: timeless guide or irrelevant anachronism? *Journal of Clinical Psychopharmacology*. 1995 Apr;15(2):96-8
<http://dx.doi.org/10.1097/00004714-199504000-00002>
- RS 9502 Shulman SR Lasagna L, editors. *FDA User Fees in an Era of Proposed FDA Reform: Proceedings from a Forum Sponsored by the Tufts Center for the Study of Drug Development, Tufts University, held at the American Academy of Arts & Sciences, Cambridge MA, May 18, 1995*. Boston: Tufts CSDD;1995

**This publication is for sale at our website <http://csdd.tufts.edu/reports>

- RS 9501 DiMasi JA. Success rates for new drugs entering clinical testing in the United States. *Clinical Pharmacology and Therapeutics*. 1995 Jul;58(1):1-14
[http://dx.doi.org/10.1016/0009-9236\(95\)90066-7](http://dx.doi.org/10.1016/0009-9236(95)90066-7)
- RS 9500 Bakke OM Manocchia M de Abajo F Kaitin KI Lasagna L. Drug safety discontinuations in the United Kingdom, the United States, and Spain from 1974 through 1993: a regulatory perspective. *Clinical Pharmacology and Therapeutics*. 1995 Jul;58(1):108-17
[http://dx.doi.org/10.1016/0009-9236\(95\)90078-0](http://dx.doi.org/10.1016/0009-9236(95)90078-0)
- RS 9599 Kaitin KI Houben H. Worthwhile persistence: the process of developing new drugs. *Odyssey: the Glaxo Wellcome Journal of Innovation in Healthcare*. 1995 Jun;1(3):54-9
- RS 9598 DiMasi J Grabowski HG Vernon J. R&D costs, innovative output and firm size in the pharmaceutical industry. *International Journal of the Economics of Business*. 1995 Jul;2(2):201-19
<http://dx.doi.org/10.1080/758519309>
- RS 9597 Kaitin KI, editor. White paper on four areas of relevance to new drug development and review in the United States. *Includes:* Kaitin KI Brown JS A drug lag update:361-73. [RS 9597a] DiMasi JA Trends in drug development costs, times, and risks:375-84. [RS 9597b] Shulman SR Hewitt P Manocchia M Studies and inquiries into the FDA regulatory process: a historical perspective:385-413. [RS 9597c] Lasagna L Improving the drug development process: needed reforms:415-24. [RS 9597d] *Drug Information Journal*. 1995;29(2):355-424
<http://dx.doi.org/10.1177//009286159502900202>
- PS 9596 Brown JS DiMasi JA Gosse ME Manocchia M Kaitin KI Shulman SR. *Incentives for the development of drugs for AIDS and other life-threatening illnesses: points to consider*. For the Public/Private Issues and Development Subcommittees of the National Task Force on AIDS Drug Development meeting, April 25, 1995
- RS 9595 DiMasi JA Hansen RW Grabowski HG Lasagna L. Research and development costs for new drugs by therapeutic category: a study of the U.S. pharmaceutical industry. *PharmacoEconomics*. 1995;7(2):152-69
<http://dx.doi.org/10.2165/00019053-199507020-00007>
- RS 9594 Bloom BR. The United States needs a national vaccine authority. *Science*. 1994 Sep 2;265(5177):1378-80
<http://dx.doi.org/10.1126/science.8073275>
- RS 9593 DiMasi JA Lasagna L. The economics of psychotropic drug development. Chapter 160 in: *Psychopharmacology: the fourth generation of progress*. Bloom FE Kupfer DJ, editors. New York: Raven Press;1995:1883-96

**This publication is for sale at our website <http://csdd.tufts.edu/reports>

<http://www.acnp.org/g4/GN401000182/Default.htm>

- RS 9592 Shulman SR Manocchia M Seibring M. The Drug Export Amendments Act of 1986: is it all it was intended to be? *Food and Drug Law Journal*. 1994;49(2):367-84
<http://www.fdpi.org/mobile/resources-detail-view/?friendlyname=the-drug-export-amendments-act-of-1986-is-it-all-it-was-intended-to-be>
- RS 9400 Kaitin KI. *Bad medicine: the prescription drug industry in the third world*, by Silverman M Lydecker M Lee PR. [book review] *Journal of Health Politics, Policy and Law*. 1994;19(4):922-5
<http://dx.doi.org/10.1215/03616878-19-4-922>
- RS 9499 Lasagna L Weintraub M, editors. *Year book of drug therapy 1994*. St. Louis: Mosby;1994*
- RS 9498 Kaitin KI. Population exposure required to assess clinical safety: a multinational retrospective study. In: *Proceedings of the Second International Conference in Harmonisation, Orlando, 1993*. Belfast, Northern Ireland: The Queen's University of Belfast;1994:358-62
- RS 9497 Lasagna L Shader RI. A white paper on the appropriateness of proposals by the FDA to modify labeling of benzodiazepine sedative-hypnotics. *Journal of Clinical Pharmacology*. 1994;34(8):812-5
<http://dx.doi.org/10.1002/j.1552-4604.1994.tb02044.x>
- RS 9496 Lasagna L. *Statement of Louis Lasagna, M.D., Dean, Tufts Sackler School of Graduate Biomedical Sciences at the National Institutes of Health CRADA forum, July 21, 1994*. Washington DC: New England Biomedical Research Coalition, 1994
- RS 9495 Lasagna L. Decision processes in establishing the efficacy and safety of psychotropic agents. In: Prien RF, Robinson DS, eds. *Clinical evaluation of psychotropic drugs: principles and guidelines*. New York: Raven;1994:13-28
- RS 9493 Shulman SR. Summary of accelerated approval regulations. In: *FDA Accelerated Approval: Dealing With Uncertainty: Summary of Proceedings*. Boston: ML Strategies;1994:6
- RS 9492 DiMasi JA Hay J Mitchell JR. The cost of drug development. *P&T* 1994 Jan;19:68-80
- RS 9491 Raiford DS Shulman SR Lasagna L. Determining appropriate reimbursement for prescription drugs: off-label uses and investigational therapies. *Food and Drug Law Journal*. 1994;49(1):37-76

**This publication is for sale at our website <http://csdd.tufts.edu/reports>

<http://www.fdi.org/resources/resources-order-box-detail-view/determining-appropriate-reimbursement-for-prescription-drugs-off-label-uses-and-investigational-therapies>

- PS 9490 Shulman SR Lasagna L, editors. *Moving Prescription Drugs to the Over-the-Counter Market: the Impact of Cost Containment and Health Care Reform. Proceedings from a forum sponsored by the Center for the Study of Drug Development, Tufts University, May 24, 1994.* Boston: Tufts CSDD, 1994
- RS 9489 Shulman SR Lasagna L, guest editors. Pricing and Reimbursement of Pharmaceuticals: an Evaluation of Cost-Containment Strategies. Proceedings of a Symposium held at Talloires, France, July 21-22, 1993. *PharmacoEconomics* 1994 6(Suppl 1). Includes: Shulman S The Canadian Patented Medicine Prices Review Board: new rules and new status:71-9
- RS 9488 Bienz-Tadmor B Brown J. Biopharmaceuticals and conventional drugs: comparing development times. *BioPharm.* 1994 Mar/Apr;7(2):44-9
- RS 9487 DiMasi JA. Risks, regulation, and rewards in new drug development in the United States. *Regulatory Toxicology and Pharmacology.* 1994;19(2):228-35
<http://dx.doi.org/10.1006/rtph.1994.1021>
- RS 9486 DiMasi JA Seibring MA Lasagna L. New drug development in the United States 1963 to 1992. *Clinical Pharmacology and Therapeutics.* 1994;55(6):609-22
<http://dx.doi.org/10.1038/clpt.1994.78>
- RS 9485 Inman WHW. Drug Safety Research Unit, University of Southampton. *PEM News.* 1993 Nov;(8)
- RS 9484 Smith ND. Quality of life studies from the perspective of an FDA reviewing statistician. *Drug Information Journal.* 1993;27(3):617-23
<http://dx.doi.org/10.1177/009286159302700306>
- RS 9483 Kaitin KI Manocchia M Seibring M Lasagna L. The new drug approvals of 1990, 1991, and 1992: trends in drug development. *Journal of Clinical Pharmacology.* 1994;34(2):120-7
<http://dx.doi.org/10.1002/j.1552-4604.1994.tb03975.x>
- RS 9382 Luce BR. Cost-effectiveness analysis: obstacles to standardisation and its use in regulating pharmaceuticals. *PharmacoEconomics* 1993;3(1):1-9
<http://dx.doi.org/10.2165/00019053-199303010-00001>
- RS 9381 Lasagna L Shulman SR. Bendectin and the language of causation. In: Foster KR Bernstein DE Huber PW, eds. *Phantom risk: scientific inference and the law.* Cambridge, MA: The MIT Press;1993:101-22

**This publication is for sale at our website <http://csdd.tufts.edu/reports>

- PS 9380 Shulman SR, editor. *Federal Support for New Drug Development: Are There Implications for Drug Pricing? A Forum sponsored by the Center for the Study of Drug Development, Tufts University, May 11, 1993*. Boston: Tufts CSDD, 1993
<http://csdd.tufts.edu/documents/www/9380Shulman.pdf>
- RS 9379 Shulman SR Gouveia W. Therapeutic substitution: an option for cost-effective prescribing? *PharmacoEconomics*. 1993;3(4):257-9
<http://dx.doi.org/10.2165/00019053-199202050-00001>
- RS 9378 Orzack LH Kaitin KI Lasagna L. Pharmaceutical regulation in the European Community: barriers to single market integration. *Journal of Health Politics, Policy and Law*. 1992;17(4):847-68
<http://dx.doi.org/10.12.15/03616878-17-4-847>
- RS 9377 Kaitin KI Bryant NR Lasagna L. The role of the research-based pharmaceutical industry in medical progress in the United States. *Journal of Clinical Pharmacology*. 1993;33(5):412-7
<http://dx.doi.org/10.1002/j.1552-4604.1993.tb04680.x>
- RS 9376 Bienz-Tadmor B. Biopharmaceuticals go to market: patterns of worldwide development. *Bio/Technology*. 1993;11(2):168-72
<http://dx.doi.org/10.1038/nbt0293-168>
- PS 9375 Bienz-Tadmor B, editor. *Center for the Study of Drug Development Proceedings of Workshop on Biotechnology, September 16, 1992*. Boston: Tufts CSDD, 1992
- RS 9374 Shulman SR Bienz-Tadmor B Seo PS DiMasi JA Lasagna L. Implementation of the Orphan Drug Act: 1983-1991. *Food and Drug Law Journal*. 1992;47(4):363-403
- RS 9276 Seo PS Kaitin KI. FDA's review of new drug applications: recent trends. *Journal of Clinical Research and Pharmacoepidemiology*. 1992;6(3):159-68
- RS 9275 DiMasi JA Hansen RW Grabowski HG Lasagna L. Research and development costs for new drugs. In: *Pharmaceutical manufacturing international 1992: the international review of pharmaceutical technology, research, and development*. Barnal P, editor. London: Sterling;1992
- RS 9274 Shulman SR Raiford DS. Promotional elements in educational programs: FDA attempts to wipe the slate clean. *P&T*. 1992;17:661-73*
- RS 9273 *The Development and Use of Antiprogesterin Drugs: Social, Political, Economic and Legal Issues, Medicine in the Public Interest Conference, February 6-7, 1992*. Boston;MIPI:1992
- RS 9272 Lerner BH. Scientific evidence versus therapeutic demand: the introduction of the sulfonamides revisited. *Annals of Internal Medicine*. 1991;115(4):315-20
<http://dx.doi.org/10.7326/0003-4819-115-4-315>

**This publication is for sale at our website <http://csdd.tufts.edu/reports>

- RS 9271 Kaitin KI Walsh HL. Are initiatives to speed the new drug approval process working? *Drug Information Journal*. 1992;26:341-9
<http://dx.doi.org/10.1177/009286159202600305>
- RS 9270 Shulman SR DiCerbo PA Ulcickas ME Lasagna L. A survey of therapeutic substitution programs in ten Boston area hospitals. *Drug Information Journal*. 1992;26(3):41-52
<http://dx.doi.org/10.1177/009286159202600105>
- RS 9269 Sheiner LB. The intellectual health of clinical drug evaluation. *Clinical Pharmacology and Therapeutics*. 1991 Jul;50(1):4-9
<http://dx.doi.org/10.1038/clpt.1991.97>
- RS 9268 Bienz-Tadmor B DiCerbo PA Tadmor G Lasagna L. Biopharmaceuticals and conventional drugs: clinical success rates. *Bio/Technology*. 1992 May;10(5):521-5
<http://dx.doi.org/10.1038/nbt0592-521>
- RS 9267 Lasagna L Shulman SR, guest editors. Cost Containment and Pharmaceuticals: Issues for Future Research. Proceedings of a Symposium held at Talloires, France, July 3-5. 1991. *PharmacoEconomics* 1992 1(Suppl 1). Includes: DiMasi JA. Rising research and development costs for new drugs in a cost containment environment:13-20. Shulman SR. The reimbursement factor in pharmaceutical regulation: rebates, cost-effectiveness, and practice guidelines:21-7
- RS 9266 Scoville B. Shifting the burden: restructuring the drug review process. *Journal of Clinical Pharmacology and Therapeutics*. 1991;49(3):229-33
<http://dx.doi.org/10.1038/clpt.1991.21>
- RS 9265 Hawkins ES Reich MR. Japanese-originated pharmaceutical products in the United States from 1960-1989: an assessment of innovation. *Clinical Pharmacology and Therapeutics*. 1992;51(1):1-11
- RS 9264 Kaitin KI. Case studies of expedited review: AZT and L-Dopa. *Law, Medicine & Health Care*. 1991;19(3-4):242-6
<http://dx.doi.org/10.1111/j.1748-720X.1991.tb01821.x>
- RS 9263 DiMasi JA Bryant NR Lasagna L. New drug development in the United States from 1963 to 1990. *Clinical Pharmacology and Therapeutics*. 1991 Nov;50(5):471-86
<http://dx.doi.org/10.1038/clpt.1991.172>
- RS 9166 Kaitin KI. Graft-versus-host disease. [letter] *New England Journal of Medicine*. 1991 Aug 1;325(5):357-8
<http://dx.doi.org/10.1056/NEJM199108013250513>

**This publication is for sale at our website <http://csdd.tufts.edu/reports>

- RS 9165 Lasagna L. The chilling effect of product liability on new drug development. In: Huber PW Litan RE, eds. *The liability maze: the impact of liability law on safety and innovation*. Washington DC: Brookings Institution;1991:334-56
- RS 9164 DiCerbo PA Kaitin KI. Recent trends in the US drug approval process. *Journal of Clinical Research and Pharmacoepidemiology*. 1991;4:235-9
- RS 9163 Fernandez-Carol CM Kaitin KI. The generic scandal and FDA reforms. *Pharmaceutical Medicine*. 1991;5:13-17
- RS 9162 Inman WHW. Drug Safety Research Unit, University of Southampton. *PEM News*. 1991 Aug;(7)
- RS 9161 DiMasi JA Hansen RW Grabowski HG Lasagna L. Cost of innovation in the pharmaceutical industry. *Journal of Health Economics*. 1991;10(2):107-42
[http://dx.doi.org/10.1016/0167-6296\(91\)90001-4](http://dx.doi.org/10.1016/0167-6296(91)90001-4)
- RS 9160 Shulman SR. Clinical practice guidelines and malpractice law: an evolving standard of care. *Food Drug Cosmetic Law Journal*. 1991;46(1):97-106
- RS 9159 DiMasi JA Kaitin KI Fernandez-Carol C Lasagna L. New indications for already-approved drugs: an analysis of regulatory review times. *Journal of Clinical Pharmacology*. 1991;31(3):205-15
<http://dx.doi.org/10.1002/j.1552-4604.1991.tb04963.x>
- RS 9158 DiMasi JA Lasagna L. Development of supplemental indications for already-approved drugs by the United States pharmaceutical industry. *Journal of Clinical Research and Pharmacoepidemiology*.1991;5:19-33
- RS 9157 Kaitin KI DiCerbo PA Lasagna L. The new drug approvals of 1987, 1988, and 1989: trends in drug development. *Journal of Clinical Pharmacology*. 1991;31(2):116-22
<http://dx.doi.org/10.1002/j.1552-4604.1991.tb03694.x>
- RS 9156 Salsburg D. Hypothesis versus significance testing for controlled clinical trials: a dialogue. *Statistics in Medicine*. 1990;9:201-11
<http://dx.doi.org/10.1002/sim.4780090302>
- RS 9155 Overall JE. Tests of one-sided versus two-sided hypotheses in placebo-controlled clinical trials. *Neuropsychopharmacology*. 1990;3(4):233-5
- RS 9154 Brown MS Wastila LJ Barash CI Lasagna L. Patient perceptions of drug risks and benefits. *Issues in Health & Safety*. 1990;1:203-16
- RS 9153 Kaitin KI Phelan NR Raiford D Morris B. Therapeutic ratings and end-of-phase II conferences: initiatives to accelerate the availability of important new drugs. *Journal of Clinical Pharmacology*. 1991;31(1):17-24

**This publication is for sale at our website <http://csdd.tufts.edu/reports>

<http://dx.doi.org/10.1002/j.1552-4604.1991.tb01882.x>

- RS 9056 Hawkins ES. Biotechnology in the US pharmaceutical industry. *Pharmaceutical Medicine* 1990;4:299-302
- RS 9055 Hawkins ES. U.S.A.: più di 400 prodotti di biotecnologia in fase di sperimentazione clinica. *Informazioni Stampa Interesse Sanitario* (Rome) 1990;#10:23-4*
- RS 9054 Shulman SR. La legislazione sulla responsabilità di produzione. *Informazioni Stampa Interesse Sanitario* (Rome) 1990 Apr 9;#15:27-8
- RS 9053 Lasagna L. Le attività del Centro per lo Studio dello Sviluppo dei Farmaci. *Informazioni Stampa Interesse Sanitario* (Rome) 1990 Apr 9;#15:26
- RS 9052 Inman WHW. Drug Safety Research Unit, University of Southampton, *PEM News*. 1988 Sep(5)
- RS 9051 Wastila LJ Richard BW DiCerbo PA Lasagna L. Viewpoint: The Catastrophic Care Act: lessons to be learned. *American Pharmacy*. 1990; NS30(6):22-3
- RS 9050 Lasagna L. On achieving consensus regarding flexible therapeutic end points. *Drug Information Journal*. 1990;24:231-4
<http://dx.doi.org/10.1177/009286159002400135>
- RS 9049 Kaitin KI. Impact of policy research on drug development strategies. *Drug Information Journal*. 1990;24:207-12
<http://dx.doi.org/10.1177/009286159002400132>
- RS 9048 Shulman SR Raiford DS. FDA regulations provide broader access to unapproved drugs. *Journal of Clinical Pharmacology*. 1990;30(2):585-7
<http://dx.doi.org/10.1002/j.1552-4604.1990.tb01860.x>
- RS 9047 Hutt PB. A history of government regulation of adulteration and misbranding of medical devices. *Food Drug Cosmetic Law Journal*. 1989;44:99-117
- RS 9046 Vodra WW. How the FDA regulates drug promotion and medical education before drug approval. *Drug Information Journal*. 1989;23:585-96
<http://dx.doi.org/10.1177/009286158902300406>
- RS 9045 Wastila LJ Lasagna L. The history of zidovudine (AZT). *Journal of Clinical Research and Pharmacoepidemiology*. 1990;4:25-37

**This publication is for sale at our website <http://csdd.tufts.edu/reports>

- PS 9044 Shulman SR Lasagna L, editors. *Trends in Product Liability Law and No-Fault Compensation for Drug-Induced Injuries. Proceedings of an International Symposium held at Talloires, France, September 14-16, 1989 by the Center for the Study of Drug Development.* Boston: Tufts CSDD, 1989. Includes: Shulman SR. Tort law reform:46-9
- RS 9043 Richard BW Melville A Lasagna L. Postapproval research as a condition of approval: an update, 1985-1986. *Journal of Clinical Research and Drug Development.* 1989;3:247-57
- RS 9042 Shulman SR. The broader message of Accutane. *American Journal of Public Health.* 1989;79(11):1565-8
<http://dx.doi.org/10.2105/AJPH.79.11.1565>
- RS 9041 Lawson DH. Use of advisory committees, consultants, and academic reviewers by drug regulatory authorities. *Drug Information Journal.* 1988;22(1):19-23
<http://dx.doi.org/10.1177/009286158802200104>
- RS 9040 Kaitin KI Melville A Morris B. FDA advisory committees and the new drug approval process. *Journal of Clinical Pharmacology.* 1989;29:886-90
<http://dx.doi.org/10.1002/j.1552-4604.1989.tb03249.x>
- RS 8941 Kaitin KI. Reply to “understanding comparisons of drug introductions between the United States and the United Kingdom”. *Clinical Pharmacology & Therapeutics.* 1989 Aug;46(2);146-8
<http://dx.doi.org/10.1038/clpt.1989.118>
- RS 8940 Lasagna L. Barriers to effective anti-infective therapy: the perspective of a clinical pharmacologist. In: *Perspectives in anti-infective therapy: current topics in infectious diseases and clinical microbiology, Vol 2.* Jackson GG Schulmberger HD Zeiler HJ, editors. Braunschweig, Germany: Vieweg,1989:284-7
- RS 8939 Richard BW Ulcickas ME Lasagna L. Approvable letters in the FDA new drug approval process. *Journal of Clinical Pharmacology.* 1989;29(8):680-4
<http://dx.doi.org/10.1002/j.1552-4604.1989.tb03402.x>
- RS 8938 Wastila LJ Ulcickas ME Lasagna L. The World Health Organization's Essential Drug List: the significance of me-too and follow-on research. *Journal of Clinical Research and Drug Development.* 1989;3:105-15
- RS 8937 Shulman SR Ulcickas ME. Update on ADR reporting regulations: products liability implications. *Journal of Clinical Research and Drug Development.* 1989;3:91-103

- RS 8936 Kaitin KI Mattison N Northington FK Lasagna L. The drug lag: an update of new drug introductions in the United States and the United Kingdom, 1977 through 1987. *Clinical Pharmacology and Therapeutics*. 1989;46(2):121-38
<http://dx.doi.org/10.1038/clpt.1989.116>
- RS 8935 Lasagna L. Congress, the FDA, and new drug development: before and after 1962. *Perspectives in Biology and Medicine*. 1989;32(3):322-43
- RS 8934 Grabowski HG. Medicaid patients' access to new drugs. *Health Affairs* 1989;7:102-14
<http://dx.doi.org/10.1377/hlthaff.7.5.102>
- RS 8933 Kowey PR Fisher L Giardina EG Leier CV Lowenthal DT Messerli FH Pratt CM. The TPA controversy and the drug approval process: the view of the Cardiovascular and Renal Drugs Advisory Committee. *JAMA*. 1988;260(15):2250-2
<http://dx.doi.org/10.1001/jama.1988.03410150098038>
- RS 8932 Nichols AL Zeckhauser RJ. The perils of prudence: how conservative risk assessments distort regulation. *Regulatory Toxicology and Pharmacology*. 1988;8:61-75
[http://dx.doi.org/10.1016/0273-2300\(88\)90007-4](http://dx.doi.org/10.1016/0273-2300(88)90007-4)
- RS 8931 Schmidt AM. Ideals and reality in actual regulatory experience. *Regulatory Toxicology and Pharmacology*. 1988;8:257-66
[http://dx.doi.org/10.1016/0273-2300\(88\)90013-X](http://dx.doi.org/10.1016/0273-2300(88)90013-X)
- RS 8930 Inman WHW. Drug Safety Research Unit, University of Southampton. *PEM News*. 1988 Sep;(5)
- RS 8929 Kaitin KI. Thalidomide revisited: new clinical uses for an old drug. *Pharmaceutical Medicine*. 1988;3:203-10
- RS 8928 Mattison N. The FDA's treatment IND: current controversies. *Pharmaceutical Medicine*. 1988;3:159-71
- RS 8927 Shulman SR Richard BW. The 1987 Canadian patent law amendments: revised pharmaceutical compulsory licensing provisions. *Food Drug Cosmetic Law Journal*. 1988 Sep;43(4):745-57
- RS 8830 Shulman SR. Drug refusal policy must include legal definition of competence. *Hospital Formulary*. 1988 Jan;23:79
- RS 8829 DiMasi JA. The notion of "acceptable risk": comment. *Journal of Clinical Epidemiology*. 1988;41(9):939-41
[http://dx.doi.org/10.1016/0895-4356\(88\)90111-4](http://dx.doi.org/10.1016/0895-4356(88)90111-4)

**This publication is for sale at our website <http://csdd.tufts.edu/reports>

- RS 8828 DiMasi JA. The economic and social impact of drug innovation on the delivery of health care: recent trends. *Private Practice*. 1988;20:32-5
- RS 8827 Lasagna L. The TPA controversy: letter and commentaries. *Journal of Clinical Research and Drug Development*. 1988;2(1):7-9
- RS 8826 *The Health Care Cost-containment Movement: a Reconsideration. Medicine in the Public Interest Conference, March 6-7, 1987*. Boston: MIPI, 1987
- RS 8825 Richard BW Lasagna L. Anorectic drugs: drug policy making at the state level. *Journal of Clinical Pharmacology*. 1988 May;28(5):395-400
<http://dx.doi.org/10.1002/j.1552-4604.1988.tb05747.x>
- RS 8824 Wittes RE. Antineoplastic agents and FDA regulations: square pegs for round holes? *Cancer Treatment Reports*. 1987;71(9):795-806
- RS 8823 Miller L Dalton M Vestal R Perkins JG Lyon G. Delays in the drug approval process: recent trends. *Journal of Clinical Research and Drug Development*. 1988;2:31-45
- RS 8822 *Checks and Balances in the Practice of Medicine and Pharmacy: Issues in Prescribing and Dispensing Drugs. Medicine in the Public Interest Conference, Jun 22-3, 1987*. Boston: MIPI, 1987
- RS 8821 Kaitin KI Trimble AG. Implementation of the Drug Price Competition and Patent Term Restoration Act of 1984: a progress report. *Journal of Clinical Research and Drug Development*. 1987;1:263-75
- RS 8820 Brown M Richard BW. Advisory committees and the drug approval process. *Journal of Clinical Research and Drug Development*. 1988;21:15-27
- RS 8819 Mattison N Trimble AG Lasagna L. New drug development in the United States, 1963 through 1984. *Clinical Pharmacology and Therapeutics*. 1988 Mar;43(3):290-301
<http://dx.doi.org/10.1038/clpt.1988.35>
- RS 8818 Roberts EB Hauptman O. The financing threshold effect on success and failure of biomedical and pharmaceutical start-ups. *Management Science*. 1987;33(3):381-94
<http://dx.doi.org/10.1287/mnsc.33.3.381>
- RS 8817 Berlin H Jonsson B. International dissemination of new drugs: a comparative study of six countries. *Managerial and Decision Economics*. 1986;7:235-42
<http://dx.doi.org/10.1002/mde.4090070404>
- RS 8816 Mattison N Richard BW. Postapproval research requested by the FDA at the time of NCE approval, 1970-1984. *Drug Information Journal*. 1987;21(3):309-29

**This publication is for sale at our website <http://csdd.tufts.edu/reports>

<http://dx.doi.org/10.1177/009286158702100310>

- RS 8815 Kaitin KI Richard BW Lasagna L. Trends in drug development: the 1985-86 new drug approvals. *Journal of Clinical Pharmacology*. 1987 Aug;27(8):542-8
<http://dx.doi.org/10.1002/j.1552-4604.1987.tb03064.x>
- RS 8721 Presented and invited papers from Tenth Anniversary Commemorative Conference. Special Issue on the Center for the Study of Drug Development. *Clinical Research Practices and Drug Regulatory Affairs*. 1987;5(5&6)*
- RS 8720 Hansen R. Effects of cost containment on pharmaceutical innovation. *Clinical Research Practices and Drug Regulatory Affairs*. 1987;5(5&6):345-54
<http://dx.doi.org/10.3109/10601338709032965>
- RS 8719 Hansen R. Pharmaceutical regulation: the past and future twenty-five years. In: Teeling-Smith G, ed. *Health economics: prospects for the future*. London: Crook Helm; 1987:259-68
- RS 8718 Lasagna L. The biological revolution: commercialization of the molecule. *Research Management Review*. 1987;1(2):5-13
- RS 8717 Lasagna L. Predicting human drug safety from animal studies: current issues. *Journal of Toxicological Sciences*. 1987;12(4):439-50
<http://dx.doi.org/10.2131/jts.12.439>
- RS 8716 Lasagna L. The desire to regulate: the wish to discover. *Drugs Under Experimental and Clinical Research*. 1987;13(11):659-64
- RS 8715 Barash CI Lasagna L. The Bendectin saga: "voluntary" discontinuation. *Journal of Clinical Research and Drug Development*. 1987;1(4):277-92
- RS 8714 Spivey RN Lasagna L Trimble AG. New indications for already-approved drugs: time trends for the new drug application review phase. *Clinical Pharmacology and Therapeutics*. 1987 Apr;41(4):368-70
<http://dx.doi.org/10.1038/clpt.1987.42>
- RS 8713 Richard BW Lasagna L. Drug regulation in the United States and the United Kingdom: the Depo-Provera story. *Annals of Internal Medicine*. 1987 Jun;106(6):886-91
<http://dx.doi.org/10.7326/0003-4819-106-6-886>
- RS 8712 Scheuplein RJ. Risk assessment and food safety: a scientist's and regulator's view. *Food Drug Cosmetic Law Journal*. 1987;42:237-50

**This publication is for sale at our website <http://csdd.tufts.edu/reports>

- PS 8711 Lasagna L, editor. *Center for the Study of Drug Development Conference on Postmarketing Surveillance of Multisource Drugs, July 9-10, 1986*. Boston: Tufts CSDD; 1986
- RS 8710 Inman WHW. Drug Safety Research Unit, University of Southampton, *PEM News*. 1987 Mar;(4)
- RS 8709 Venulet J. Informativity of adverse drug reactions data in medical publications. *Drug Information Journal*. 1985;19:357-65
<http://dx.doi.org/10.1177/009286158501900327>
- RS 8708 Lasagna L. On reducing waste in foreign clinical trials and postregulation experience. *Clinical Pharmacology and Therapeutics*. 1986 Oct;40(4):369-72
<http://dx.doi.org/10.1038/clpt.1986.192>
- RS 8707 Grabowski HG. Health care cost containment and pharmaceutical innovation. In: *Pharmaceuticals for the elderly: new research and new concerns*. Washington DC: Pharmaceutical Manufacturers Association, Office of Policy Analysis, 1986:25-8
- RS 8706 Keefe DL Ehrreich SJ Levitt B. Problems in new-drug development: therapeutic agents for ventricular arrhythmias. *Journal of Clinical Pharmacology*. 1986;26:562-6
<http://dx.doi.org/10.1002/j.1552-4604.1986.tb02950.x>
- RS 8705 Kaitin KI. Impact of generic drugs on the pharmaceutical marketplace. *Private Practice*. 1986 Sep;18:18-20 (Originally appeared as "Generic firms shun research, share rewards.")
- RS 8704 Lasagna L. Clinical testing of products prepared by biotechnology. *Regulatory Toxicology and Pharmacology*. 1986;6(4):385-90
[http://dx.doi.org/10.1016/0273-2300\(86\)90006-1](http://dx.doi.org/10.1016/0273-2300(86)90006-1)
- PS 8703 Appley MH Lasagna L, editors. *Who are the elderly? Report of a Conference on the Definition of Aging, June 23, 1986*. Boston: The Center for the Study of Drug Development, 1986
- RS 8609 Lasagna L. The Lilly Prize lecture. University of London, December 1986. On assuring pharmacotherapeutic progress in the 21st century. *British Journal of Clinical Pharmacology*. 1987;23(6):659-65
<http://dx.doi.org/10.1111/j.1365-2125.1987.tb03099.x>
- RS 8608 Lasagna L. The economics of generic prescribing: winners and losers. *JAMA*. 1986 Nov 14;256(18):2566
<http://dx.doi.org/10.1001/jama.1986.03380180128035>

**This publication is for sale at our website <http://csdd.tufts.edu/reports>

- RS 8607 Lasagna L, editor. *Therapeutic Substitution Symposium. Report of Medicine in the Public Interest Conference held at Tufts University, Dec 4-5, 1985*. Boston: MIPI, 1986
- RS 8606 Mattison N. Drug development in the United States. In: *Proceedings: 1985 Research and Scientific Development Conference*. Washington DC: Proprietary Association, 1986*
- RS 8605 Hansen RW. New pharmaceuticals reduce cost of illness. *Canadian Journal of Pharmacy*.1986 Jun;119(6):318-25
- RS 8604 Lasagna L Werkö L. International differences in drug regulation philosophy. In: Special section -- The evaluation of drugs: An international perspective. Lasagna L Werkö L, guest editors. *International Journal of Technology Assessment in Health Care*. 1986;2(4):615-8
<http://dx.doi.org/10.1017/S0266462300003445>
- RS 8603 Mattison N. Review of compendium of new drug approvals in eleven industrialized countries, 1970-83, by the Office of Planning and Evaluation, Food and Drug Administration. *Journal of Clinical Psychopharmacology*. 1986;6(1):63-4*
- RS 8602 Salsburg DS. The religion of statistics as practiced in medical journals. *American Statistician*. 1985;39(3):220-3
<http://dx.doi.org/10.1080/00031305.1985.10479435>
- RS 8601 Sharlin HI. EBD: a case study in communicating risk. *Risk Analysis* 1986;6(1):61-8
<http://dx.doi.org/10.1111/j.1539-6924.1986.tb00194.x>
- RS 8600 Berry CL. Unprovable verities. *Human Toxicology*. 1985;5(3):159-60
- RS 8699 Weintraub M Northington F. Drugs that wouldn't die. *Journal of the American Medical Association*. 1986 May 2;255(17):2327-8
<http://dx.doi.org/10.1001/jama.1986.03370170091042>
- RS 8698 Spivey RN Trimble AG. Effect of the Drug Price Competition Act on market exclusivity of new drugs: a simulation. *Drug Information Journal*. 1986;20(1):27-35
<http://dx.doi.org/10.1177/009286158602000105>
- RS 8697 Mattison N. Pharmaceutical innovation and generic drug competition in the USA: effects of the Drug Price Competition and Patent Term Restoration Act of 1984. *Pharmaceutical Medicine*. 1986;1:177-85
- RS 8696 Inman WHW. Drug Surveillance Research Unit, University of Southampton. *PEM News*. 1985 Dec;(3)

**This publication is for sale at our website <http://csdd.tufts.edu/reports>

- RS 8695 Lasagna L. Clinical trials in the natural environment. In: *Drugs Between Research and Regulations: Proceedings of the 5th International Meeting of Pharmaceutical Physicians, Munich, Oct 14-7, 1984*. Steichele C Abshagen U Koch-Weser J, editors. New York: Springer-Verlag, 1985:45-9
- RS 8694 Kitch E. Vaccines and product liability: a case of contagious litigation. *Regulation*. 1985 May/Jun
- RS 8693 Napke E. Adverse reactions: some pitfalls and postulates. In: *Side effects of drugs annual 7*. Dukes M, editor. Amsterdam: Excerpta Medica, 1983
- RS 8692 Girard M. Testing the methods of assessment for adverse drug reactions. *Adverse Drug Reactions and Acute Poisoning Reviews*. 1984;4:237-44
- RS 8691 Walker SR Schultz E Schuppan D Gelzer J. A comparative retrospective analysis of data for short- and long-term animal toxicity studies on 40 pharmaceutical compounds. *Archives of Toxicology*. 1984; Suppl 7:485-7
http://dx.doi.org/10.1007/978-3-642-69132-4_102
- RS 8592c Lasagna L. Preface: Conceptual remarks on post-marketing drug surveillance. In: *Clinical and social pharmacology: post-marketing period*. Alloza JL, editor. Aulendorf, Germany: Editio Cantor, 1985:9,11-3
- RS 8592b Alloza JL Lasagna L. Drug information supplied in four national compendia: a comparative study. In: *Clinical and social pharmacology: post-marketing period*. Alloza JL, editor. Aulendorf, Germany: Editio Cantor, 1985:85-101
- RS 8592 Wardell WM Mattison N. Drug development and regulation in the United States: prospects for shortening development time by concurrent review and post-marketing surveillance. In: *Clinical and social pharmacology: post-marketing period*. Alloza JL, editor. Aulendorf, Germany: Editio Cantor, 1985:152-60
- RS 8591 Mattison N. Sources of change affecting the U.S. pharmaceutical industry in the 1980s. *Pharmaceutical Medicine*. 1985;1:89-96*
- RS 8590 Shapiro MF Charrow RP. Scientific misconduct in investigational drug trials. *New England Journal of Medicine*. 1985;312(11):731-6
<http://dx.doi.org/10.1056/NEJM198503143121128>
- RS 8589 Diamond AL Laurence DR. Product liability in respect of drugs. *British Medical Journal*. 1985 Feb 28;290(6465):365-8
<http://dx.doi.org/10.1136/bmj.290.6465.365>
- RS 8588 Waife SO Lasagna L. From DNA to NDA--the impact of recombinant DNA technology on new drug development. *Regulatory Toxicology and Pharmacology*. 1985;5(2):212-24

**This publication is for sale at our website <http://csdd.tufts.edu/reports>

[http://dx.doi.org/10.1016/0273-2300\(85\)90036-4](http://dx.doi.org/10.1016/0273-2300(85)90036-4)

- RS 8587 Lasagna L. *Post-Approval Pharmaceutical Research and Development, Medicine in the Public Interest Conference, May 16-7, 1984*. Boston: MIPI, 1984
- RS 8586 Weintraub M. The French drug approval process II: the clinical basis for negative decisions by the Commission for Authorization of Marketing a Medication. *Journal of Clinical Pharmacology*. 1985;25(3):156-63
<http://dx.doi.org/10.1002/j.1552-4604.1985.tb02819.x>
- RS 8585 Spivey RN Lasagna L Trimble AG. New drug applications: how long to gain approval? *Clinical Pharmacology and Therapeutics*. 1985;37(4):361-6
<http://dx.doi.org/10.1038/clpt.1985.54>
- RS 8584 Maxwell RA. The state of the art of the science of drug discovery -- an opinion. *Drug Development Research*. 1984 Nov 21;4:375-89
<http://dx.doi.org/10.1002/ddr.430040402>
- RS 8583 Lasagna L. Techniques for ADR reporting. In: *Detection and prevention of adverse drug reactions*. Stockholm: Almqvist & Wiksell International, 1984:146-51
- RS 8582 Dunne JF. Statement before the Subcommittee on Health and Environment, US House of Representatives, July 27, 1984
- PS 8581 *Center for the Study of Drug Development Conference on the Changing of Prescription Drugs to Over-the-Counter Status, March 19, 1984*. Boston: Tufts CSDD;1984
- RS 8580 Faust RE. Envisioning the future of R&D: Part I and Part II. *Pharmaceutical Executive*. 1984 Oct;4(9)Sep;4(10)
- RS 8579 Sheck L Cox C Davis HT Trimble AG Wardell WM Hansen R. Success rates in the United States drug development system. *Clinical Pharmacology and Therapeutics*. 1984 Nov;36(5):574-83
<http://dx.doi.org/10.1038/clpt.1984.224>
- RS 8479 Wardell WM Sheck LE. Is pharmaceutical innovation declining?: interpreting measures of pharmaceutical innovation and regulatory impact in the USA, 1950-1980. In: *Arne Ryde Symposium on Pharmaceutical Economics, Helsingborg, Sweden, 27-28 September, 1982*. Lindgren B, editor. Helsingborg: Swedish Institute for Health Economics and Liber Förlag, 1984:177-89
- RS 8478 Lasagna L. *Impediments to Vaccine Research, Medicine in the Public Interest Conference, Jan 9-10, 1984*. Boston: MIPI;1984

**This publication is for sale at our website <http://csdd.tufts.edu/reports>

- RS 8477 Inman WHW. Drug Surveillance Research Unit, University of Southampton, *PEM News*. 1984 Aug;(2)
- RS 8476 Mattison N Thomas E Trimble AG Wardell WM. The development of self-originated new drugs by Swiss pharmaceutical firms, 1960 to 1980. *Regulatory Toxicology and Pharmacology*. 1984;4(2):157-73
[http://dx.doi.org/10.1016/0273-2300\(84\)90038-2](http://dx.doi.org/10.1016/0273-2300(84)90038-2)
- RS 8475 Bakke OM Wardell WM Lasagna L. Drug discontinuations in the United Kingdom and the United States, 1964 to 1983: issues of safety. *Clinical Pharmacology and Therapeutics*. 1984 May;35(5):559-67
<http://dx.doi.org/10.1038/clpt.1984.78>
- RS 8474b Bakke OM. Drug selection in a regulated society: the Norwegian experience. *Hospital Formulary*. 1984 May;19:411-2,5,8,21
- RS 8474 Weintraub M. P&T committees and drug regulation in Norway: lessons to be learned. *Hospital Formulary*. 1984;19:347
- RS 8473 Weintraub M. Ethical concerns and guidelines in research in geriatric pharmacology and therapeutics: individualization, not codification. *Journal of the American Geriatrics Society*. 1984;32(1):44-8
- RS 8472 Herman SS. The noninstitutional review board: a case history. *IRB: A Review of Human Subjects Research*. 1984 Jan/Feb;6(1):1-3,12
<http://dx.doi.org/10.2307/3564062>
- PS 8471 Freedman DX. When does a new drug become old? Remarks presented at the Food and Drug Law Institute's 27th Annual Education Conference, Dec 13, 1983
- RS 8470 Lavori PW Louis TA Bailar JC III Polansky M. Designs for experiments--parallel comparisons of treatment. *New England Journal of Medicine*. 1983;309(21):1291-9
<http://dx.doi.org/10.1056/NEJM198311243092105>
- RS 8469 Vane JR. Wellcome relief: new drugs for the Third World. *The Health Sciences*. 1982 Oct 15
- RS 8468 Hutt PB. The importance of patent term restoration to pharmaceutical innovation: will extending patent life increase drug innovation? A search for answers. *Health Affairs*. 1982;1(2):5-24
<http://dx.doi.org/10.1377/hlthaff.1.2.6>
- RS 8374 Lasagna L. Generic drugs and the elderly. *Journal of the American Geriatrics Society*. 1983;31(9):571-2

- RS 8373 Lasagna L. The effect of the drug lag on the nation's health. *Clinical Evaluation* 1983;11(11):63-7
- RS 8372 Lasagna L. How much regulation is desirable in industry? In: *Regulation and restraint in contemporary medicine in the UK and the USA*. L'Etang H, editor. London: The Royal Society of Medicine and MacMillan, 1983:177-82
- RS 8371 Wardell WM. Regulation of the discovery, development, and supply of new drugs: lessons for medicine. In: *Regulation and restraint in contemporary medicine in the UK and the USA*. L'Etang H, editor. London: The Royal Society of Medicine and MacMillan, 1983:3-12
- RS 8370 Wardell WM. The role of regulators. In: *The second pharmacologic revolution*. Wells N, editor. London: Office of Health Economics; 1983:105-9*
- RS 8369 Lasagna L. Discovering adverse drug reactions. *JAMA*. 1983 Apr 22-29; 249(16):2224-5
<http://dx.doi.org/10.1001/jama.1983.03330400070028>
- RS 8368 Wardell WM. Can improved post-marketing surveillance (Phase IV) permit earlier drug approval? In: *Society and medication: conflicting signals for prescribers and patients*. Morgan JP Kagan DV, editors. Lexington MA: DC Heath, 1983:73-81
- RS 8367 Superior Court of New Jersey, Appellate Division. Carol Ann Feldman, an infant, by her parent and guardian *ad litem* Harold Feldman, Plaintiffs - Appellants vs. Lederle Laboratories, a corporation, and American Cyanamid Co., a corporation, Defendants - Respondents. Nov 1983
- RS 8366 Inman WHW. Drug Surveillance Research Unit, University of Southampton. *PEM News*. 1983 Aug;(1)
- RS 8365 Covington TR. Toward a rational approach to the issue of prescribing authority for pharmacists. *Drug Intelligence and Clinical Pharmacy*. 1983;17(9):660-6
- RS 8364 May MS Wardell WM Lasagna L. New drug development during and after a period of regulatory change: clinical research activity of major U.S. pharmaceutical firms, 1958 to 1979. *Clinical Pharmacology and Therapeutics*. 1983;33(6):691-700
<http://dx.doi.org/10.1038/clpt.1983.95>
- RS 8363 Young JH. Public policy and drug innovation. *The American Institute of the History of Pharmacy*. 1982;24:1-56
<http://www.jstor.org/stable/41110241>
- RS 8362 Paton WD. Animal experimentation and medical research: a study in evolution. *Conquest*. 1979 Feb;169:1-14

**This publication is for sale at our website <http://csdd.tufts.edu/reports>

- RS 8361 Hutt PB. Investigations and reports respecting FDA regulation of new drugs, Part I) and Part II. *Clinical Pharmacology and Therapeutics*. 1983;33(4):537-48; 33(5):674-87
<http://dx.doi.org/10.1038/clpt.1983.73>
- RS 8360 Wardell WM May MS Trimble AG. New drug development by U.S. pharmaceutical firms with analyses of trends in the acquisition and origin of drug candidates, 1963-1979. *Clinical Pharmacology and Therapeutics*. 1982 Oct;32(4):407-17
<http://dx.doi.org/10.1038/clpt.1982.181>
- RS 8359c Griffin JP Long JR. New procedures affecting the conduct of clinical trials in the United Kingdom. *British Medical Journal*. 1981;283(6289):477-9
<http://dx.doi.org/10.1136/bmj.283.6289.477>
- RS 8359b Griffin JP Diggle GE. A survey of products licensed in the United Kingdom from 1971-1981. *British Journal of Clinical Pharmacology*. 1981;12(4):453-63
<http://dx.doi.org/10.1111/j.1365-2125.1981.tb01251.x>
- RS 8359 Diggle GE Griffin JP. Licensing times in granting marketing authorizations for medicines--a comparison between the U.K. and U.S.A. *Pharmacy International*. 1982;3(7):230-6
- RS 8358c Zbinden G. Current trends in safety testing and toxicological research. *Naturwissenschaften* 1982;69(6):255-9
<http://dx.doi.org/10.1007/BF00396431>
- RS 8358b Zbinden G Flury-Roversi M. Significance of the LD 50 test for the toxicological evaluation of chemical substances. *Archives of Toxicology*. 1981 Apr;47(2):77-99
<http://dx.doi.org/10.1007/BF00332351>
- RS 8358 Task Force of Past Presidents of Society of Toxicology. Animal data in hazard evaluation: paths and pitfalls. *Fundamental and Applied Toxicology*. 1982 May/Jun;2(3):101-7
[http://dx.doi.org/10.1016/S0272-0590\(82\)80089-4](http://dx.doi.org/10.1016/S0272-0590(82)80089-4)
- RS 8357b Mahler H. Essential drugs for all. *Papers presented at the Eleventh IFPMA Assembly, Washington DC, Jun 7-8, 1982*:64-70
- RS 8357 Lall S. The pharmaceutical industry in India: the economic costs of regulation. *Papers presented at the Eleventh IFPMA Assembly, Washington DC, Jun 7-8, 1982*:51-7
- PS 8356 Cuatrecasas P. *Contemporary drug development--dilemmas*. Boston MA: Center for the Study of Drug Development, Feb 1983. [Subsequently published in *Regulatory Toxicology and Pharmacology*. 1984;4(2):1-2]

**This publication is for sale at our website <http://csdd.tufts.edu/reports>

- RS 8355b Kitchens CS. Human Experimentation Committee vs. Edward Jenner. *Journal of the Florida Medical Association*. 1981;68(5):346-8
- RS 8355 Lasagna L. Reader's Guide II: Legitimizing the doctor's Bible. *The Sciences* 1980 Sep; Statistics: a new co-carcinogen. *The Sciences* 1980 May; Green grass, blue sky. *The Sciences* 1978 May; Flights of fancy. *The Sciences* 1977 Oct
- RS 8262 Wardell WM. Is pharmaceutical innovation declining? *Pharmaceutical Technology*. 1982 Sep
- RS 8261 Lasagna L. An expanding orphanage of new drugs. *Regulation*. 1982;6(6):46-7
- RS 8260 Wardell WM Mattison N. The assessment of medical technologies using risk-benefit, cost-benefit, and cost-effectiveness analysis. In: *WMA Follow-up Committee on Development and Allocation of Medical Care Resources*. Tokyo: Japan Medical Association;1982;84-98*
- RS 8259 Hansen RW. The relationship between regulation and R&D in the pharmaceutical industry: a review of literature and public policy proposals. *Proceedings of the Symposium and Workshop: the Effectiveness of Medicines in Containing Health Care Costs: Impact of Innovation, Regulation, and Quality, Jun 1982*. Washington DC: National Pharmaceutical Council and Project HOPE Center for Health Information;53-74
- RS 8258 Lasagna L. How can society facilitate the adoption of orphan drugs? In: *Orphan drugs*. Karch FE, editor. New York: Marcel Dekker;1982:200-5
- RS 8257 Wardell WM. Deregulation of drug development: if effective, can it be safe? In: *Drug safety--progress and controversies*. Paris; New York: Pergamon, 1982:33-40*
- RS 8256 Wardell WM Mattison N. Private sector initiatives. In: *Meeting human needs: toward a new philosophy*. Meyer JA, editor. Washington DC: American Enterprise Institute for Public Policy Research;1982:383-404*
- RS 8255 Wardell WM. Can improved post-marketing surveillance permit drug approval? *Drug Therapy*. 1982;12(2):143-53*
- RS 8254 Weintraub M. The French drug approval process. *Journal of Clinical Pharmacology*. 1982 May/Jun;22(5 & 6):213-22
<http://dx.doi.org/10.1002/j.1552-4604.1982.tb02664.x>
- RS 8253c McMahon FG. *The report of the Commission on the Federal Drug Approval Process, overview and summary*. Washington DC: GPO, Apr 1982

**This publication is for sale at our website <http://csdd.tufts.edu/reports>

- RS 8253b Schweiker RS. Remarks by the Honorable Richard S. Schweiker to the National Pharmaceutical Council Symposium. June 23, 1982
- RS 8253 Pharmaceutical Manufacturers Association. Proposed revision of IND/NDA regulations -- executive summary. Letter to the FDA, Apr 15, 1982
- RS 8252 Shubin S. The MAC program and advisors to the government. *Hospital Formulary*. 1981 Aug;16(8):869-79
- RS 8251 Lasagna L. Will all new drugs become orphans? *Clinical Pharmacology and Therapeutics*. 1982 Mar;31(3):285-9
<http://dx.doi.org/10.1038/clpt.1982.34>
- RS 8250 Wardell WM. *A statement on pharmaceutical patent life and innovation*. Submitted to the Subcommittee on Investigations and Oversight of the Committee on Science and Technology, U.S. House of Representatives. Feb 4, 1982
- RS 8249 Phelps JR. Disqualification of investigators. Remarks by James R. Phelps, Esq. before the Food and Drug Law Institute Symposium on Disqualification Investigators, Mar 6, 1980
- RS 8248c Hutt PB. Medical device regulation: reasonable, workable. *Legal Times of Washington*. 1980 May 5;2(48):12-3
- RS 8248b Buzzell HO. Cooperation and conflict. *Medical Device and Diagnostic Industry*. 1981;3(1):10-1
- RS 8248 Kennedy RS. Clinical investigations with medical devices: new rules. *Journal of the American Medical Association*. 1981 May;245(20):2052-5
<http://dx.doi.org/10.1001/jama.1981.03310450044021>
- RS 8154 Lasagna L Wardell WM Hansen RW DiRaddo J. Approaches to evaluating the impact of regulation--the example of pharmaceutical innovation. In: Caceres CA, ed. *The Management of technology in health and medical care*. Dedham: Artech House, 1981:463-73*
- RS 8153 Wardell WM Velo GP, editors. *Drug development, regulatory assessment, and postmarketing surveillance*. NATO Advanced Institutes Series, 39 (Series A: Life Sciences) New York: Plenum; 1981*
<http://dx.doi.org/10.1007/978-1-4684-4055-3>
- RS 8152 Hansen RW. *Testimony before the Subcommittee on Health and the Environment, Committee on Interstate and Foreign Commerce, United States House of Representatives on HR 1937: Patent term restoration, April 1, 1981*. Rochester NY: Center for Research in Government Policy and Business, Graduate School of Management, University of Rochester, (Working Paper Series No. PAS 81-7) 1981*

**This publication is for sale at our website <http://csdd.tufts.edu/reports>

- RS 8151 Wardell WM. Patients' needs in drug development and regulation. *Annals of the New York Academy of Sciences*. 1981;368:187-202*
<http://dx.doi.org/10.1111/j.1749-6632.1981.tb15448.x>
- RS 8150 Hansen RW. The cost of regulation in the pharmaceutical industry: economic implications of three recent studies. In: *Economic costs of FDA regulations: a set of studies of some economic effects of Food and Drug Administration regulation of human pharmaceuticals*. Washington DC: Pharmaceutical Manufacturers Association; Mar 1981:9-32*
- RS 8149 Eisman MM Wardell WM. Incremental time study: an analysis of time spent in the development and approval of drugs for the US market. In: *Economic costs of FDA regulations: a set of studies of some economic effects of Food and Drug Administration regulation of human pharmaceuticals*. Washington DC: Pharmaceutical Manufacturers Association; Mar 1981:53-82*
- RS 8148 Lasagna L. The ethical and scientific basis of regulation. In: Turner P Padgham C Hedges A, eds. *Clinical Pharmacology & Therapeutics: Lectures, Symposia and Therapeutic Sessions of the First World Conference on Clinical Pharmacology and Therapeutics, London, August 3-9, 1980*. Baltimore: University Park Press; 1980:3-8
- RS 8147 Fredrickson DS. A history of the recombinant DNA guidelines in the United States. In: Morgan J Whelan WJ, eds. *Recombinant DNA and genetic experimentation*. New York: Pergamon; 1979;151-6
- RS 8146 Lasagna L. Readers guide I: The powerful cipher. *The Sciences* 1980 Feb; Sleep and the golden mean. *The Sciences* 1980 Nov; The writing on the wall. *The Sciences* 1979 Oct; Fortified booze. *The Sciences* 1979 Feb; Not so simple, Simon says. *The Sciences* 1978 Sep
- RS 8145 DiRaddo J Wardell WM. Research activity on systemic contraceptive drugs by the U.S. pharmaceutical industry, 1963-1976. *Contraception*. 1981 May;23(4):345-66
[http://dx.doi.org/10.1016/0010-7824\(81\)90025-1](http://dx.doi.org/10.1016/0010-7824(81)90025-1)
- RS 8144 Eisman MM Wardell WM. The decline in effective patent life of new drugs. *Research Management*. 1981;21(1):18-21
- RS 8143 Sackett DL Gent M. Controversy in counting and attributing events in clinical trials. *New England Journal of Medicine*. 1979 Dec 27;301(26):1410-2
<http://dx.doi.org/10.1056/NEJM197912273012602>
- RS 8142 Crout JR. *The drug regulatory system: reflections and predictions*. Speech presented at The Food and Drug Law Institute, Dec 1980. Rochester, NY: Center for the Study of Drug Development, 1981

**This publication is for sale at our website <http://csdd.tufts.edu/reports>

- RS 8141b Bonchek LI. Are randomized trials appropriate for evaluating new operations? *New England Journal of Medicine*. 1979 Jul 5;301(21):44-5
<http://dx.doi.org/10.1056/NEJM197907053010110>
- RS 8141 Lasagna L. Dear hearts. *The Sciences*. 1980 Oct;29:29
- RS 8060 Wardell WM. *Prepared statement on emerging issues in science and technology: a compilation of reports on CRS Workshops. Conducted for the Committee on Science and Technology, US House of Representatives, 96th Congress, 2nd Session, by the Science Policy Research Division, Congressional Research Service, Library of Congress*. Washington DC: U.S. GPO, Dec 1980:356-62*
- RS 8059 Hansen RW. *Effects of incremental costs on pharmaceutical innovation*. (Working Paper Series No. GPB-81-2) Rochester NY: Graduate School of Management, University of Rochester, Dec 1980
- RS 8058 Hansen RW. *The cost of regulation in the pharmaceutical industry: economic implications of three recent studies*. (Working Paper Series No. PS 81-2) Rochester NY: Graduate School of Management, University of Rochester, Dec 1980
- RS 8057 Wardell WM. Therapeutic drugs as an example of the regulation of health care: efficient and inefficient ways of utilizing resources. In: *Proceeding of the World Medical Association Follow-Up Committee Meeting on Development and Allocation of Medical Care Resources*. Tokyo: Japan Medical Association, 1980:139-50*
- RS 8056 Wardell WM. Drug therapy (a response to questions on specific aspects of drug regulation). *Private Practice*. 1980 Oct:24-31*
- RS 8055 Lasagna L. Postmarketing surveillance. *Triangle*. 1980;19(3/4):107-11
- RS 8054 Lasagna L. Regulation and constraint of medical research: rights and human welfare. *American Review of Respiratory Disorders*. 1980;122:361-4
- RS 8053 Wardell WM. What is the proper role of a drug regulatory agency? In: Marcus AW, ed. *Risk and regulation in medicine*. London: Association of Medical Advisors in the Pharmaceutical Industry; 1980:95-113*
- RS 8052 Wardell WM DiRaddo J. The measurement of pharmaceutical innovation. *Journal of Clinical Pharmacology*. 1980;20(1):1-9
<http://dx.doi.org/10.1002/j.1552-4604.1980.tb01660.x>
- RS 8051 Lasagna L. Pharmacology's labs have moved faster than the regulators. *Medical Tribune*. 1980 May 7;21:17

**This publication is for sale at our website <http://csdd.tufts.edu/reports>

- RS 8050 Wardell WM. The changing role of government in prescriptive drugs. In: *Pharmaceuticals in North America: the Public Interest. Proceedings of the 22nd Annual Seminar sponsored by the Institute of Canadian-American Studies, Windsor, Ontario, Nov 1980.* Murray JA, editor. Windsor: University of Windsor Press, 1980:54-70*
- RS 8049 Franceti I Lasagna L Weintraub M Karch FE. Prescription prices under the New York Generic Substitution Law. *Annals of Internal Medicine.* 1980;92(3):419-23
<http://dx.doi.org/10.7326/0003-4819-92-3-419>
- RS 8048 Ricardo-Campbell R Eisman MM Wardell WM Crossley R. Preliminary methodology for controlled cost-benefit study of drug impact: the effect of cimetidine on days of work lost in a short-term trial in duodenal ulcer. *Journal of Clinical Gastroenterology.* 1980;2:37-41*
- RS 8047 Lasagna L. Relationship between government and industry in clinical trials. In: *Issues in Research with Human Subjects. Proceedings of NIH Symposium, March 20-21, 1978, Bethesda, MD.* [NIH Pub 80-1858] Washington DC: US GPO; 1980:151-5
- RS 8046 Hansen RW. *Pharmaceutical development costs by therapeutic categories.* (Working Paper Series No. GPB-80-6) Rochester, NY: Graduate School of Management, University of Rochester; Mar 1980*
- RS 8045 Lasagna L. Risk/benefit factors in international drug registration. In: *Proceedings of the International Federation of Pharmaceutical Manufacturers Associations (IFPMA) Symposium on International Drug Registration, 1979 Oct 2-5, The Intercontinental Hotel, Geneva, October 2-5, 1979.* Zurich: IFPMA; 1980:227-33
- RS 8044 Wardell WM DiRaddo J Gringeri A. Preliminary analysis of the rate of development of new drugs by British-owned pharmaceutical firms, 1964-1977. In: Marcus AW, ed. *Risk and regulation in medicine.* London: Association of Medical Advisors in the Pharmaceutical Industry; 1980:117-9*
- RS 8043 McMahon FG Wardell WM Hayes AH Jr. Statement of the American Society for Clinical Pharmacology and Therapeutics on the Drug Regulation Reform Act of 1978 (HR 11611). *Clinical Pharmacology and Therapeutics.* 1978 Sep;24(3):374-81
- RS 8042 Wardell WM. The US drug efficacy study and its implementation (DESI). *Agents and Actions.* 1978;8(4):421-2*
<http://dx.doi.org/10.1007/BF01968667>

- RS 8041 Wardell WM. *Part I: Statement on Sections 108 e,g,h, and Section 185 of the Drug Regulation Act of 1978*. Hearings before the Subcommittee on Health and the Environment of the Committee on Interstate and Foreign Commerce, US House of Representatives. 95th Congress 2nd Session on HR 11611. *Part 2: Drug Regulation Reform Act of 1978*. (Serial No. 95-170) 1978:2129-34*
- RS 8040 Wardell WM DiRaddo J Trimble AG. Development of new drugs originated and acquired by United States-owned pharmaceutical firms, 1963-1976. *Clinical Pharmacology and Therapeutics*. 1980 Aug;28(2):270-7
<http://dx.doi.org/10.1038/clpt.1980.160>
- RS 8039 Letters to the editor. *in re: the drug lag*. *Regulation*. 1980 Mar/Apr;4(2):59-60
- RS 8038 Holder AR. The FDA's final regulations: IRBs and medical devices. *IRB: a Review of Human Subjects Research*. 1980 Jun/Jul;2(6):1-4
- RS 8037 Taylor J. *The U.S. pharmaceutical industry: a socio-economic analysis: a checklist of sources*. Rochester, NY: St. John Fisher College; Jan 1980
- PS 8036 Gross F. *Constraints on progress in drug development*. Rochester, NY: Center for the Study of Drug Development; Jun 1980
- PS 8035 Gross F. *Directions and implications of drug legislation and regulation in Europe*. Rochester, NY: Center for the Study of Drug Development; Jun 1980
- PS 8034 Scribner B. Statement presented by Dr. Thomas Morgan for Dr. Belding Scribner before the FDA Public Hearing on Investigational Device Exemptions, Aug 7, 1978. Rochester, NY: Center for the Study of Drug Development; 1980
- PS 8033 Letter to the Honorable Henry A. Waxman (Chairman, Subcommittee on Health and the Environment, United States House of Representatives) from the Honorable George E. Brown, Jr. (Chairman, Subcommittee on Science, Research, and Technology, United States House of Representatives) *in re: the FDA's process for approving new drugs*. Jul 26, 1979. Rochester, NY: Center for the Study of Drug Development; 1980
- PS 8032 Merrill RA. *Problems involving federal conflict of interest restrictions on members of FDA advisory committees and agency officials*. Rochester, NY: Center for the Study of Drug Development; Apr 1980
- RS 8031 Lasagna L. Who will adopt the orphan drugs? *Regulation*. 1979 Nov/Dec;(6):27-32
- RS 8030 Wardell WM. The drug lag revisited: comparison by therapeutic area of patterns of drugs marketed in the United States and Great Britain from 1972 through 1976. *Clinical Pharmacology and Therapeutics*. 1978 Nov;24(5):499-524

**This publication is for sale at our website <http://csdd.tufts.edu/reports>

- RS 8029 Levine RJ. Changing federal regulation of IRBs, Part II: DHEW's and FDA's proposed regulations. *IRB: A Review of Human Subjects Research*. 1979 Nov;1(7):1-5,12
- PS 8028 Shubin S. *Prisoner research*. Rochester, NY: Center for the Study of Drug Development; Jan 1980
- RS 7947 Wardell WM. Scientific criteria and methods for drug assessment: requirements in the United States of America. In: *Drug assessment: criteria and methods*. Bowers JZ Velo GP, editors. Amsterdam; New York: Elsevier; 1979:91-100*
- RS 7946 Wardell WM. *Statement on the Food and Drug Administration's process for approving new drugs*. Hearings before the Subcommittee on Science, Research and Technology of the Committee on Science and Technology, US House of Representatives. June 19, 21, and July 11, 1979. 96th Congress 1st Session. Washington DC: GPO, 1979:51-91,455-7,488-849*
- RS 7945 Wardell WM. Present problems in drug regulation. In: Teeling-Smith G Wells N, eds. *Medicines for the Year 2000*. London: Office of Health Economics; 1979:87-90*
- RS 7944 DiRaddo J Wardell WM. Methodology for measuring the effects of regulation on pharmaceutical innovation: regulatory disposition and national origin of new chemical entities in the United States. In: *Federal regulation and chemical innovation*. Hill CT, editor. Washington DC: American Chemical Society Symposium, (Series 109) 1979:127-50*
<http://dx.doi.org/10.1021/bk-1979-0109.ch009>
- RS 7943 Lasagna L. The future of OTCs: scientist's view. *Proceedings of the 1979 Research and Scientific Development Conference, December 4-5, 1979, New York. Sponsored by the Scientific Affairs Committee*. New York: Proprietary Association; 1979:4-8, 21-34
- RS 7942 Lasagna L. The impact of regulation on the development of psycho-active drugs. In: *National Institute on Drug Abuse Research Monograph Series 27. Problems of Drug Dependence 1979. Proceedings of the 41st Annual Meeting*. 1979:29-35
- RS 7940 Lasagna L. Report of Washington Drug Conference on the Drug Regulation Reform Act of 1978, Washington D.C. July 11, 1978. *Journal of Clinical Pharmacy*. 1979;4:167-73
<http://dx.doi.org/10.1111/j.1365-2710.1979.tb00152.x>
- RS 7939 Lasagna L. Toxicological barriers to providing better drugs. *Archives of Toxicology*. 1979;43(1):27-33
<http://dx.doi.org/10.1007/BF00695871>

**This publication is for sale at our website <http://csdd.tufts.edu/reports>

- RS 7938 Lasagna L. Prescription drugs: the investment with the biggest dividends. *Private Practice*. 1979;11(5):42-3
- RS 7937 Wardell WM Tsianco MC Anavekar SN Davis HT. Postmarketing surveillance of new drugs. I. Review of objectives and methodology. *Journal of Clinical Pharmacology*. 1979;19(2):85-94
<http://dx.doi.org/10.1002/j.1552-4604.1979.tb02464.x>
- RS 7936 Wardell WM Tsianco MC Anavekar SN Davis HT. Postmarketing surveillance of new drugs: II. Case studies. *Journal of Clinical Pharmacology*. 1979;19(2):169-84
<http://dx.doi.org/10.1002/j.1552-4604.1979.tb01649.x>
- RS 7935 Wardell WM. Are these requirements enough or too much? In: DeSchaepdryver AF Gross FH Lasagna L Laurence DR, eds. *The Scientific Basis of Official Regulation of Drug Research and Development. Proceedings of a Satellite Symposium of the 7th International Congress of Pharmacology*. Ghent: Heymans Foundation; 1979:66-81
- RS 7934 Wardell WM. History of drug discovery, development, and regulation. In: Chien RI, ed. *Issues in pharmaceutical economics*. Lexington, MA: DC Heath; 1979:3-11
- RS 7933 Wardell WM. The impact of regulation on new drug development. In: Chien RI, ed. *Issues in pharmaceutical economics*. Lexington MA: DC Heath; 1979:145-9
- RS 7932 Wardell WM. Scientific criteria and methods for drug assessment: postmarketing surveillance. In: Bowers JZ Velo GP, eds. *Drug assessment: criteria and methods*. New York: Elsevier; 1979:229-34*
- RS 7931 Wardell WM. Innovation in antiepileptic drug therapy. *Workshop on Antiepileptic Drug Development. Bethesda MD: National Institute of Neurological and Communicative Disorders and Stroke*. (Monograph 21 App VI/NIH 78-186) Washington DC: GPO; 1979:29-41*
- RS 7930 Lasagna L. The uncertain future of drug development. *Drug Intelligence and Clinical Pharmacy*. 1979;13(4):192-4
- RS 7929 Lasagna L Wardell WM Hansen R DiRaddo J. Problem-solving technology: approaches to evaluating the impact of regulation -- the example of pharmaceutical innovation. *Clinical Engineering*. 1979 Mar-Apr;7(2):13-8
- RS 7928 Wardell WM. Controls of drug utilization: national and international implications. In: Duchene-Marullaz P, ed. *Advances in pharmacology and therapeutics*. New York: Pergamon; 1979:161-8*

**This publication is for sale at our website <http://csdd.tufts.edu/reports>

- RS 7927 Wardell WM. Rx: more regulation or better therapies. *Regulation*. 1979 Sep/Oct;3(5):25-33
- RS 7926b Lasagna L. The diseases and drug needs of the Third World. *Journal of Chronic Diseases*. 1979;32(6):413-4
[http://dx.doi.org/10.1016/0021-9681\(79\)90101-2](http://dx.doi.org/10.1016/0021-9681(79)90101-2)
- RS 7926 Wardell WM DiRaddo J. Innovation and availability in the United States of drugs for tropical diseases. Rochester NY: Center for the Study of Drug Development, 1979. Summary of a paper in the *Institute of Medicine Conference Proceedings: Pharmaceuticals for Developing Countries*. Washington, DC: National Academy of Sciences; 1979
- RS 7925 Shubin S. Triazole and public drug policies. *Perspectives in Biology and Medicine*. 1979 Winter;22(2 pt 1):185-204
- RS 7924 Halberstam MJ. Too many drugs? Part I and Part II. *Forum on Medicine*. 1979 Mar;2(3):170-6; 1979 Apr;2(4):284-91
- RS 7923 Hansen RW. The pharmaceutical development process: estimates of development costs and times and the effects of proposed regulatory changes. In: Chien R, ed. *Issues in pharmaceutical economics*. Lexington MA: DC Heath; 1979:151-81
- RS 7922 Hutt PB. Unresolved issues in the conflict between individual freedom and government control of food safety. *Food Drug Cosmetic Law Journal* 1978;33(10):558-89
- RS 7830 Wardell WM Hassar M Anavekar SN Lasagna L. The rate of development of new drugs in the United States, 1963 through 1975. *Clinical Pharmacology and Therapeutics*. 1978 Aug;24(2):133-45
- RS 7829 De Schaepdryver AF Gross FH Lasagna L Laurence DR, editors. *The Scientific Basis of Official Regulation of Drug Research and Development. Proceedings of a Satellite Symposium of the 7th International Congress of Pharmacology. Ghent, July 24-25, 1978*. Ghent: Heymans Foundation; 1978*
- RS 7828 Lasagna L. Generic substitution: trick or treat? *Journal of the American Medical Association*. 1978 May 5;239(18):1888
<http://dx.doi.org/10.1001/jama.1978.03280450060031>
- RS 7827 Lasagna L. The development and regulation of new medications. *Science*. 1978 May 26;200(4344):871-3
<http://dx.doi.org/10.1126/science.644328>
- RS 7826 Lasagna L. The New York State generic substitution law: an exercise in surrealism. *Drug Therapy*. 1978 May;8(5):31-2

**This publication is for sale at our website <http://csdd.tufts.edu/reports>

- RS 7825 Wardell WM. History and application of drug safety and efficacy requirements in the United States. *Agents and Action*. 1978; 8(4):420-1*
<http://dx.doi.org/10.1007/BF01968666>
- RS 7824 Petursson SR Wardell WM Curran JP. National rates and patterns of consumption of antihypertensive drugs in relation to their availability in the United States, the United Kingdom, Australia, and New Zealand. *Annals of the New York Academy of Sciences*. 1978;304:320-30*
<http://dx.doi.org/10.1111/j.1749-6632.1978.tb25609.x>
- RS 7823 Wardell WM. A close inspection of the 'calm look': rhetorical amblyopia and selective amnesia at the FDA. *Journal of the American Medical Association*. 1978;239(19):2004-11
<http://dx.doi.org/10.1001/jama.1978.03280460072023>
- RS 7822 Wardell WM, editor. *Controlling the use of therapeutic drugs: an international comparison*. Washington DC: American Enterprise Institute for Public Policy Research; 1978*
- PS 7821 *Report of Washington Conference on the Drug Regulation Reform Act of 1978 (S 2755; HR 12980) July 17, 1978*. Rochester, NY: Center for the Study of Drug Development; Jul 17, 1978
- PS 7820 Pycszak F. *Application of some principles of readability research in the preparation of patient package inserts*. Rochester, NY: Center for the Study of Drug Development; Nov 1978
- PS 7819 Mellinger GD Balter MB Huffine CL Manheimer DI. *Progress report on a study of public judgments regarding ethical issues in biomedical research*. Rochester, NY: Center for the Study of Drug Development; 1978
- RS 7818 Watson JD. In defense of DNA. In: *Annual Report 1976, Cold Spring Harbor Laboratory*. Cold Spring Harbor, NY: The Laboratory;1976
- RS 7817 Wardell WM. Foreward and introduction. In: *Controlling the use of therapeutic drugs: an international comparison*. Washington DC: American Enterprise Institute; Jun 1978
- PS 7816 Landau RL. *What you should know about estrogens, or the perils of Pauline*. Rochester, NY: Center for the Study of Drug Development; Jun 1978
- PS 7815 Lasagna L. Testimony of Louis Lasagna, M.D. on the Drug Regulation Reform Act of 1978, before the Subcommittee on Health and Scientific Research, Committee on Human Resources, Apr 12, 1978. (Subsequently published in *Medical Marketing and Media* 1978;13(7):22-6 and *Resident Physician* 1978;24(8):90

**This publication is for sale at our website <http://csdd.tufts.edu/reports>

- RS 7814 Swisher SN. The introduction of adenine fortified blood preservatives: introduction and an interpretation of its history. *Transfusion*. 1977 Jul/Aug;17(4):309-15
<http://dx.doi.org/10.1046/j.1537-2995.1977.174772168>
- PS 7812 Crout JR. *The nature of regulatory choices*. Rochester, NY: Center for the Study of Drug Development; Jan 1978
- PS 7811 Remington R. *Post-marketing surveillance: a comparison of methods*. Rochester, NY: Center for the Study of Drug Development; Jan 1978
- RS 7713 Lasagna L. Current patterns of research activity. In: *Trends and Prospects in Drug Research and Development, Proceedings of the 11th CIOMS Round Table Conference, Dec 8-9, 1977, Geneva, Switzerland*. Geneva: Council for International Organisations of Medical Science, [1977]:43-7
- RS 7712 Lasagna L. *Postmarketing surveillance of drugs. Medicine in the Public Interest Conference, Elkridge MD, October 29-31, 1977*. Washington DC: MIPI, 1977
- RS 7711 Hansen RW. *Regulation and pharmaceutical innovation: a review of the literature on monetary measures of costs and benefits*. (Working paper) Rochester, NY: Center for the Study of Drug Development; Jun 1977*
- RS 7710 Roll GF. Reform in drug regulation overdue. *Connecticut Medicine*. 1977 Jun;41(1):27-31*
- RS 7709 Lasagna L. *International drug regulation*. Université René Descartes lecture, May 26, 1977, Paris. [Occasional paper No. 73] Washington DC: American Enterprise Institute; 1977
- RS 7708 Wardell WM. Postmarketing surveillance, drug monitoring and adverse drug reactions: a case-study approach to the analysis of problems and possible solutions. In: *Drug Monitoring. Proceedings of an International Workshop held in Honolulu, Hawaii, January 1977*. Gross FH Inman WHW, editors. New York: Academic, 1977:241-54*
- RS 7707 Lasagna L. The adversary system and drug regulation. *Connecticut Medicine*. 1977 Jan;41(1):54-5
- PS 7706 Hansen R. Comments on the proposed change in the FDA's trade secrets policy. Rochester NY: Center for the Study of Drug Development, Oct 1977 (Subsequently published in *American Journal of Pharmacy*. 1977;149(5):133-7)
- PS 7705 Kessler II. *Putting reason into regulation*. Rochester, NY: Center for the Study of Drug Development; Oct 1977

**This publication is for sale at our website <http://csdd.tufts.edu/reports>

- PS 7704 Lasagna L. Current status of international drug regulation. Rochester NY: Center for the Study of Drug Development, Jun 1977 (Subsequently published in *Medical Marketing and Media* 1978;12(2):37-43)
<http://dx.doi.org/10.1007/BF03284217>
- RS 7703 Morgan JP. Watching the monitors: "PAID" prescriptions, fiscal intermediaries, and drug-utilization review. *New England Journal of Medicine*. 1977 Feb 3;296(5):251-6
<http://dx.doi.org/10.1056/NEJM197702032960505>
- RS 7702b Schmidt AM. Some homework is needed. Excerpts from an address delivered at the Annual Banquet, 20th Annual Food and Drug Law Institute, Food and Drug Administration Educational Conference, Washington DC, December 7, 1976. Rochester NY: Center for the Study of Drug Development, Feb 1977
- PS 7702 Herzog J. *Recurrent criticisms: a history of investigations of the FDA*. Rochester, NY: Center for the Study of Drug Development; Mar 1977
- RS 7701c Karch FE Lasagna L. Evaluating adverse drug reactions. *ADR Bulletin*. 1976 Aug;(59):204-7
<http://dx.doi.org/10.1097/00012995-197608000-00001>
- RS 7701b Lasagna L. DAWN's early light: a flickering flame. [Reader's guide] *Sciences*. 1976 Nov-Dec;16(6):28-9
- PS 7701 Roll GF. *Of politics and drug regulation*. Rochester, NY: Center for the Study of Drug Development; Jan 1977
- RS 7605 Wardell WM. Monitored release and postmarketing surveillance: foreign and proposed US systems. In: *Impact of Public Policy on Drug Innovation and Pricing. Proceedings of the Third American University Seminar on Pharmaceutical Public Policy Issues, Washington DC, Dec 1975*. Mitchell S Link EA, editors. Washington DC: American University, 1976:289-311*
- RS 7604 Bergman J Halberstam MJ Hubbard WN Jr Lasagna L Nelson G Schmidt AM. [Discussion panel] *Reforming Federal Drug Regulation; Round Table Sponsored by the American Enterprise Institute for Public Policy Research, Washington DC, Feb 23, 1976*. Washington DC: The Institute, 1976
- RS 7603 Lasagna L. International cooperation in drug testing in a changing world. In: Lucchelli PE Bergamini N Bachini V, eds. *Rationality of Drug Development. Proceedings of the Second International Meeting of Medical Advisors in the Pharmaceutical Industry, Florence, Italy, Oct 13-5, 1975*. New York: Elsevier; 1976:3-5

- RS 7602 Hassar M Clymer H Wardell WM Lasagna L. National origin of new chemical entities admitted to the US market from 1963-1974. *Clinical Pharmacology and Therapeutics* 1976 Jan;19(1):108 [abstract]
- PS 7601b Hutt PB. *Balanced government regulation of consumer products*. Rochester, NY: Center for the Study of Drug Development; Nov 1976
- PS 7601 Lasagna L. *Drug discovery and introduction: regulation and over-regulation*. Rochester, NY: Center for the Study of Drug Development; Nov 1976
- WP 7600c Wardell WM Hassar M Lasagna L. The rate of new drug discovery: the output, flow, and regulatory disposition of new chemical entities produced by the U.S. pharmaceutical industry since 1962. Rochester NY: Center for the Study of Drug Development, Aug 1976. (Subsequently published in *Clinical Pharmacology and Therapeutics*. 1977;21(1):122)
- RS 7600b Lasagna L. Consensus among experts: the unholy grail. *Perspectives in Biology and Medicine*. 1976;19(4):537-48
- RS 7600 Blackwell B Stolley PD Buncher R Klimt CR Temple R Venn D Wardell W. Panel 4: Phase IV investigations. *Clinical Pharmacology and Therapeutics*. 1975 Nov;18(5 pt.2):653-6